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Abstract 
 
Eukaryotic DNA is organized in the form of chromatin whose basic unit is the 
nucleosome. The four core histones forming the nucleosome, H2A, H2B, H3 and H4 
can be highly post-translationally modified, especially on their N-terminal tail 
protruding from the nucleosome particle. Histone post-translational modifications 
(PTMs) work combinatorially to establish chromatin states defined by specific gene 
expression status. Found in embryonic stem cells (ESCs) at promoters of key 
developmental genes, bivalent chromatin is the combination of the active chromatin 
mark, trimethylation of lysine 4 on histone H3 (H3K4me3) and the repressive mark, 
H3K27me3. Established and maintained by Polycomb (Pc) and Trithorax (Trx) 
proteins, bivalency is proposed to keep gene transcription repressed but poised for 
activation. How bivalent domains are organized within the nucleus and how they are 
installed by Pc and Trx are still unknown. In this work, we aim to answer these 
questions by designing probes that enable live cell imaging of bivalent domains and by 
studying the installation and removal of H3K4 methylation on nucleosomes.  
The current lack of live cell imaging methods for PTM patterns prompted us to 
engineer genetically encoded sensors that bind to bivalent marks in a multivalent 
fashion. These sensors contain a fluorescent protein and two reader domains, joined by 
flexible linkers. Their selectivity for bivalent nucleosomes was tested in a pulldown 
assay with a library of differently modified reconstituted nucleosomes. To this end, we 
obtained site-specifically modified histones via Expressed Protein Ligation (EPL). The 
best probe was then applied in live ESCs to visualize bivalent domains. Subsequent 
imaging by confocal microscopy revealed the organization of bivalent chromatin into 
discrete and local clusters. Furthermore, this probe was employed to monitor loss of 
bivalency upon treatment with a small molecule epigenetic inhibitor. 
Then we studied the histone-lysine N-methyltransferase SET1B and lysine-
specific histone demethylase 1A (LSD1), enzymes that install and remove methyl 
groups on H3K4, respectively. We measured a mid-micromolar affinity for LSD1 to 
reconstituted nucleosomes using microscale thermophoresis. This interaction might 
have an impact on the recruitment of LSD1 to its target genes. We then measured the 
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activity of SET1B complex on symmetrically modified H3K27me3 nucleosomes and 
on asymmetrically modified H3K4me3 nucleosomes. We showed that H3K27me3 does 
not influence the activity of SET1B complex, whereas H3K4me3 activates SET1B-
mediated installation of methyl groups at K4 on the opposite H3 tail. This findings 
might have important implications concerning the generation of bivalent chromatin. 
Together these results gave insights about multivalent binding of tandem reader 
domains, subnuclear organization of bivalent chromatin and installation of bivalent 
marks. In the future, we envisage to develop multivalent sensors for other PTM patterns 
of biological interest. 
 
Key words: histone post-translational modifications, expressed protein ligation, 
bivalent chromatin, embryonic stem cells, reader domains, genetically encoded sensors, 
multivalent binding, site-specifically modified nucleosomes, LSD1, SET1B 
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Résumé 
 
L’ADN eucaryote est organisé sous la forme de chromatine dont l’unité de base 
est le nucléosome. Les quatre histones formant le nucléosome peuvent porter des 
modifications post-traductionnelles, principalement sur leur queue N-terminale. Ces 
modifications fonctionnent de manière combinatoire pour établir des états distincts de 
chromatine définis par leur statut d’expression des gènes. La chromatine bivalente, 
trouvée dans les cellules souches embryonnaires aux promoteurs de gènes importants 
pour le développement, est la combinaison de la marque active tri-méthylation de la 
lysine 4 sur l’histone H3 (H3K4me3) et de la marque répressive H3K27me3. La 
bivalence est établie et maintenue par les protéines Polycomb (Pc) et Trithorax (Trx). 
Il a été proposé que la chromatine bivalente garde les gènes réprimés mais prêts à être 
activés. A ce jour, la manière dont les domaines bivalents sont organisés dans le noyau 
et la façon dont ils sont installés par Pc et Trx demeurent inconnues. Dans cette thèse, 
nous visons à répondre à ces questions en développant des senseurs qui permettent 
d’observer les domaines bivalents dans les cellules vivantes et en étudiant l’installation 
et le retrait des groupes méthyle sur H3K4. 
Le manque actuel de méthodes pour imager les combinaisons de modifications 
dans les cellules vivantes nous a poussés à concevoir des senseurs génétiquement 
encodés qui reconnaissent les marques bivalentes de manière multivalente. Ces 
senseurs contiennent une protéine fluorescente et deux domaines « lecteur » joints par 
des connecteurs flexibles. Leur sélectivité pour des nucléosomes bivalents a été testée 
grâce à une bibliothèque de nucléosomes portant différentes modifications. Pour cela, 
nous avons obtenu des histones avec un (plusieurs) site(s) spécifiquement modifié(s) à 
l’aide de la réaction de ligature de protéines exprimées (EPL). Le meilleur senseur a 
ensuite été utilisé dans des cellules souches embryonnaires vivantes pour visualiser les 
domaines bivalents. Nous avons ensuite observé les cellules à l'aide d'un microscope 
confocal et révélé que la chromatine bivalente est organisée sous forme de grappes. 
Par la suite, nous avons étudié les enzymes histone-lysine N-méthyl transférase 
SET1B et lysine-spécifique histone démethylase 1A (LSD1) qui respectivement dépose 
et enlève les groupes méthyle sur H3K4. Nous avons utilisé la thermophorèse à micro-
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échelle pour mesurer une affinité micro-molaire entre LSD1 et des nucléosomes. 
Ensuite, nous avons évalué l’activité du complexe SET1B sur des nucléosomes portant 
H3K27me3 de manière symétrique et sur des nucléosomes portant H3K4me3 de 
manière asymétrique. Nous avons montré que H3K27me3 n’a pas d’influence sur 
l’activité de SET1B alors que H3K4me3 active la mise en place de groupes méthyle par 
SET1B sur la queue opposée. 
En tout, ces résultats donnent des informations cruciales sur l’organisation sous-
nucléaire de la chromatine bivalente et sur l’installation des marques bivalentes. A 
l'avenir, nous envisageons de développer des senseurs multivalents ciblant d’autres 
combinaisons de modifications. 
 
Mots clés: modifications post-traductionnelles des histones, ligation de 
protéines exprimées, chromatine bivalente, cellules souches embryonnaires, domaines 
« lecteur », senseurs génétiquement encodés, liaison multivalente, nucléosomes 
spécifiquement modifiés, LSD1, SET1B 
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Chapter 1. Introduction 
 
1.1 Gene expression regulation and chromatin in eukaryotes 
 
1.1.1 Nuclear DNA under the form of chromatin 
 
The structure of chromatin 
The human genome with its ~ 6 billion DNA base pairs (bp) is about four 
meters in length and encodes for all genetic information required for development 
and maintenance of body functions throughout its lifetime. The nucleus of a human 
cell is in the range of 5 - 10 μm in diameter and yet contains all chromosomes. 
Nuclear DNA is organized in the form of chromatin, which compacts it and tightly 
controls access of the transcription machinery to genes. Chromatin, the nucleoprotein 
complex composed of DNA and histone proteins, adopts different conformations 
during the cell cycle. Chromatin takes the form of highly compact mitotic 
chromosomes during mitosis, whereas during interphase chromatin appears in a more 
relaxed form, organized in subnuclear chromosome territories. Chromatin has several 
layers of organization (Figure 1). The nucleosome, the basic unit of chromatin, is a 
pseudo-symmetric structure composed of 147 bp of DNA wrapped around a histone 
octamer in 1.65 turns of a left-handed helix. The first high resolution crystal structure 
of the nucleosome core particle was determined by the Richmond group in 1997.1 
The histone octamer is composed of two copies of the four core canonical histones 
H2A, H2B, H3, H4 or their variants (H2A.X for instance). Nucleosomes cover the 
whole genome with a repeat length of ~ 160 - 200 bp even though some portions of 
the genome are richer or poorer in nucleosomes.2 A nucleosome array represents the 
structure known as “beads-on-a-string” first described by Don and Ada Olins in 
1974.3 Nucleosome arrays can further fold into 30 nm chromatin fibres;4 the structure 
of these fibres has been of longstanding debate among the scientific community. Two 
models are proposed: the two-start helix model with zigzag conformation was 
initially proposed by Woodcock et al.5 and the solenoid one-start helical 
conformation was first proposed by Finch and Klug in 1976.4 Tetranucleosome 
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structures and other studies support the two-start helical model,6–9 whereas studies 
by the Rhodes group support the solenoid model.10,11 The 30 nm fibre is however a 
short range organizational motif, as over long length scales chromatin appears highly 
heterogeneous in interphase and mitotic cells.12,13 
Figure 1. Chromatin organization. From the level of chromosomes to nucleosomes, chromatin is 
organized into different structures. From left to right: schematic view of a mitotic chromosome, high 
order structures, two-start helical 30 nm chromatin fibre, nucleosome array with “beads-on-a-string” 
conformation, ribbon representation of a human nucleosome core particle (PDB: 3AFA) with 146 bp 
double stranded DNA shown in grey, histone H3.1, H4, H2A, H2B represented in blue, red, yellow 
and green, respectively. Unstructured N-terminal histone tails are not displayed here. 
 
Epigenetics: discovery and definition 
Within eukaryotes, all cells composing an organism carry the same genetic 
information, although they differ in phenotype. Each cell type is characterized by a 
particular gene expression profile that defines cell function, morphology and location 
within the body. For proper functioning of the organism, a tight control of gene 
expression is required. The study of the biological mechanisms that control gene 
expression is known as the field of epigenetics, literally meaning “over the genetics”. 
The term of “epigenetics” was first used by Waddington in 1939 for whom it referred 
to the link between genes and development.14,15 This term has evolved and nowadays 
an epigenetic trait is considered as “a stably heritable phenotype resulting from 
changes in a chromosome without alterations in the DNA sequence”.16 
The three following phenomena are generally considered as epigenetic 
mechanisms: DNA methylation (and other DNA modifications) (Figure 2. A), 
histone post-translational modifications (PTMs) (detailed in 1.1.2) (Figure 2. B) and 
RNA-mediated silencing. Historically, the first phenomenon proposed as epigenetic 
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was DNA methylation,17 which is known to repress gene transcription and is 
involved in gene imprinting.18,19 Histone PTMs (or marks) encompass a large 
diversity of chemical modifications and can be found on all four core histones. In 
2015, more than 540 different histone PTMs were reported.20 Histone marks are 
involved in a variety of chromatin-associated events such as transcription, genome 
stability, chromatin compaction, DNA replication and repair.21 Finally, RNA-
mediated silencing is based on sequence complementarity with the messenger RNA 
and is involved in X-chromosome inactivation.22,23 Epigenetic phenomena are 
involved in many crucial cellular processes such as differentiation, mitosis, apoptosis 
and are involved in cancer as well as in mental disorders.24,25 
Figure 2. DNA and histone modifications are epigenetic marks. A. Chemical structures of DNA 
methylation (5mC: 5-methylcytosine) and other DNA modifications (5hmC: 5-
hydroxymethylcytosine; 5fC: 5-formylcytosine; 5caC: 5-carboxylcytosine). B. Chemical structures of 
some histone post-translational modifications (Rme: Arginine monomethylation; Sphos: Serine 
phosphorylation; Kac: Lysine acetylation; Kme1/2/3: Lysine mono-, di- and trimethylation; KUb: 
Lysine ubiquitination). 
 
Epigenetic inheritance 
The definition of epigenetics contains the notion of inheritance through 
mitosis and meiosis. However, unlike DNA sequence, histone and DNA 
modifications are labile, i.e. they are reversibly deposited and removed from their 
substrate by specific enzymes (this topic is detailed in 1.1.2). This raises the question 
if histone and DNA modifications are indeed stably inherited during cell division and 
across multiple generations. Evidence that the DNA methyltransferase DNMT1 is 
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preferentially active on hemi-methylated DNA (DNA methylated on one strand only) 
supports the hypothesis that DNMT1 installs methyl groups on the newly synthesized 
DNA strand at methylated positions of the parental strand.26,27 This provides a 
mechanism for mitotic DNA methylation inheritance. However, de novo DNA 
methylation by DNMT3A/B occurs as well and is particularly important during 
development.28,29 Regarding histone modifications, several studies showed that 
methylation at Lysine 9 and 27 of histone H3 (H3K9me and H3K27me) are inherited 
during cell division or even from parents to offspring.30–32 It is however unclear 
which and to what extent histone modifications are stably inherited. 
Inheritance through multiple generations is assumed to be mainly driven by 
non-coding RNA.33–35 DNA methylation at imprinted genes is also an example of 
transgenerationally inherited epigenetic marks.18 However the transgenerational 
inheritance of histone marks is under debate. During spermatogenesis, most of the 
histones are replaced by protamines,36 limiting but not abolishing paternal 
transmission of histone marks to offsprings.37 Although oocytes and zygotes undergo 
major epigenetic reprogramming,38 maternal transgenerational inheritance of 
H3K9me3 exists at pericentric heterochromatin.39 Transgenerational inheritance of 
epigenetic modifications was first proved in 1999 by Morgan et al. at the agouti locus 
in mouse.40 More recently, Greer et al. and Gu et al. showed transgenerationally 
inherited epigenetic footprints in C. Elegans for H3K4me3 and H3K9me3, 
respectively.41,42 In Drosophila and mouse, paternal transgenerational inheritance of 
gene expression reprogramming or of chromatin state reprogramming was 
highlighted by the use of a specific paternal diet.43,44 
 
1.1.2 Histone post-translational modifications regulate gene 
expression 
 
Histone modifications and their functions 
Histones are highly conserved chromatin-associated proteins that can be 
categorized as core histones (H3, H4, H2A and H2B) or linker histones (H1 and H5). 
Core and linker histones can be further classified as canonical histones (expressed 
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during S phase and cover the majority of the genome) or histone variants (can 
substitute for the canonical histones). All four core histones can be post-
translationally modified, mainly on their unstructured N-terminal tail protruding 
from the nucleosome, but also on their globular domain. Examples of histone PTMs 
include lysine acetylation, ubiquitination, mono-, di- and trimethylation, arginine 
mono- and dimethylation, serine phosphorylation (Figure 2. B). Histone marks 
control gene expression via a number of mechanisms such as chromatin compaction 
or decompaction, recruitment of protein effectors, inhibition or activation of 
chromatin modifiers and remodelers.21 Histone modifications are differently 
distributed along chromosomes and their level vary during cell cycle.45 Some histone 
marks are known to be associated with euchromatin, a chromatin type characterized 
by a decondensed state and active gene transcription. Active chromatin marks include 
H3K4 di- and trimethylation (present at active promoters) and acetylation of H3 and 
H4.46 Conversely, other histone PTMs are associated with heterochromatin, a 
compact chromatin type where genes are silenced. The repressive chromatin mark 
H3K9me3 is characteristic of constitutive heterochromatin, a highly condensed HP1-
associated chromatin state found at gene-poor regions. H3K27me3 is the hallmark of 
facultative heterochromatin, a Polycomb-associated chromatin state. Histone PTMs 
can act via trans or cis effects. In cis, the covalent modification changes per se the 
compaction state and/or the dynamics of chromatin. Examples of marks having a cis 
effect include H4K20me3, which stabilizes a compact nucleosome fibre,47 
H2BK120Ub48 and H4K16ac,49 which open chromatin arrays. On the contrary, a 
mark acting in trans recruits (or prevent the recruitment of) chromatin effector 
proteins (or complexes), which consequently triggers (or blocks) downstream 
signalling. For example, H3K4me3 recruits transcription machinery, whereas 
H3K27me3 recruits Polycomb group proteins (detailed in 1.2.2). 
 
Readers, writers and erasers of histone marks 
Histone PTMs represent a very dynamic layer of epigenetic information. 
Modifications are deposited and removed on histones by enzymes called writers and 
erasers, respectively. Writers of acetyl marks include the acetyltransferase GCN5 
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(H3K9/K14/K18-specific), which uses acetyl-CoA.50 Methyl groups are deposited 
by methyltransferases, which uses S-adenosylmethionine (SAM). Examples of 
methyltransferases include the H3K4-specific mixed-lineage leukaemia (MLL) 
complexes, the H3K27-specific Polycomb repressive complex 2 (PRC2) and the 
H3K9-specific Suv(ar) family.45 Kinases such as Aurora kinase B use ATP to 
catalyse the installation of a phospho group on H3S10 and H3S28.51 Examples of 
erasers include the lysine demethylases of the Jumonji family and LSD1.45 
The cell uses small protein binding modules as a general way to decode 
protein PTMs and therefore trigger downstream signalling cascades.52 Such 
interaction domains also exist for histone marks and are called reader domains. They 
are small (between 50 and 110 residues) folded protein domains that can recognize 
histone PTMs in a specific manner (Figure 3).53 Reader domains typically harbour a 
cavity or a surface groove that accommodates the modified residue. Amino acids 
forming this cavity provide specificity for the PTM type (methylation versus 
acetylation for instance) and PTM state (mono- versus di- and trimethylation). 
Reader domains typically make interactions with flanking residues thereby 
recognizing sequence context. 
Figure 3. Reader domains as histone PTM binding modules. A. Amino acid sequence of histone H3.1 
from residue 1 to 30 with examples of PTMs and associated reader domains. The protein in which 
reader domains are found are indicated. “me” corresponds to trimethylation. B. Ribbon representation 
of BPTF PHD bound to H3K4me3 peptide (PDB: 2FUU), HP1 chromodomain bound to H3K9me3 
peptide (PDB: 1KNE) and BRD3 bromodomain bound to H3K18ac peptide (PDB: 5HJC).54–56 
Histone peptides are displayed in red with the modified residue in sticks. 
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The first reported reader-PTM interaction is the recognition of acetyl lysine 
by a bromodomain (Figure 4. A).57 Bromodomains are found for example in the 
transcription regulators of the BET family.58,59 Lysine methylation is recognized by 
chromodomains (CD), Tudor domains and Plant Homeodomains (PHD) among 
others (Figure 4. A). Examples include the recognition of H3K9me3 by the 
chromodomain of HP1,60 the binding of methylated H3K4 by the PHD of BPTF56 or 
the recognition of methylated H3K27 by the chromodomain of the Polycomb protein 
Pc.61 Generally, reader domains specific for methyllysine harbour an aromatic cage 
to accommodate the di- or trimethyl ammonium group via cation-π interactions. 
Methyllysine binders also interact with residues flanking the modified amino acid to 
reach high sequence specificity. A striking example for this is provided by the 
chromodomains of HP1 and Polycomb (Pc). Although K9 and K27 residues are 
located in a similar sequence motif, chromodomain of HP1 is specific for H3K9me3, 
whereas chromodomain of Pc is specific for H3K27me3.62 For PHD and 
chromodomains, specificity for the methyl state is generally inferior compared to 
sequence specificity, with increasing KDs from trimethyl to unmethylated 
lysine.56,62,63 Discrimination between unmethylated/monomethylated and 
di/trimethylated states is usually pronounced (1 or more orders of magnitude 
differences in KDs), whereas preference for trimethyl versus dimethyl is less marked 
(1.7- and 10-fold difference in KDs for HP1 CD and TAF3 PHD, respectively). 
PHD zinc fingers are considered as a special case compared to other reader 
domains.64 The majority of them are specific for methyl H3K4 but some recognize 
H3K14ac65 or unmethylated H3K4.66 For some PHD, the binding to methyl H3K4 is 
inhibited by methylation of H3R2, which is accommodated in an adjacent binding 
pocket.63,67 This crosstalk mechanism is also observed for other reader domains such 
as the HP1 chromodomain, which is displaced from H3K9me3 by H3S10 
phosphorylation.68 
 
The histone code hypothesis and chromatin states 
Reader domains are found in chromatin-associated proteins or complexes 
such as remodelers and modifiers. Numerous chromatin effectors contain several 
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reader domains and bind to histone marks in a multivalent fashion.69–71 Several 
binding modes exist: cis- or trans-intranucleosomal binding and internucleosomal 
binding (Figure 4. B and C). TAF1 binds to diacetylated H4 tail with a tandem 
bromodomain in a cis-intranucleosomal fashion,72 whereas BPTF recognizes PTMs 
on two different histones (H3K4me3 and H4K16ac) on the same nucleosome in a 
trans-nucleosomal interaction.73 HP1 forms dimers which bind H3K9me3 in an 
internucleosomal fashion.74,75 Individually, reader domains are modest affinity 
binders with typical KDs in the micromolar range. In the case of multivalent binding 
of tandem reader domains, the apparent affinity is higher. Indeed, once the first 
reader-PTM binding event occurred, the second binding is facilitated thanks to a 
significantly decreased cost in entropy (Figure 4. D and E).69 
Figure 4. Reader domains recognize histone PTMs individually or combinatorially. A. 
Chromodomains and PHD are generally specific for methylated lysines, bromodomains recognize 
acetylated lysine residues and Tudor domains can bind methylated lysines or arginines. Here, “me” 
can correspond to mono-, di-, or trimethylation. B. Cis-intranucleosomal multivalent binding: tandem 
bromodomains of TAF1 recognize two modifications on the same tail (diacetylated H4). Trans-
intranucleosomal multivalent binding: tandem PHD-bromodomain of BPTF bind to two marks on 
different histones (H3K4me3 and H4K16ac). C. Internucleosomal multivalent binding: HP1 binds 
H3K9me3 on different nucleosomes. D. and E. For similar individual reader domain affinities, 
bivalent binding is stronger than monovalent binding. The entropy cost is negligible for the second 
binding event thanks to a favourable pre-arrangement of the second domain. 
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Combinatorial readout of epigenetic marks by multivalent effectors forms the 
basis of the histone code hypothesis.76,77 This hypothesis proposes that patterns of 
histone marks rather than individual marks serve as recruitment platforms and are 
combinatorially decoded by chromatin effectors containing multiple reader domains. 
It implies that combinations of histone marks produce distinct biological outputs via 
a multivalent readout. Some PTMs are often found together and others rarely coexist. 
Additionally, combinations of histone marks are often associated with a particular 
gene expression state (silenced or transcribed), and thus form a chromatin state. 
These observations support the histone code hypothesis and suggest that histone 
PTM patterns define specific chromatin states associated with a certain gene 
expression status.78–81 The above-mentioned euchromatin and heterochromatin are 
two examples of chromatin states. Methods to detect and analyse combinations of 
histone marks involve sequential chromatin immunoprecipitation (ChIP) or mass 
spectrometry (MS) (discussed in 1.2.3).82,83 
 
1.2 Bivalent chromatin in embryonic stem cells 
 
 1.2.1 Pluripotent stem cells 
 
Cell potency and embryonic development 
Stem cells are characterized by three features: the capacity to differentiate 
into any cell type forming an organism (i.e. pluripotency), the ability to proliferate 
indefinitely and the capacity to maintain an undifferentiated state (i.e. self-
renewal).84 Along the different stages of embryonic development, cell potency 
progressively decreases (Figure 5).85 After fertilization, the zygote (or fertilized egg) 
undergoes several cellular divisions to form the morula embryo (16-cell state).86 At 
this stage, all cells are totipotent, i.e. they can give rise to embryonic or extra-
embryonic tissues.87 After a few cell divisions, the morula becomes the hollow sphere 
known as blastocyst.86 The outer layer of the blastocyst forms the trophectoderm 
(TE), which will form extra-embryonic tissues (such as placenta), whilst the inner 
cell mass (ICM) is composed of pluripotent cells, i.e. they can give rise to any of the 
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somatic cells forming an organism.88 The ICM will then produce the three types of 
germs layers, endoderm, mesoderm and ectoderm, all composed of multipotent stem 
cells (i.e. having the ability to differentiate into multiple but limited cell types). Later 
during embryonic development, cell potency further decreases: oligopotent, 
unipotent and fully differentiated (or somatic) cells.89 The adult organism is 
composed of somatic cells but also contains stem cells that represent a pool of 
undifferentiated cells dedicated to the production of new somatic cells.90,91 
Keeping pluripotent cells in culture is of high interest not only for 
fundamental research but also for applications in regenerative medicine.92 Induced 
pluripotent stem cells (iPSCs) are very promising for personalized regenerative 
medicine, whereas embryonic stem cells (ESCs) and cancer stem cells (CSCs) are 
rather used in fundamental research. iPSCs are obtained by reprogramming of 
somatic cells therefore representing an unlimited source of stem cells. 
Reprogramming can be achieved by several ways such as retroviral transduction of 
pluripotency-associated transcription factors,93 by delivery of recombinant 
transcription factors94,95 or by treatment with small molecule compounds.96 CSCs 
arise from adult stem or progenitor cells that undergo mutation(s).97 Found in several 
human cancers, they represent a minority of the cell population of tumours. Despite 
their low number, they are thought to be the source of all tumour cells, to be 
responsible for relapse after remission and for the appearance of metastasis.97 
Therefore they represent an important target in the development of anti-cancer drugs 
for a long-lasting cancer remission.  
In this work, mouse ESCs (mESCs) were used. They were first isolated by 
Evans & Kaufman in 1981 from a mouse blastocyst.98 ESCs are derived from the 
pluripotent cells forming the ICM. Upon culturing in a suitable medium, pluripotency 
and self-renewal capacities are maintained. Due to a short G1 phase, mouse ESCs 
have a cell cycle of ~ 4 - 5 hours,99 much shorter compared to more differentiated 
cells. For a non-synchronized culture, 70 % of mouse ESCs are in S phase (and 20 
% in G1), whereas this phase represents only 25 % of an embryonic fibroblast culture 
(and 70 % for G1).100 
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Figure 5. Schematic view of embryonic development and origin of cultured pluripotent stem cells. 
From the totipotent zygote to the somatic cells of an adult organism, cell potency decreases (blue 
triangle). Mouse embryonic stem cells (mESCs) are derived from the ICM of the blastocyst and 
induced pluripotent stem cells (iPSCs) can be obtained from somatic cells (plain double arrows). 
Cancer stem cells (CSCs) arise from adult stem cells (dotted arrow) and drive tumourgenesis. PB: 
Polar bodies; PN: Pronuclei; ICM: Inner cell mass; TE: Trophectoderm. 
 
Pluripotent stem cells have particular epigenetic and gene expression 
landscapes that reflect their unique differentiation and self-renewal potentials.101 
Tight control of transcription factors (TFs) expression levels and chromatin 
machineries is required to keep the balance of pluripotent state and a disruption in 
regulatory mechanisms leads to differentiation. A variety of factors and pathways 
participates in pluripotency maintenance and some are discussed here (Figure 6). At 
the centre of pluripotency maintenance networks is the core regulatory circuit 
composed of three transcription factors, OCT4 (Octamer-binding transcription factor 
4 or Pou5f1), SOX2 (Sry box-containing gene 2) and NANOG.102,103 OCT4, SOX2 
and NANOG (abbreviated OSN) are highly expressed in the ICM and knockouts of 
any of them in mouse embryos lead to development failure.104–106 In mouse ESCs, 
OSN levels are tightly controlled to maintain pluripotency. A variation in the 
expression level of one or a combination of these three master TFs leads to 
differentiation to a specific lineage.107–110 For example, a moderate level of OCT4 
allows to maintain mouse ESCs in an undifferentiated state, whereas high OCT4 
expression promotes lineage commitment to mesoderm or ectoderm. Finally, low 
OCT4 expression leads to trophectoderm formation.107 OSN positively regulate the 
expression of many pluripotency-associated genes and negatively regulate lineage-
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specific genes. They also positively regulate their own expressions via binding to 
their promoters, therefore forming an auto-regulatory feedback loop.111,112 
LIF (Leukaemia Inhibitory Factor) is indispensable to maintain proliferation 
and pluripotency of mouse ESCs.103,113 LIF is a cytokine secreted by the murine 
embryonic fibroblasts (MEFs) (so called feeder cells) and is routinely added as a 
supplement in the culture medium in the case of a feeder-free culture of mouse ESCs. 
LIF removal leads to spontaneous differentiation.114 Upon binding to its membrane 
heterodimeric receptor (GP130/LIFR), LIF activates three major signalling 
pathways.102,113 First, the JAK/STAT3 signalling pathway involves the 
phosphorylation of JAK1 & 2 (Janus kinases), which then phosphorylates and 
activates STAT3 (Signal transducer and activator of transcription 3). Phosphorylated 
STAT3 forms a homodimer that is translocated into the nucleus where it regulates 
transcription of pluripotency-associated genes such as Klf4 and Nanog. Secondly, the 
PI3K/AKT pathway is activated upon LIF binding to it receptor. JAK proteins 
activate PI3K, which then phosphorylates and activates AKT kinases. AKTs 
inactivate GSK3 by phosphorylation of the latter at serine 9 and by favouring its 
nuclear export. GSK3 inactivation leads to upregulation of pluripotency-associated 
factors such as Nanog and c-Myc. The third signalling cascade activated by LIF is 
the MAPK/Erk pathway. JAK kinases phosphorylate SHP2, which then triggers a 
signalling cascade involving MEK and MAPK kinases. This cascade induces 
differentiation by down regulating pluripotency genes like Nanog and Tbx3. 
Therefore, LIF triggers not only pro-pluripotency pathways but also a pro-
differentiation pathway.  
Another crucial pathway for pluripotency maintenance is the canonical WNT 
signalling. In the absence of the glycoprotein WNT, GSK3 forms a complex with 
other proteins that binds, phosphorylates and triggers the proteosomal degradation of 
ß-catenin. Upon binding of WNT to the heterodimeric receptor Frizzled (FZ)/ LRP, 
GSK3 is recruited at the receptor and displaced from ß-catenin.115 This leads to an 
accumulation of unphosporylated ß-catenin, which enters the nucleus and 
upregulates pluripotency-associated genes such as Oct4.116 Although GSK3 is part 
of both the WNT and the PI3K/AKT pathways, the two pathways are actually 
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independent.117,118 Other regulatory pathways involving chromatin remodelers or 
non-coding RNA for instance, are important for self-renewal of mouse ESCs.102 
Figure 6. Regulatory networks controlling pluripotency maintenance and lineage commitment. Upon 
binding to its receptors, LIF activates three major intracellular pathways: the JAK/STAT3 pathway 
(in green), the PI3K/AKT pathway (in yellow) and the MAPK/Erk pathway (in blue). The canonical 
WNT pathway is also implicated in pluripotency maintenance (in purple). The core regulatory circuit 
is composed of NANOG, SOX2 and OCT4 forming an auto-regulatory feedback loop (in brown). 
Inhibitors of GSK3 and MEK (depicted as yellow boxed text) can be used as supplements in the 
culture medium in addition to LIF.  
 
To sustain pluripotency of mouse ESCs, two small molecule inhibitors may 
be added in a serum-free medium in addition to LIF. This culture medium is known 
as 2i/LIF. The GSK3 inhibitor called CHIR99021 has IC50 in the range of 5 - 10 nM 
for mouse GSK3α and GSK3ß (Figure 7. A).119 Treatment with CHIR99021 
increases cytosolic level of ß-catenin,119,120 which suggests that this molecule triggers 
the WNT pathway. However, this inhibitor might also block GSK3 in the PI3K/AKT 
pathway. The second small molecule supplemented in 2i/LIF medium is either of the 
two following MEK inhibitors: PD184352 is used as supplement together with 
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CHIR99021 and a FGF receptor inhibitor; PD0325901 is a more potent MEK 
inhibitor compared to PD184352 and is used in combination with CHIR99021 
(Figure 7. B and C). Inhibition of MEK1 and MEK2 blocks the pro-differentiation 
MAPK/Erk pathway. Initially, the GSK3 and MEK inhibitors were used without LIF 
to show that ESC derivation and self-renewal can be achieved by blocking 
differentiation without the need of any pluripotency activating stimuli.121 The two 
inhibitors are now widely used in combination with LIF to enhance pluripotency.122 
Mouse ESCs cultured in LIF containing medium present heterogeneous 
morphologies and gene expression patterns,123–125 whereas these two parameters are 
more homogenous for cells cultured in 2i/LIF.126–128 
Figure 7. Chemical structures of CHIR99021 (A), PD184352 (B) and PD0325901 (C). 
 
 1.2.2 Polycomb and Trithorax complexes in pluripotent stem cells 
 
Signalling cascades and external factors involved in pluripotency and self-
renewal were detailed in chapter 1.2.1. This chapter concerns the nuclear and 
chromatin-associated components regulating development and ESC proliferation. 
Compared to somatic cells, stem cells have a permissive transcription landscape and 
a highly dynamic and open chromatin.129–131 Two families of evolutionarily 
conserved regulators of gene expression are indispensable for proper embryonic 
development: Polycomb group (PcG) and Trithorax group (TrxG) proteins.132–134 
PcG and TrxG proteins were first identified as key repressors and activators, 
respectively, of the homeotic genes known as Hox genes in Drosophila.135,136 In 
yeast, mammals as well as Drosophila, PcG and TrxG proteins are organized in 
several types of multimeric protein complexes with different enzymatic activities 
towards chromatin. 
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Polycomb Repressive Complexes 
In mammals, PcG proteins form two distinct complexes: Polycomb repressive 
complexes 1 and 2 (PRC1/2), which have different subunit compositions and 
enzymatic activities.137 PRC2 catalyses the installation of mono-, di- and trimethyl 
groups on lysine 27 of histone H3.138,139 H3K27me3 is associated with gene 
silencing.140,141 H3K27me2 is localized at intergenic regions, whereas H3K27me1 is 
localized at active gene bodies.142 PRC2 complex contains the H3K27-specific 
methyltransferase EZH2 (or its homolog EZH1) comprising the catalytic SET 
domain. The other core components are the proteins EED, SUZ12 and 
RBAP46/48.132,133 The WD40 repeat protein EED is essential for PRC2 activity.143 
This subunit was reported to bind to repressive marks, including H3K27me3, 
therefore leading to allosteric activation of PRC2.144 This finding provides a 
mechanism for local spreading of H3K27me3. SUZ12 was demonstrated to be 
important for complex stability as well as activity145,146 and forms with RBAP46/48 
the minimal module for nucleosome binding.143 
Additional non-core proteins such as JARID2, AEBP2 and PCL proteins can 
be associated with PRC2 and modulate its activity and/or targeting.133 JARID2 was 
reported to play an important role in PRC2 recruitment to target genes.147,148 The zinc 
finger protein AEBP2 was reported to stimulate PRC2 activity145 and PCL proteins 
modulate PRC2 targeting and function.149–151  
PRC1 has a more heterogeneous composition compared to PRC2. Its catalytic 
subunit is RING1A or RING1B, H2AK119-specific E3 ubiquitin ligases. 
H2AK119Ub was shown to be involved in transcriptional repression of target 
genes152 and RING1A/B were found to have an essential role in repressing 
developmental regulators in mouse ESCs.153 The PRC1 complexes can be classified 
as canonical (containing PCGF4/2, CBX2/4/6/7/8, PHC1/2/3 and RING1A/B) or 
non-canonical (containing RYBP, KDM2B, PCGF1 and RING1A/B) depending on 
their subunit compositon.133 The non-canonical PRC1 subunit KDM2B is a H3K4- 
and H3K36-specific demethylase containing a CXXC domain, which binds to 
unmethylated CpG DNA. KDM2B was proposed to recruit non-canonical PRC1 to 
unmethylated CpG islands.154–156 The canonical PRC2 subunit PCGF4 enhances 
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ubiquitin ligase activity,157 while PHC proteins promote PRC1 clustering though 
polymerization.158 Protein Pc, the Drosophila counterpart of CBX proteins, binds to 
H3K27me3 through its chromodomain, therefore recruiting canonical PRC1 to 
H3K27me3-marked genes (Figure 8).139 The human PRC1-associated CBX proteins 
have lower affinity and specificity for H3K27me3, therefore questioning the validity 
of this recruitment mechanism for mammals.159 Observations of PRC1-mediated 
H2AK119 ubiquitination independently of PRC2 further challenge this hierarchical 
model.160,161 More recently, it was proposed that non-canonical PRC1-dependent 
H2AK119 ubiquitination leads to PRC2 binding and subsequent H3K27 methylation 
(Figure 8).162,163 Supporting this model, PRC2 complex containing AEBP2 and 
JARID2 was found to bind H2AK119Ub nucleosomes and this interaction promotes 
PRC2-mediated H3K27 methylation.164 
Figure 8. Interplay between PRC2, canonical and non-canonical PRC1 complexes. The classical 
model involves methylation of H3K27 by PRC2 (black arrow n°1.), local spreading by EED-mediated 
recruitment of PRC2 to H3K27me3 nucleosomes (black dotted arrow), canonical PRC1 recruitment 
via CBX proteins, which bind to H3K27me3 (black arrow n°2.) and subsequent H2AK119 
ubiquitination by canonical PRC1 RING1A/B (black arrow n°3.). The alternative model entails 
H2AK119 ubiquitination by non-canonical PRC1 RING1A/B (grey arrow n°I.), recruitment of PRC2 
to H2AK119Ub nucleosomes (grey line n°II.) and subsequent H3K27 methylation by PRC2 (grey 
arrow n°III.) 
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MLL complexes 
The Trithorax group is a heterogeneous family of proteins including 
chromatin modifiers and remodelers associated with active gene transcription.165 
This group encompasses the NURF and SWI/SNF complexes as well as the 
COMPASS family. In yeast, SET1 is the TrxG protein responsible for methylation 
of H3K4. SET1 was found within a multiprotein complex called COMPASS 
(complex of proteins associated with SET1). In Drosophila, the COMPASS family 
is composed of 3 multimeric complexes, SET1, Trithorax (Trx) and Trithorax-related 
(Trr). In mammals, this family contains 6 members (two homologs of each 
Drosophila complex) called MLL complexes (Table 1).133 The catalytic subunit of 
mammalian MLL complexes consists of one of the SET-domain containing proteins 
with a H3K4-specific methyltransferase activity, SET1A/B or MLL1/2/3/4.166,167 All 
3 H3K4 methylation states are associated with active gene transcription.168 
H3K4me2 and H3K4me3 are mainly found next to transcription start sites (TSSs), 
whereas H3K4me1 is located at enhancers.168,169 WDR5, RBBP5, ASH2L and 
DPY30 (WRAD) together with the catalytic subunit form the core MLL 
complexes.133 WDR5 is important for the stability of the complex.170 Allis and 
coworkers proposed that this subunit binds to H3K4me2 nucleosomes, therefore 
serving as a recognition module.171 However, another study showed that the WDR5 
protein does not interact with H3K4 and is not able to discriminate between 
unmodified, mono-, di- or tri-methylated H3 tail.172 ASH2L was reported to contain 
a DNA-binding motif suggesting a recruitment role for this subunit.173,174 ASH2L 
together with RBBP5 and the SET-containing protein MLL1 were proposed to form 
a joint catalytic centre for methylation of H3K4.175 RBBP5 is essential for complex 
stability and was proposed to undergo a phosphorylation switch controlling core 
complex formation and activity.176 As for DPY30, it was shown to modulate MLL-
mediated H3K4 methylation and to be crucial for ESC differentiation.177 
Additionally to WRAD, other proteins can associate with SET proteins such as 
Menin, which modulates activity and targeting of MLL1/2;178 the H3K27-specific 
demethylase UTX, which coordinates H3K27me3 demethylation with methylation 
of H3K4 at TSS of active genes;179 and the unmethylated CpG-binding protein CFP1, 
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which regulates target sites of SET1A/B.180 MLL complexes have non-redundant 
roles. Indeed, SET1A/B are considered as the default H3K4 methyltransferases and 
deposit di- as well as tri-methyl marks mainly at active promoters.181 MLL1/2 appear 
to be more specific for Hox genes.181 MLL2 was shown to deposit H3K4me3 at 
bivalent promoters (detailed in 1.2.3).182,183 MLL3/4 install H3K4me1 at poised 
enhancers.184 Importantly, MLL3/4 were found to be part of a macromolecular 
complex called ASCOM (ASC-2 complex), which acts as a transcriptional 
coregulator.185 
 
Mammalian 
TrxG complex 
Subunit composition 
(non-exhaustive) 
Main function and redundancy 
SET1A SET1A, WDR5, ASH2L, 
RBBP5, DPY30, CFP1 
Default H3K4 methyltransferase, 
deposits di- and tri-methyl at active 
promoters. Redundant with SET1B 
SET1B SET1B, WDR5, ASH2L, 
RBBP5, DPY30, CFP1 
Default H3K4 methyltransferase, 
deposits di- and tri-methyl at active 
promoters. Redundant with SET1A 
MLL1 MLL, WDR5, ASH2L, 
RBBP5, DPY30, Menin 
Deposits mono-, di- and tri-methyl on 
H3K4. Non-redundant with other MLL 
complexes 
MLL2 MLL2, WDR5, ASH2L, 
RBBP5, DPY30, Menin 
Deposits mono-, di- and tri-methyl on 
H3K4. Among its targets are bivalent 
developmental genes. Non-redundant 
with other MLL complexes 
MLL3 MLL3, WDR5, ASH2L, 
RBBP5, DPY30, UTX 
Deposits H3K4me1 at poised 
enhancers. Can be part of ASCOM 
complex. Redundant with MLL4 
MLL4 MLL4, WDR5, ASH2L, 
RBBP5, DPY30, UTX 
Deposits H3K4me1 at poised 
enhancers. Can be part of ASCOM 
complex. Redundant with MLL3 
Table 1. Subunit composition and functions of mammalian MLL complexes. 
 
It is worth noting that the nomenclature of proteins MLL2 and MLL4 can be 
confusing in the literature.186 MLL2 is sometimes named MLL4 and inversely. In 
this work, MLL2 corresponds to the Trithorax homolog KMT2B, whereas MLL4 
corresponds to the Trithorax-like homolog KMT2D. 
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PcG and TrxG protein regulate gene expression 
In mouse, homozygous gene deletion of any of the 6 TrxG proteins 
(SET1A/B, MLL1/2/3/4) leads to developmental failure and death of the embryo, 
highlighting the crucial role of MLL complexes in development.187–190 The same 
phenotype is observed for double knockouts of EZH2, EED, SUZ12 or RING1B, 
demonstrating that PcG proteins are essential for proper embryonic 
development.146,191–194 In mouse ESCs, the two PcG complexes are dispensable for 
pluripotency maintenance but required for proper differentiation.195  
H3K27me3 is widely distributed in the genome and spans large genomic 
regions, whereas H3K4me3 forms smaller peaks. The high abundancy of H3K27 
methylation states (~ 20 % H3K27me1, ~ 50 % H3K27me2 and ~ 10 - 20 % 
H3K27me3 in mouse ESCs196) is consistent with the fact that H3K27 methylation is 
associated with reversibly silenced regions (facultative heterochromatin) unlike the 
DNA- and H3K9-methylation, which impose a more static gene repression at 
centromeres and telomeres (constitutive heterochromatin).  
Originally discovered at Hox genes in Drosophila, it is currently the 
consensus that PcG and TrxG proteins are found genome-wide in mammals and are 
associated with gene repression and activation, respectively. However, the way in 
which these complexes lead to gene expression control is more elusive. It was shown 
that PRC1 imposes gene repression via several mechanisms: it blocks RNA 
Polymerase (Pol) II,197 inhibits the nucleosome remodeling complexes 
SWI/SNF198,199 and induces chromatin compaction.200–202 Within PRC2, the catalytic 
subunit EZH2 binds to DNA methyltransferases and thus could serve as a recruitment 
platform for DNA methylation-mediated repression.203 As for TrxG proteins, several 
links were found between active gene transcription, MLL complexes and H3K4me3. 
TFIID, part of the RNA Polymerase II pre-initiation complex, contains the protein 
TAF3, which has a PHD finger binding specifically to H3K4me3.63 This mark is also 
recognized by the PHD finger of BPTF, a subunit of the remodeling complex 
NURF.56,204 The Drosophila ASH2 protein was demonstrated to affect the 
phosphorylation status of RNA Polymerase II, therefore influencing its activity.205 
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Several studies suggest that PcG and TrxG complexes establish and maintain 
repressive and active transcriptional states by installing histone PTMs that inhibit 
binding and/or activity of the opposite complex(es). Indeed, PRC2 binding and 
activity on H3K27 are inhibited by active chromatin marks such as H3K4me3206,207 
and H3K27ac.208–211 In the same way, the repressive chromatin mark H3K27me3 
inhibits binding and activity of the SET1A complex.212  
 
Nuclear organization of chromatin into subcompartments 
One aspect that is believed to be crucial for effective activation and silencing 
is the sequestration of genes into dedicated subcompartments.213 Analysis of 
chromatin contacts by chromatin conformation capture (3C) techniques revealed 
chromosomal regions within which sequences preferentially contact each other.214,215 
These so called topologically associated domains (TADs) were proposed to organize 
the genome according to gene expression state and histone modifications.214–218 Such 
architectural features are believed to keep genes in a local environment enriched in 
activation- or repression-associated proteins. In Drosophila, PcG proteins are found 
in discrete foci, named Polycomb bodies where genes are silenced.219,220 Genomic 
regions that are distant or even located on different chromosomes were found to 
associate into Polycomb bodies.221,222 In mammalian cells, the existence of Polycomb 
bodies is not yet confirmed. PRC1 was proposed to function as a “3D organizer” and 
to spatially constraint genes in a silenced network.223 Polymerization of PHC2, a core 
component of PRC1, plays an essential role in PRC1 clustering as well as in robust 
gene silencing and might be key to the organization of silenced genes into Polycomb 
bodies.158 Similarly, transcriptionally active genes are organized into functional 
compartments called transcription factories.224,225 Intra- and interchromosomal 
interactions occur within sets of active genes, therefore forming transcription 
foci.226,227 Moving out of the factories switches off gene transcription, whereas 
induction provokes relocation of a gene into a transcription factory.226,228 This 
demonstrates the intimate link between active transcription and location in such 
subcompartments. Cook and coworkers counted more than 2’000 extranucleolar 
RNA Pol II and III transcription factories per human nucleus.229,230 They also 
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measured a diameter of ~ 70 - 80 nm for each factory and calculated that each factory 
contains between 20 and 30 active RNA Pol II. A transcription factory can be 
described as a subnuclear compartment where several RNA Pol II units transcribe 
distal genes as well as genes located on different chromosomes. 
How TrxG and PcG proteins are recruited to their target genes is a 
longstanding question. In Drosophila, Polycomb and Trithorax responsive elements 
(PREs and TREs) are genomic regions that recruit Pc and Trx complexes, 
respectively. For PREs, this recruitment is thought to take place via interaction with 
transcription factors such as PHO, which contains a sequence-specific DNA-binding 
domain.231–233 However, no mammalian PREs and TREs have been described until 
now. CpG islands are overrepresented in PcG targets and were proposed to contribute 
to PcG recruitment.234 As previously mentioned, some subunits of MLL and 
Polycomb complexes are suspected to have a role in recruitment (CFP1, WDR5, 
ASH2L for MLL complexes and KDM2B, JARID2, PCL proteins for Polycomb 
complexes). Finally, non-coding RNA was suggested to recruit and modulate PcG 
and TrxG protein complexes.235–240 
 
1.2.3 Bivalent chromatin decorates developmental genes in 
embryonic stem cells 
 
H3K4me3 and H3K27me3 are associated with opposite gene expression 
states and are present at different genomic locations in somatic cells. However, these 
two marks are not mutually exclusive. In 2006 and 2007, several groups found 
H3K4me3 and H3K27me3 to coexist at promoters of key developmental genes 
(mainly TF genes) in mouse as well as in human ESCs.241–244 These so called bivalent 
domains, defined as large H3K27me3 regions harbouring smaller H3K4me3 regions, 
are not only found at key developmental genes but also at genes controlling 
morphogenesis and encoding cell surface receptors.245 Bivalent genes are repressed 
or expressed at low levels and bivalency resolves upon differentiation, leaving the 
gene marked with either H3K4me3 or H3K27me3 or none of them (Figure 
9).241,245,246 Therefore bivalent chromatin was proposed to keep developmentally 
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important genes silenced but poised for activation in pluripotent stem cells. Bivalent 
domains were also detected in more differentiated states and in cancer cells, although 
at lower levels.245–256 The correlation between bivalency and pluripotency led to the 
hypothesis that bivalent chromatin reflects lineage potential and keeps the plasticity 
(or “stemness”) of ESCs.245 However, the function(s) of bivalent domains is (are) 
still a subject of debate. In 2013, close to 4’000 and 3’000 genes were reported to be 
bivalent in human and mouse ESCs, respectively and more are discovered every 
year.257 These numbers represent ~ 13 % and ~ 20 % of proteins coding genes in 
mouse and human, respectively.258 Ku et al. mapped the occupancy of Polycomb 
complexes genome-wide by ChIP-seq in human and mouse ESCs and classified 
bivalent domains into two functionally distinct categories according to their PRC1 
occupancy.259 The authors found that PRC2 occupies essentially all bivalent genes, 
whereas PRC1 occupies a conserved subset of them. The PRC1-positive bivalent 
genes are more efficient at retaining H3K27me3 upon differentiation, cover larger 
genomic regions and are more enriched in TF genes, compared to the PRC1-negative 
bivalent genes. 
Figure 9. Schematic view of epigenetic bivalency. In pluripotent stem cells, such as ESCs, the 
coexistence of H3K4me3 and H3K27me3 represses key developmental genes (lineage-specific 
genes). After differentiation, bivalent genes remain marked with either H3K4me3 (rendering gene 
transcription active) or H3K27me3 or none of them (both keep genes repressed). 
 
Bivalent marks are present in an asymmetric fashion on nucleosomes 
The discovery of bivalent chromatin raised the question of how H3K4me3 
and H3K27me3 are distributed on nucleosomes: Are H3K4me3 and H3K27me3 
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present on the same nucleosomes (bivalent nucleosomes) or on different 
nucleosomes? Do H3K4me3 and H3K27me3 reside on the same H3 or on opposite 
H3 molecules? Are H3K4me3 and H3K27me3 randomly distributed or one 
conformation is preferred? To answer these questions, several techniques were used 
and are detailed below. 
ChIP is a widely used method to map histone modifications enrichment 
genome-wide.260 In this technique, fixed cells are sonicated to fragment chromatin 
and the protein (or mark) of interest is then immunoprecipitated. The recovered DNA 
can be analysed by various techniques such as quantitative polymerase chain reaction 
(qPCR), micro-chip or sequencing. Most of the bivalent domains were discovered by 
ChIP-based methods and declared ‘bivalent’ when both H3K4me3 and H3K27me3 
were detected. Although this technique is informative about enrichment of single 
histone modifications, ChIP data have to be interpreted carefully when considering 
combinations of histone modifications. Indeed, two marks can appear as if they are 
enriched at the same loci but might originate from different cell subpopulations or 
from different alleles. Sequential ChIP (or Re-ChIP) overcomes this limitation, by 
immunoprecipitating the chromatin recovered from a first IP. Bernstein et al. used 
Re-ChIP to show the coexistence of H3K4me3 and H3K27me3 at the Irx2 
promoter.241 The second reason why conventional ChIP data are complex to interpret 
when considering a pair of marks is because it yields relative and not quantitative 
enrichments. Bivalent domains are declared ‘bivalent’ when levels of H3K4me3 and 
H3K27me3 are above certain thresholds. These thresholds might be set at different 
values in different research groups rendering impossible the comparison of ChIP data 
coming from different sources. In 2015, Grzybowski et al. developed a ChIP-seq-
based method in which semi-synthetic barcoded nucleosomes are used as internal 
standards, enabling to measure actual histone modification densities.261 With this 
method, the authors found the sum of H3K4me3 and H3K27me3 densities being 
superior to 100 % for transcriptionally silent genes. This confirms the coexistence of 
H3K4me3 and H3K27me3 on the same nucleosomes at ~ 35 % of all genes in mouse 
ESCs (considering protein coding genes258, 35 % represents ~ 7’900 genes). 
Furthermore, the authors classified bivalent nucleosomes into two categories: the 
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canonical bivalency, in which case genes are silent, contain between 70 - 100 % 
H3K27me3 and 1 - 60 % H3K4me3 near their TSS, whereas a new class of formally 
bivalent and highly transcriptionally active genes are characterized by nearly 100 % 
H3K4me3 and between 10 - 40 % H3K27me3. This finding suggests that the 
dominant modification controls the transcriptional state. 
Knowing that H3K4me3 and H3K27me3 are indeed present on the same 
nucleosomes, different conformations are possible: symmetric (with both H3 copies 
carrying K4me3 and K27me3), cis asymmetric (with one H3 molecule unmodified 
and the other H3 carrying K4me3 as well as K27me3) and trans asymmetric bivalent 
nucleosomes (with K4me3 on one H3 copy and K27me3 on the other H3 tail). 
Several methods were used to obtain information about the conformation of bivalent 
nucleosomes. In 2012, Voigt et al. used an immunoaffinity purification method on 
native mononucleosomes followed by MS to show that H3K4me3 and H3K27me3 i) 
coexist on the same nucleosomes and ii) are present on different H3 molecules.246 
This trans asymmetric conformation (Figure 10. A) was confirmed in 2016 by Sen 
et al.262 More recently, Shema et al. adopted a single molecule approach using total 
internal reflection fluorescence (TIRF) microscopy and fluorescently labelled 
antibodies to analyse mononucleosomes isolated from mouse ESCs.263 The authors 
showed that 0.5 % of nucleosomes in mouse ESCs are truly bivalent with both marks 
on the same nucleosomes (considering a nucleosome repeat length of ~ 190 bp, this 
represents ~ 147’000 nucleosomes).2,258 They also demonstrated that the majority (94 
%) of bivalent nucleosomes are trans asymmetric. Contrary to Voigt et al., Shema et 
al. found that bivalent nucleosomes modified on the same tail (symmetric or cis 
asymmetric) do actually exist and represent 6 % of bivalent nucleosomes. 
In summary, bivalent domains have the following characteristics: 
1. The quantities of H3K27me3 and H3K4me3 are 70 - 100 % and 1 - 60 %, 
respectively.261 This implies that some nucleosomes in bivalent domains 
carry only H3K27me3 (in a symmetric or asymmetric fashion). 
2. H3K4me3 and H3K27me3 are present on the same nucleosomes in a trans 
asymmetric fashion.246,261,263 
3. A small portion of bivalent nucleosomes have the two marks on the same 
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histone H3 (either in a cis asymmetric or in a symmetric configuration).263 
In view of these findings, a bivalent promoter can be depicted as a genomic 
region containing a majority of trans asymmetric bivalent nucleosomes, some 
H3K27me3 nucleosomes and rare symmetric or cis asymmetric bivalent 
nucleosomes (Figure 10. B). 
Figure 10. Bivalent marks are found asymmetrically in mouse ESCs. A. Schematic view of a trans 
asymmetric bivalent nucleosome. B. Schematic view of the nucleosome composition of a bivalent 
domain, containing mainly trans asymmetric bivalent nucleosomes, some H3K27me3 nucleosomes 
(symmetric or asymmetric) and a few nucleosomes with K4me3 and K27me3 on the same H3 tail 
(depicted here as symmetric bivalent nucleosome). “me” represents trimethylation at H3K4 and 
H3K27 in green and red, respectively. 
 
Little is known about the 3D organization of bivalent domains. One can 
speculate that they are gathered into subnuclear compartments, similarly to 
Polycomb bodies and transcription factories, where they might be coregulated by 
Polycomb and Trithorax proteins. 
 
Installation, regulation and resolution of bivalent domains 
Bivalent marks are not randomly distributed since they are present on the 
same nucleosomes and for the majority of nucleosomes, on opposite H3 tails. This 
suggests mechanisms that write, maintain and erase bivalent marks in a controlled 
manner. Concerning regulation and function(s) of bivalent domains, the following 
interrogations remain to be answered:  
1. How do PRC2 and MLL complexes write bivalent marks at promoters of 
developmental genes? Which mark is deposited first?  
2. How is bivalency maintained in ESCs and resolved upon differentiation? 
What mechanism controls whether a bivalent gene resolves to active or 
repressed state?  
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3. Do bivalent domains have biological function(s)? Is asymmetry critical for 
its function(s)? How does asymmetry influence the binding and enzymatic 
activity of chromatin effectors? 
Currently, these questions have only preliminary and sparse answers (Figure 
11). De novo appearance of bivalent domains is observed in several cases such as 
reprogramming of somatic cells into iPSCs,264 mitosis-to-meiosis during germ line 
production265,266 and even during differentiation into adult tissue cells.247,249 On the 
other hand, differentiation of ESCs witnesses an important decrease in the number of 
bivalent genes.241,245,246 Moreover, bivalent domains are dynamically regulated 
during the cell cycle in pluripotent cells with an increased abundance in G1 phase.267 
These observations suggest a tight regulation of the installation, maintenance and 
removal of bivalent marks. PRC2 is responsible for installing H3K27me3 and 
occupies nearly all bivalent regions.259 MLL2 was identified as the H3K4 
methyltransferase responsible for installing H3K4me3 at bivalent genes in 
ESCs.182,183,267 PRC2 activity is inhibited by the presence of H3K4me3 on the same 
tail (cis inhibition), whereas SET1-like H3K4 methyltransferases binding and 
activity are inhibited by the presence of H3K27me3 on the same tail.206,207,212 These 
findings are in line with the fact that bivalent marks are present in majority in trans 
conformation on nucleosomes. However, how MLL2 and PRC2 are recruited to 
bivalent genes is unclear. Lynch et al. proposed that the signal for chromatin 
bivalency is encoded into the local DNA sequence.268 Indeed, bivalent promoters are 
enriched in CpG dinucleotides and the majority of bivalent genes (93 % in stem cells) 
overlaps with CpG islands (CGIs),245,247,269 proposed to be necessary and sufficient 
to recruit PRC2.234 However, not all CGIs/promoters are bivalent and bivalency is 
also found at intragenic CGIs,270 at gene bodies and upstream of TSSs.249,262 
Therefore, CGIs are only a partial answer to the question of recruitment. 
MicroRNA,271 crosstalks with H2A.Z or other histone modifications248,262,269 and 
unmethylated CpGs272,273 are potential regulatory mechanisms for installation and 
maintenance of bivalent marks. Concerning the resolution of bivalency, the H3K27-
specific demethylase UTX was proposed to play a role in the activation of bivalent 
genes during differentiation of ESCs.274 Downregulation of LSD1 during 
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differentiation might represent an additional mechanism for the activation of bivalent 
genes.275 
Whether bivalent domains have a biological function remains unclear. First 
of all, co-occupancy of PcG and TrxG proteins was observed not only in mammals 
but also in Drosophila,276,277 suggesting that bivalent/poised state is a conserved 
feature among species. Two opposite views have emerged concerning a potential 
function of bivalent domains. The above-mentioned hypothesis proposed by 
Bernstein et al. suggests that bivalency keeps developmental genes silent but poised 
for activation. This model is supported by the resolution of bivalency for the majority 
of bivalent genes upon differentiation241,245,246 and by the presence of bivalent 
chromatin at developmental genes in germ lines.37,278–280 Furthermore, poised RNA 
Pol II (phosphorylated at serine 5) was detected at bivalent regions281 and was shown 
to be important for proper differentiation,282 also supporting the poised state 
hypothesis. However, despite the global decrease in the number of bivalent genes in 
adult tissues and somatic cells compared to ESCs, some genes acquired de novo 
bivalency in adult tissues, suggesting an alternative role for bivalent domains.249 
Bivalency was proposed to have a protective role from aberrant DNA 
hypermethylation, a hallmark of cancer.265,269,283,284 On the other hand, several 
studies suggest that bivalent state does not have a particular function. Maupetit-
Méhouas et al. state that bivalent chromatin is the default state of inactive 
CGIs/promoters.284 Lynch et al. suggest that bivalency is the result of the competition 
between Polycomb silencing and transcriptional activation.268 This view is consistent 
with the observation that bivalent regions with H3K4me3 > H3K27me3 have in 
general higher expression levels than bivalent regions with H3K4me3 < 
H3K27me3.261,269 Finally, loss of H3K4me3 at bivalent promoters in MLL2-/- mESCs 
does not prevent activation of these genes upon retinoic acid induced differentiation, 
arguing against the model in which the bivalent state controls gene expression.182,183 
Although the poised gene expression hypothesis seems to be the most widely 
accepted among scientists, some evidence argue against this model. 
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Figure 11. Overview of potential function(s), subnuclear organization and mechanisms regulating 
installation and resolution of bivalent domains. PRC2 and MLL2 install H3K27me3 and H3K4me3, 
respectively, at promoters of developmental genes. Upon resolution, bivalent genes are converted to 
either active or repressed genes. Dashed arrows indicate elements that might influence the formation 
of bivalent domains. Whether bivalent chromatin have a biological function and how it is organized 
in the nucleus are still unclear. 
 
In conclusion, bivalency is an intriguing combination of histone PTMs 
associated with opposite transcriptional states. Present at high levels in pluripotent 
cells, it decorates inactive key developmental genes. Although researchers have 
reached an agreement on the trans asymmetric conformation of bivalent 
nucleosomes, their biological function is still a subject of debate. Several questions 
about bivalent domains remain open. In particular, how these domains are organized 
in the 3D space within the nucleus is uncertain. How bivalent domains are 
dynamically regulated during cell cycle and during cellular differentiation is also 
unknown. In the current work, we designed probes targeting bivalent marks in order 
to answer these questions. To test in vitro the binding of these probes to bivalent 
PTMs, we needed access to histones with site-specific methylation marks. To this 
end, we used expressed protein ligation and synthetic peptides. 
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1.3 Protein engineering to introduce modifications in nucleosomes 
 
 1.3.1 Site-specific introduction of modifications in proteins 
 
Having access to large amounts of homogeneously labelled or modified 
proteins is central to study their function. For example, labelling proteins with small 
molecule fluorophores is crucial for many microscopic applications.285 Introduction 
of unnatural amino acids (Uaas) such as crosslinkers can give insights about a 
protein’s interactome.286,287 Introducing PTMs in a site-specific manner into proteins 
enables to investigate their biological effects as well as to develop probes that target 
modified proteins. Multiple methods are available to site-specifically introduce non-
proteinogenic amino acids into proteins: cysteine-directed conjugation, genetic code 
expansion (such as amber codon suppression), native chemical ligation (NCL) and 
its variant, expressed protein ligation (EPL) (Figure 12). NCL and EPL are described 
in 1.3.2. 
First described by Schultz’s and Chamberlin’s groups in 1989, genetic code 
expansion involves the development of an orthogonal aminoacyl-tRNA 
synthetase/tRNA pair.288,289 In this method, the Uaa is encoded by the amber codon 
UAG such that an engineered tRNA synthetase loads the Uaa on the CUA-codon 
tRNA. In a second step, the ribosomal machinery translates the mRNA into protein 
by incorporating the Uaa in place of the amber codon (Figure 12. A). This technique 
can be applied in bacteria, yeast as well as mammalian cells and a large variety of 
non-proteinogenic amino acids can be introduced into proteins. The same Uaa can 
be incorporated at multiple sites within one protein.290 Genetic code expansion was 
adapted to four-base codons to introduce multiple Uaas in proteins in an orthogonal 
manner.291,292 However, the main challenge is to reach orthogonality with the 20 
natural aminoacyl-tRNA synthetase/tRNA pairs. One of the drawback of this 
technique is the lack of modularity. Indeed, for every Uaa of interest, a new pair of 
aminoacyl-tRNA synthetase/tRNA needs to be developed. Pyrolysyl-tRNA 
synthetase/tRNA pairs were developed to introduce acetyllysine as well as more 
exotic PTMs in H3.293–295 Precursors of mono- and dimethyllysine can be 
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incorporated into H3 by amber codon suppression and subsequently converted by 
chemical means (Figure 12. B).296–298 This method can also be used to introduce 
lysines with a thiol moiety, subsequently ligated with a ubiquitin thioester, yielding 
a native isopeptide bond (Figure 12. B).299 
Figure 12. Site-specific introduction of Uaas in proteins and more specifically of PTMs into histones. 
A. Amber codon suppression can be used to produce acetyllysine histones. B. Precursors can be 
incorporated by amber codon suppression into histones and then converted to mono- or 
dimethyllysine. δ-thiol lysine can be incorporated into proteins and subsequently ligated with 
ubiquitin thioester resulting in an isopeptide bond. C. Cysteine can be converted to a variety of histone 
PTMs analogues as well as S-S linked ubiquitin. D. Dehydroalanine can be used to convert cysteine 
or phosphoserine into a variety of histone PTMs. 
 
Cysteine-directed conjugation makes use of the nucleophilicity of the sulphur 
atom to site-specifically label proteins carrying one or several cysteine mutation(s). 
This method is straightforward, therefore enabling large amounts of modified 
proteins to be synthesized. However, these reactions are not traceless since the 
sulphur atom replaces the native γ-carbon atom of the side chain. Concerning histone 
PTMs, cysteine-directed conjugations were applied to obtain methyl- and 
acetyllysine analogues as well as methylarginine analogues (Figure 12. C).300–302 
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This method was also used to produce disulfide linked ubiquitinated or sumoylated 
histones (Figure 12. C).48,303,304 Finally, dehydroalanine represents an alternative to 
obtain modified proteins.305 Dehydroalanine can be obtained either from cysteine 
(incorporated by conventional mutagenesis) or from phosphoserine (incorporated by 
amber codon suppression) and subsequently converted to histone PTMs or histone 
PTMs mimics (Figure 12. D).306–308 
 
1.3.2 Expressed protein ligation to introduce modifications in 
histones 
 
NCL consists in ligating an N-terminal cysteine peptide with a C-terminal 
thioester peptide, yielding a native amide bond. This traceless ligation is used in EPL 
to join a peptide with a recombinant protein. EPL is a method of choice to obtain 
milligram amounts of site-specifically modified histones. Typically, one of the two 
pieces to ligate is a synthetic peptide obtained by solid phase peptide synthesis 
(SPPS), whereas the other piece is recombinantly expressed. 
 
Solid phase peptide synthesis  
SPPS was developed in the group of Robert Bruce Merrifield in the 60s and 
is based on the successive addition of amino acids on a solid support (Figure 
13).309,310 In SPPS, the peptide is synthesized from the C- to the N-terminus. To avoid 
multiple additions of the same amino acid on the peptide, amino acid’s α-amino 
group are protected by tert-butoxycarbonyl (Boc) or fluorenylmethyloxycarbonyl 
(Fmoc) protecting groups. The α-carboxy group of each amino acid is activated prior 
to coupling with the peptide. For this purpose, various coupling reagents are 
available, the most common being N,N’-dicyclohexylcarbodiimide (DCC), HBTU 
and HATU. The Hünig’s base N-ethyldiisopropylamine (DIPEA) is used during 
activation. Unreacted reagent is washed away and α-amino group deprotection is 
performed (with piperidine for Fmoc group or with trifluoroacetic acid (TFA) for 
Boc group). Reactive side chains carry orthogonal protecting groups, which are 
removed upon cleavage from the resin (with TFA for Fmoc SPPS or with 
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hydrofluoric acid (HF) for Boc SPPS). Originally, Boc was used as α-amino 
protecting group. However, anhydrous HF requires specific handling. For this 
reason, the milder Fmoc strategy is generally preferred. Automation of SPPS allows 
to synthesize peptides with minimal handling. 
Figure 13. Fmoc SPPS with hydrazine 2-chlorotrityl resin results in peptide hydrazide. A. Each SPPS 
cycle starts with Fmoc deprotection by piperidine treatment, followed by reaction with Fmoc-
protected pre-activated amino acid. Following piperidine deprotection of the last added amino acid, 
resin cleavage and side chain deprotection is performed by reacting with TFA. Fmoc group and 
chlorotrityl linker are indicated in red and blue, respectively. B. Structures of reagents used for Fmoc 
SPPS. 
 
A wide variety of non-proteinogenic amino acids can be incorporated into 
peptides by SPPS. However, full length proteins are often required to study their 
functions. With an efficiency of ~ 99 % for each coupling steps, the length limit of 
SPPS is ~ 50 - 60 amino acids. For instance, the theoretical yield for the synthesis of 
a peptide consisting of 50 residues is 61 % (considering a 99 % yield for each cycle). 
Ligating two (or more) peptides represents a strategy to synthesize full length 
proteins. 
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Native chemical ligation 
Several chemical strategies exist to join two unprotected peptides and obtain 
a native amide bond: Staudinger ligation,311,312 KAHA ligation,313,314 salicylaldehyde 
ester- mediated ligation315 and NCL. NCL joins two peptides in aqueous conditions 
and produces a native peptide bond.316,317 In NCL, the amino terminal peptide (N- 
fragment) harbours a C-terminal thioester, which reacts in a trans-thioesterification 
reaction with the N-terminal cysteine of the carboxyl terminal peptide (C-fragment) 
(Figure 14). The formed thioester then undergoes an S to N acyl shift, therefore 
yielding a native amide bond. Thioester peptides can be produced by Boc SPPS via 
benzylic thiols or alkyl thioesters.318–320 Fmoc SPPS also enables to obtain C-
terminal thioester peptides by using a diamino benzoic acid (Dbz) linker or by 
producing N-methyl cysteine peptides or bis(2-sulfanylethyl) amido (SEA) peptides 
as surrogates.321–323 An alternative strategy to produce thioester peptides by Fmoc 
SPPS consists in converting in situ a hydrazide moiety to an azide by addition of 
sodium nitrite (NaNO2) followed by addition of a small molecule thioester, such as 
2-mercaptoethanesulfonic acid sodium (MESNa) or 4-mercaptophenylacetic acid 
(MPAA).324,325 The C-terminal hydrazide group can be easily obtained via SPPS by 
reacting 2-chlorotrityl resin with hydrazine prior to adding the first amino acid 
(Figure 13).326 
Figure 14. Mechanism of native chemical ligation. The C-terminal thioester on the N-fragment is 
obtained from a hydrazide moiety by reaction with NaNO2 and a thiol (MPAA or MESNa). The 
thioester is then reacted with the N-terminal cysteine of the C-fragment in a trans-thioesterification. 
The formed thioester subsequently undergoes S to N acyl shift, yielding a native peptide bond between 
the N- and C-fragments. 
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Expressed protein ligation 
Ligating two synthetic peptides via NCL limits the length of the ligation 
product to ~ 120 amino acids. However, most protein sequences have more residues. 
Successive NCLs can be performed to produce fully synthetic proteins. However, 
EPL represents a powerful alternative to obtain full length modified proteins. First 
described by Muir et al., EPL makes use of recombinant protein expression and 
ligates two fragments in the same way than NCL.327 In EPL, either the C- or the N-
fragment is a recombinant protein and the other fragment is a synthetic peptide that 
carries single or multiple Uaa(s). This high modularity enables the installation of 
modifications both at the N- or C-terminal end of proteins.  
In case the modification to incorporate is close (< 60 residues) to the N-
terminus in the amino acid sequence, the N-fragment with C-terminal thioester is 
obtained from a synthetic peptide hydrazide and the C-fragment is obtained 
recombinantly as a fusion protein with a cleavable tag at the N-terminus, such as 
SUMO (Figure 15. A).328–330 Upon SUMO cleavage by the SUMO protease ULP1, 
the N-terminal cysteine is obtained. Other tags and their corresponding proteases 
were also used to produce recombinant proteins with N-terminal cysteine: factor 
Xa,331 tobacco etch virus (TEV),332 thrombin333 and 3Cpro proteases.334 In case the 
modification to introduce is close to the C-terminal (< 60 residues), the C-fragment 
containing the N-terminal cysteine is produced by SPPS and the N-fragment is 
recombinantly expressed as a fusion protein with an intein (Figure 15. B).327 Inteins 
are self-excising protein domains found in various organisms, which ligate the 
flanking polypeptides in a process called protein (cis-)splicing.335,336 Inteins also 
exist as split unstructured polypeptides that assemble and refold prior to (trans-) 
splicing.337,338 The first step in splicing is an N to S acyl shift (Figure 15. B). 
Engineered (split) inteins, which are unable to proceed with the following steps of 
splicing, can be reacted with an exogenous thioester to form the N-fragment with a 
C-terminal thioester.327,339–341 A split intein column can be used for one-step 
purification and thioester formation.342 
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Figure 15. Expressed protein ligation is a semi-synthesis strategy that combines NCL and recombinant 
protein expression to obtain full length modified proteins. A. The N-fragment harbouring the 
modification (displayed as a red circle) is obtained by SPPS as a peptide hydrazide and is converted 
in situ to a thioester. The N-terminal cysteine of the C-fragment is obtained upon cleavage of the 
SUMO tag with ULP1. Subsequent ligation reaction yields an N-terminally modified full length 
protein. B. The C-fragment carrying the modification is produced by SPPS with an N-terminal 
cysteine. The N-fragment is expressed as a fusion protein with an intein. After N to S acyl shift, the 
intein thioester is reacted with an exogenous thioester to yield the N-fragment thioester. Subsequent 
ligation reaction leads to a C-terminally modified full length protein. 
 
Ligation and desulfurization 
The product of NCL contains a cysteine residue at the junction point. Due to 
scarcity of this amino acid in proteins, ligation methods at non-cysteine junction 
points have emerged and desulfurization represents the most widespread.343,344 
Desulfurization of cysteine results in alanine, whereas desulfurization of ß- or γ-thiol 
amino acids results in a variety of proteinogenic amino acids, such as valine,345,346 
phenylalanine,347 glutamine,348 threonine,349 leucine,350,351 glutamate,352 asparate,353 
tryptophan,354 arginine,355 proline356–358 as well as isopeptide bonds on lysine.359,360 
Desulfurization was originally performed with Pd/Al2O3 or Raney Nickel.343,344 
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However, Pd/Al2O3 desulfurization can cause degradation of protecting groups and 
Raney Nickel reaction can lead to epimerization of secondary alcohols.361,362 For 
these reasons, a milder metal-free radical-based desulfurization was developed 
(Figure 16).363 According to Wan & Danishefsky, the radical desulfurization starts 
with the removal of a hydrogen atom from cysteine by reaction with the radical 
initiator VA-044, resulting in a sulphur radical (Figure 16. A). In a second step, the 
phosphorus atom of tris(2-carboxyethyl)phosphine (TCEP) abstracts the sulphur 
atom from cysteine, yielding an alkyl radical. This alkyl radical is proposed to 
propagate the chain reaction by removing an H from other ligation products (Figure 
16. B). Finally, alkyl radical yields alanine in place of the original cysteine (Figure 
16. C). 
Figure 16. Mechanism of radical-based desulfurization of cysteine. A. Initiation: the radical initiator 
VA-044 removes H from the sulphur atom of cysteine. B. Propagation: TCEP abstracts the sulphur 
atom, resulting in the formation of an alkyl radical. Alkyl radicals propagate a chain reaction by 
removing H atoms for other cysteines. C. Termination: alanine is generated from the alkyl radical. 
 
One-pot ligation/desulfurization reactions 
In order to avoid a loss of material due to intermediate purification, one-pot 
ligation and desulfurization reactions would be advantageous. Typical thiols used to 
facilitate NCL reaction are MESNa or MPAA. The aryl thiol MPAA is incompatible 
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with one-pot ligation/desulfurization because it acts as a radical scavenger.364,365 
MESNa allows one-pot ligation/desulfurization; however, its kinetics is slower than 
MPAA.366 Therefore, 2,2,2-trifluoroethanethiol (TFET) was proposed as efficient 
thiol additive that enables one-pot ligation/desulfurization.367 Nevertheless, TFET-
thioester peptides are prone to hydrolysis. Methyl thioglycolate (MTG) represents an 
alternative to this issue.368 
 
EPL for semi-synthesis of modified histones 
EPL is a method of choice for introducing PTMs in histones since lots of 
PTMs are located close to the N-terminus. For instance, EPL was used to produce 
semi-synthetic H3 or H4 with lysine acetylation,49,73,369 serine phosphorylation370 or 
lysine trimethylation on the N-terminal tail.73,212,369 To introduce modification(s) in 
the middle of a protein (i.e. more than ~ 60 residues away from the C- or N-terminus 
in the amino acid sequence) or for introducing multiple modifications both at the C- 
and N-terminus, a three-piece ligation strategy can be adopted.371,372 For instance, a 
three-piece approach employed a photolytic thiol-bearing ligation auxiliary to 
introduce ubiquitin on the ε-amino group of lysine in H2B or H2A, yielding a native 
isopeptide bond.373–375 
The semi-synthetic modified histones can thus be refolded together with the 
other core histones, resulting in modified octamers. These octamers can then be used 
for nucleosome reconstitution with suitable DNA molecules such as the 601 strong 
nucleosome positioning sequence.376 By constructing adapted DNA pieces, 
oligonucleosomes (array of multiple nucleosomes separated by linker DNA) can be 
reconstituted. Combining EPL with DNA ligation at non-palindromic overhangs, 
heterotypic nucleosome arrays can be assembled from a set of differently modified 
nucleosomes.377–379 Our group recently developed a chemical route to produce 
asymmetrically modified nucleosomes, i.e. with sister histones harbouring different 
modifications.207 Additionally, DNA barcoding allowed the creation of a nucleosome 
library for which each member displays a distinct combination of histone PTMs.380 
These techniques enable the access to various chromatin templates and help to 
address important biological questions, such as the functions and mechanisms of 
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chromatin-associated proteins,379 the effects of histone PTMs on nucleosome 
stability and chromatin compaction49,375 intra- and internucleosomal histone 
modification crosstalks,207,212,370,373,374,380 combinatorial readout of histone PTMs73 
and chromatin effector kinetics.75 
 
1.4 Aims 
 
Histone modifications work in synergy to install chromatin states. Bivalent 
chromatin is the combination of H3K4me3, deposited by MLL complexes, and 
H3K27me3, installed by PRC2. Bivalency is proposed to keep key developmental 
genes in a poised state in ESCs. The subnuclear distribution of this combinatorial 
chromatin state in live cells as well as its dynamics is currently unknown due to a 
lack of suitable imaging techniques. Furthermore, how bivalent chromatin is 
established by PcG and TrxG proteins is unclear. In the present work, we aimed to 
address these questions by engineering genetically encoded sensors for bivalent 
chromatin and by assessing the influence of H3K4me3 and H3K27me3 on the 
activity of the H3K4-specific methyltransferase SET1B. 
1. Currently, no live cell imaging method exists for combinations of histone 
marks. This prompted us to develop genetically encoded probes based on naturally 
occurring reader domains and apply this strategy for bivalent chromatin, a histone 
PTM pattern of high biological interest. After testing the probes with reconstituted 
nucleosomes containing site-specifically modified histones, we aimed to observe the 
subnuclear localization of bivalent domains in live stem cells. Furthermore, we tested 
the influence of epigenetic drug treatments on bivalent domains. 
2. To investigate the influence of histone PTM crosstalks on the installation 
of H3K4 methylation, we tested the H3K4 methyltransferase activity of SET1B on 
symmetrically modified H3K27me3 and asymmetrically modified H3K4me3 
nucleosomes. 
Accomplishment of these goals yielded insights about the subnuclear 
organization of bivalent chromatin and about the crosstalk between H3K4me3 and 
H3K27me3. The realization of project 1 revealed that bivalent domains are organized 
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into local clusters. In project 2, we uncovered a positive feedback mechanism by 
which H3K4me3 stimulates SET1B activity. We expect that our work will promote 
future research perspectives concerning combinatorial chromatin states. 
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Chapter 2. Development and evaluation of genetically encoded 
probes selective for bivalent histone marks 
 
The work described in this chapter is the preprint version of the article entitled 
“Engineered multivalent sensors to detect coexisting histone modifications in living 
stem cells” accepted in Cell Chemical Biology. The following persons contributed to 
this project: Aurore M.-F. Delachat, Nora Guidotti, Andreas L. Bachmann, Antonio 
C. A. Meireles-Filho, Horst Pick, Carolin C. Lechner, Cédric Deluz, Bart Deplancke, 
David M. Suter and Beat Fierz.  
Aurore M.-F. Delachat and Beat Fierz designed the study. Aurore M.-F. 
Delachat performed the cloning and recombinant expression of the different probe 
variants as well as the in vitro binding assays with nucleosomes and peptides. Aurore 
M.-F. Delachat, Carolin C. Lechner and Nora Guidotti made the modified peptides, 
histones and octamers used in the different binding assays. Aurore M.-F. Delachat 
and Horst Pick performed the immunofluorescence experiments. Horst Pick 
performed the confocal imaging of HEK cells and helped with the mESC culture and 
imaging. Aurore M.-F. Delachat performed the confocal imaging of ESCs, the local 
maxima count and the Western Blot (WB) of acid-extracted histones. Aurore M.-F. 
Delachat and Antonio C. A. Meireles-Filho performed the ChIP experiments. 
 
2.1 Project background and outline 
 
Mapping the genomic location of PTM patterns is crucial to understand 
chromatin function and organization. As discussed in 1.2.3, ChIP-based methods 
enable to map histone PTMs genome-wide and to detect the coexistence of multiple 
PTMs (Re-ChIP). ChIP can also be used to obtain quantitative information with a 
single-nucleosome precision.261 Additionally, immunoprecipitation of 
mononucleosomes can be coupled with MS or single-molecule TIRF microscopy to 
have insights about nucleosome symmetry.246,262,263 Mapping genomic location of 
histone marks in a combinatorial manner is essential to unravel the function of 
chromatin states, but detecting subnuclear organization of PTM patterns is also of 
42 
 
high importance. Immunofluorescence coupled with confocal microscopy is widely 
used to visualize subcellular distribution of protein PTMs at the single cell level. 
However, this technique does not enable to prove the coexistence of multiple PTMs 
in close proximity as the focal volume is typically ~ 250 nm ×  500 nm. To 
circumvent this limitation, Hattori et al. developed a single cell imaging method 
based on proximity ligation assay.381 The authors used a pair of modification-specific 
antibodies as templates for rolling circle amplification that takes place only when the 
two histone PTMs of interest are in close proximity. Coupled with confocal 
microscopy, this method allows the detection of two different histone marks in close 
vicinity (~ 30 nm) and therefore the observation of the subnuclear organization of 
chromatin states. In a different approach, antibody fragments targeting two different 
epitopes were used to construct bispecific detection reagents for 
immunohistochemistry.382 
The above-mentioned techniques rely on the availability and specificity of 
antibodies (or antibody fragments) for the PTMs of interest. These criteria are not 
always straightforward to attain. Furthermore, antibody-based methods require 
sample fixation and permeabilisation, rendering impossible live cell imaging. 
Currently, imaging strategies to visualize patterns of histone PTMs in living cells are 
very limited. However, such methods exist for single histone marks. For instance, 
fluorescently labelled antibody fragments loaded in live cells localize at modified 
histones, enabling to visualize their subnuclear organization.383,384 Genetically 
encoded sensors are more suitable for long term tracking and for living organisms. 
Genetic fusions of a fluorescent protein (FP) with an antibody fragment were used to 
follow histone acetylation or methylation in live cells.385–387 The use of naturally 
occurring reader domains to design sensors targeting histone modifications 
represents an interesting alternative to antibodies. Fluorescence resonance energy 
transfer (FRET) sensors using bromo-, chromodomains and 14-3-3(τ) were used to 
follow levels of histone acetylation, methylation and phosphorylation, 
respectively.388–393 Reader domains were also used in bioluminescence or 
bimolecular fluorescence complementation (BiFC) approaches.394–396 Recently, 
bromo- and chromodomains were used in tandem repeats separated by flexible 
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linkers to target histone acetylation and methylation, respectively.397,398 In these 
studies, the authors highlighted the enhanced affinity for the PTM of interest in the 
case of tandem reader domains compared to single reader domain constructs. 
The lack of live cell imaging method for chromatin states prompted us to set 
up a modular strategy for the development and optimization of genetically encoded 
probes targeting combinations of histone PTMs. We took advantage of the abundance 
of reader domains in nature to design fusion constructs that bind selectively to a 
pattern of histone marks. By including a FP in the fusion proteins, we used direct 
fluorescence as readout for microscopic purposes. We designed probes to target one 
of the most intriguing pattern of histone PTMs, bivalent chromatin.  
First of all, we designed several variants for which different parameters such 
as linker length were varied. The selectivity of recombinant sensors was assessed in 
vitro with binding assays using reconstituted nucleosomes with semi-synthetic 
methylated histones. In this step, the best performing variant was selected and its 
affinity for modified histone peptides was then quantified. Following this validation 
step, the recombinant sensor was used to visualize bivalent chromatin in mouse 
ESCs. The change of subnuclear distribution of the sensor upon reader domain 
mutations confirmed the selectivity for bivalent chromatin in vivo. Finally, the probe 
was used to observe the influence of epigenetic small molecule modulators on 
bivalent domains. 
 
2.2 Results  
 
2.2.1 Design of variants 
 
As described in 1.1.2, individual reader domains have mild affinities for their 
target histone mark, whereas multivalent chromatin effectors reach higher affinities 
for PTM patterns. We sought to use this multivalency effect to envision bivalent 
chromatin probes as engineered proteins composed of two reader domains, one 
specific for H3K4me3 and one specific for H3K27me3 (Figure 17. A). We named 
these sensors chromatin sensing multivalent probes, abbreviated cMAPs. 
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Additionally to two reader domains, cMAPs contain a FP as a reporter as well as 
nuclear localization signals (NLS) (one at the N- and one at the C-terminus) and 
purification/detection tags (FLAG tag at the N-terminus, His6 and HA tags at the C-
terminus). FP and reader domains are connected by linkers into one single fusion 
protein.  
Additionally to using direct fluorescence as readout, we aimed to develop 
split engineered sensors for BiFC applications.399 For this reason, Venus was chosen 
for its good performance in BiFC assays400 and was initially placed in the middle of 
the construct (with flanking reader domains). Furthermore, Venus is characterized 
by a fast chromophore maturation.401 Among the known natural reader domains for 
H3K4me3 and H3K27me3, we carefully chose well characterized ones. The 
chromodomain (CD) of the Drosophila polycomb (Pc) protein binds to H3K27me3 
peptide with a measured affinity of 5 µM (Figure 17. B, left panel).62 Crystal 
structures revealed that tryptophan and tyrosine residues form an aromatic cage to 
accommodate the hydrophobic charged ammonium group.61,62 Importantly, Pc CD 
discriminates between H3K27me3 and H3K9me3 with a 25-fold selectivity.62 
Concerning H3K4me3-specific reader domains, the plant homeodomain (PHD) of 
the human transcription initiation factor TFIID subunit 3 (TAF3) binds to H3K4me3 
peptide with an affinity of 160 nM (Figure 17. B, right panel).63 Crystal structure 
indicates also an aromatic cage as the trimethyllysine binding site.402 In order to 
equilibrate the binding affinities between the two reader domains, another PHD was 
chosen with a KD in the same range than the one of Pc CD; the mouse ING2 PHD 
binds H3K4me3 peptide with a KD of 1.5 µM.403 From chain statistics, an average 
distance of 4 nm can be estimated for H3K4me3 and H3K27me3 occurring on the 
same histone tail, and a distance of 10 nm when they reside on different H3 tails 
(Figure 17. C). As H3 tails are unstructured and highly flexible, these distances are 
subjected to high variations. Based on these considerations, we designed linkers that 
have an appropriate length to span the distance between the two target PTMs but that 
are not excessively long, which would result in a poor gain in affinity for the 
multivalent effect. 
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Figure 17. Design of the sensors cMAPs. A. Scheme of cMAPs general structure. B. Crystal structures 
of the reader domains. Ribbon representation of Pc CD (PDB: 1PDQ) and TAF3 PHD (PDB: 5C13) 
in complex with H3K27me3 and H3K4me3 peptides (shown as sticks), respectively. H3K27me3 and 
H3K4me3 residues are displayed in red and green, respectively. The residues displayed in pink form 
the binding site. C. Ribbon representation of a bivalent nucleosome (PDB: 1KX5) with estimations of 
the distances between the residues H3K4 and H3K27. H3, H4, H2A and H2B are represented in blue, 
green, yellow and orange, respectively. D. Domain arrangement of cMAP1-6. Linker length and 
flexibility are indicated for each variant. 
 
We first designed cMAP1 and cMAP6 where Venus is flanked by Pc CD at 
its N-terminus and by ING2 and TAF3 PHD at its C-terminus, respectively (Figure 
17. D). The alpha helical linker between the PHD and bromodomain of BPTF was 
previously demonstrated to be required for optimal bivalent binding to 
H3K4me3/H4K16ac nucleosomes.404 Therefore, we thought to use polyproline 
stretches as linkers between Venus and the reader domains for cMAP1 and cMAP6. 
In aqueous solvents, polyproline stretches adopt a left-handed helical conformation 
(called PolyProline II) with a 3-fold symmetry. Therefore a polyproline linker fixes 
the orientation of the two linked domains to ~ 120 ° between each other and decreases 
greatly the flexibility of the protein. 
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Flexible linkers composed of GGGGS repeats are widely used in protein 
engineering.382,387–390,398 We then derived cMAP2 and cMPA3 from the cMAP6 
construct replacing the polyproline linkers by 3 and 1 GGGGS repeats, respectively.  
We then speculated that tandem reader domains (only separated by a short 
flexible linker) might bind to their target with higher affinity compared to when they 
are spaced with Venus. Thus, we designed cMAP4 in which the order of the domains 
is permuted to have Pc CD and TAF3 PHD only separated by a 7 amino acid flexible 
linker. 
An analysis of cMAP3 sequence with a nucleolar localization sequence 
prediction tool revealed a potential nucleolar localization signal at the C-terminus of 
TAF3 PHD (Figure 18. A).405 In order to avoid any influence of this amino acid 
stretch in the subnuclear localization of the sensor, we created cMAP5 in which 9 
residues at the N-terminus of TAF3 PHD were deleted. Analysis of cMAP5 sequence 
with the same tool revealed a prediction score below the critical threshold for the 
entire sequence (Figure 18. B). Importantly, structural analysis of the TAF3 PHD 
suggests that the 9 deleted residues are not critical for H3K4me3 binding.402 
Figure 18. Scores for predicted nucleolar localization sequence for cMAP3 (A) and cMAP5 (B) 
obtained on http://www.compbio.dundee.ac.uk/www-nod/ 
 
Several characteristics were varied in the 6 cMAP constructs described here: 
length and stiffness of linkers, domain organization, origin and length of PHD. By 
varying these different parameters, we aspired to optimize the selectivity of cMAPs 
for bivalent nucleosomes (i.e. carrying both H3K4me3 and H3K27me3) versus 
monovalent nucleosomes (i.e. carrying either H3K4me3 or H3K27me3). To test the 
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binding and selectivity of these 6 constructs, we performed in vitro binding assays 
with recombinant cMAPs and a nucleosome library composed of differently 
modified semi-synthetic histones. 
 
2.2.2 Recombinant expression and purification of the probes 
 
In order to test their binding towards bivalent marks, cMAP1-6 were 
recombinantly expressed. The constructs were cloned in bacterial vectors and 
expressed in E. Coli by IPTG induction. cMAP proteins were then purified by Ni-
NTA affinity purification. Importantly, the resin-bound proteins were washed with a 
buffer containing 1M NaCl to eliminate genomic DNA. SDS PAGE analysis showed 
that the purified proteins were at least 95 % pure from proteinic contaminants (Figure 
19. A). Proteins concentration was determined by UV-vis spectroscopy from the 
Venus absorption peak (Figure 19. B). 260 / 280 nm ratios between 0.73 and 0.96 
were measured, indicating a negligible contamination by nucleic acid. Yields 
between ~ 1 and ~ 23 mg of protein per litre culture were obtained. Following buffer 
exchange, Ni-NTA purified cMAP proteins were used for binding assays. 
A deeper analysis of cMAP2, 3 and 6 was performed by subjecting proteins 
to anion exchange chromatography (AIEX). A gradually increasing salt 
concentration (from 50 mM to 1 M) was used for elution with a constant pH at 7.8. 
At this pH value, cMAP2, 3 and 6 are slightly positively charged, as their pI is 8.06. 
As expected, proteins eluted in the flow-through (between 0 and 7 mL elution 
volume) (Figure 19. C). Two smaller peaks appeared at elution volumes ~ 27 mL and 
~ 34 mL. After analysis by UV-vis spectroscopy (Table 2) and SDS PAGE (Figure 
19. C), we determined that the peak at ~ 27 mL elution volume contained mainly 
cMAP protein, whereas the peak at ~ 34 mL elution volume contained mainly nucleic 
acid. This AIEX analysis revealed that cMAPs have a low but non-negligible affinity 
for DNA. cMAP2 was further subjected to size exclusion chromatography (SEC) and 
the fractions were analysed by SDS PAGE (Figure 19. D). The obtained single peak 
indicated that the protein was monomeric. 
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Figure 19. Purification of cMAPs. A. SDS PAGE analysis of cMAP1-6 purified by Ni-NTA affinity 
column. B. Representative UV-vis absorption spectrum of cMAP proteins. C. AIEX trace of cMAP2 
and SDS PAGE analysis of the corresponding fractions. D. Gel filtration trace of cMAP2 and SDS 
PAGE analysis of the corresponding fractions. 
 
 Ratio 260 / 280 Absorption at 
515 nm 
Main 
component 
Peak between 0 and 7 mL elution 
volume 
0,54 Yes cMAP 
Peak at ~ 27 mL elution volume 0,67 Yes cMAP 
Peak at ~ 34 mL elution volume 1,88 No Nucleic acid 
Table 2. UV-vis spectrometric analysis of the AIEX fractions of cMAP2 purification. 
 
With pure recombinant cMAPs in hands, we then synthesized modified 
histone peptides and full length histones via EPL. 
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2.2.3 Production of nucleosomes using site-specifically modified, 
semi-synthetic histone proteins 
 
Site-specifically modified histone peptides and full length histone proteins 
were synthesized via EPL. Histone peptides were used for quantitative measurement 
of affinities, whereas full length modified histones were used for nucleosome 
reconstitution further employed in binding assays (described in 2.2.4).  
Peptides 1b (H3(1-14)K4me3), 1d (H3(1-28)K27me3) and 1e (H3(1-
28)K4me3K27me3) corresponding to residues 1-14 or 1-28 of human H3.1 with 
lysine 4 or/and 27 trimethylated were synthesized on hydrazine 2-chlorotrityl resin 
by SPPS using the Fmoc protection strategy. The peptides hydrazide 1b, 1d and 1e 
were purified by RP-HPLC on a preparative scale and characterized by analytical 
RP-HPLC and ESI-MS (Figures 20 - 22, Table 3). 
Figure 20. RP-HPLC chromatogram (A) and ESI-MS (B) of purified peptide 1b (H-
ARTK(me3)QTARKSTGGK-NH-NH2). Gradient 0 % - 70 % solvent B in 30 min. Calculated mass: 
1545.9 Da, found: 1545.8 Da, 310.2 [M+5H]5+, 387.5 [M+4H]4+, 516.3 [M+3H]3+, 773.7 [M+2H]2+, 
830.3 [M+TFA+2H]2+. 
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Figure 21. RP-HPLC chromatogram (A) and ESI-MS (B) of purified peptide 1d (H-
ARTKQTARKSTGGKAPRKQLATKAARK(me3)S-NH-NH2). Gradient 0 % - 70 % solvent B in 30 
min. Calculated mass: 3053.8 Da, found: 3054.3 Da, 340.4 [M+9H]9+, 382.8 [M+8H]8+, 437.3 
[M+7H]7+, 510.1 [M+6H]6+, 611.8 [M+5H]5+, 764.5 [M+4H]4+, 792.3 [M+TFA+4H]4+, 1056.3 
[M+TFA+3H]3+. 
 
Figure 22. RP-HPLC chromatogram (A) and ESI-MS (B) of purified peptide 1e (H-
ARTK(me3)QTARKSTGGKAPRKQLATKAARK(me3)S-NH-NH2). Gradient 0 % - 70 % solvent 
B in 30 min. Calculated mass: 3095.9 Da, found: 3095.6 Da, 387.9 [M+8H]8+, 443.3 [M+7H]7+, 516.9 
[M+6H]6+, 620.1 [M+5H]5+, 642.9 [M+TFA+5H]5+, 774.9 [M+4H]4+, 803.3 [M+TFA+4H]4+, 832.0 
[M+2TFA+4H]4+. 
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Name Sequence MW 
calculated 
(Da) 
MW 
observed 
(Da) 
Yields 
1b H-ARTK(me3)QTARKSTGGK-NH- 
NH2 
1545.9 1545.8 24 % 
1d H-ARTKQTARKSTGGKAPRKQLAT 
KAARK(me3)S-NH-NH2 
3053.8 3054.3 38 % 
1e H-ARTK(me3)QTARKSTGGKAPRK 
QLATKAARK(me3)S-NH-NH2 
3095.9 3095.6 15 % 
Table 3. Peptides 1b, 1d and 1e used for Expressed Protein Ligation to produce site-specifically 
modified histone peptides and full length histone proteins. 
 
Synthesis of modified full length histones 3b (H3K4me3), 3d (H3K27me3) 
and 3e (H3K4me3K27me3) was performed by ligation of peptides 1b, 1d or 1e with 
truncated versions of H3 histone protein, followed by desulfurization. For this 
purpose, N-terminal truncated variants of human H3.1_C110A variant 2 (H3(Δ1-14, 
A15C)) and 2’ (H3(Δ1-28, A29C)) were recombinantly expressed as N-terminal 
fusions to a His6-SUMO tag. Following Ni-NTA affinity purification, refolding and 
cleavage of the His6-SUMO tag from the His6-SUMO-H3(Δ1-14, A15C) and His6-
SUMO-H3(Δ1-28, A29C) fusion proteins were achieved by dialysis with 
recombinant SUMO protease ULP1. Histones 2 and 2’ were purified by RP-HPLC 
on a preparative scale and characterized by analytical RP-HPLC and ESI-MS 
(Figures 23 - 24). 
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Figure 23. RP-HPLC chromatogram (A) and ESI-MS (B) of purified N-terminal truncated histone 2 
H3(Δ1-14, A15C). Gradient 0 % - 70 % solvent B in 30 min. Calculated mass: 13769 Da, observed: 
13767 Da, 725.6 [M+19H]19+, 765.8 [M+18H]18+, 810.8 [M+17]17+, 861.4 [M+16H]16+, 918.8 
[M+15H]15+, 984.4 [M+14H]14+, 1060.0 [M+13H]13+, 1148.2 [M+12H]12+, 1252.5 [M+11H]11+, 
1377.8 [M+10H]10+. 
 
Figure 24. RP-HPLC chromatogram (A) and ESI-MS (B) of purified N-terminal truncated histone 2’ 
H3(Δ1-28, A29C). Gradient 47 % - 62 % solvent B in 30 min. Calculated mass: 12261 Da, observed: 
12261 Da, 646.4 [M+19H]19+, 682.2 [M+18H]18+, 722.3 [M+17H]17+, 767.3 [M+16H]16+, 818.4 
[M+15H]15+, 876.8 [M+14H]14+, 944.1 [M+13H]13+, 1022.7 [M+12H]12+, 1115.4 [M+11H]11+. 
 
Ligation and subsequent desulfurization of truncated histone 2 with peptide 
1b yielded full length modified histone 3b. In the same way, ligation and 
desulfurization of truncated histone 2’ with peptide 1d and 1e yielded full length 
modified histones 3d and 3e, respectively. Histones 3d and 3b were synthesized by 
standard EPL. In a typical ligation reaction, between 1 and 2 μmol of H3 tail peptide 
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hydrazide was dissolved in an acidic buffer to a final concentration of 2.5 mM. The 
peptide solution was kept at - 10 °C and NaNO2 was added to a final concentration 
of 18 mM. After mixing, the peptide was incubated at - 10 °C for 20 min, yielding 
the peptide-azide. Typically, 0.6 μmol of truncated recombinant H3 protein was 
dissolved in a buffer with 0.2 M MPAA to a final concentration of 1 mM. The molar 
ratios peptide / protein was 4:1. The protein in MPAA ligation buffer was added to 
the peptide-azide and the pH was adjusted to 7.0. The reaction was monitored by 
analytical RP-HPLC. After 1 h, TCEP was added to a final concentration of 20 mM. 
When the reaction had reached completion, ligation product was purified by semi-
preparative RP-HPLC. The ligation product was characterized by analytical RP-
HPLC and ESI-MS. The obtained protein was then desulfurized to convert the 
cysteine into alanine at the ligation site. For this purpose, the protein was dissolved 
in a buffer containing 250 mM TCEP to a final concentration of 0.5 mM. Glutathione 
and VA-044 radical starter were added to final concentrations of 40 mM and 20 mM, 
respectively. The pH was adjusted to 6.5 and the reaction was allowed to proceed at 
37 °C. The reaction was monitored by analytical RP-HPLC and ESI-MS. When the 
reaction had reached completion, desulfurization product was purified by semi-
preparative RP-HPLC. The purified protein was characterized by analytical RP-
HPLC and ESI-MS (Figures 25 – 26, Table 4). 
For histones 3e and 3b, a previously described one-pot ligation-
desulfurization strategy was used.207,367 Briefly, between 1 and 2 μmol of H3 tail 
peptide hydrazide was dissolved in ligation buffer to a final concentration of 10 mM 
and the pH readjusted to 3.0. The peptide solution was kept at - 20 °C and NaNO2 
was added to a final concentration of 15 mM. After mixing, the peptide was incubated 
at - 20 °C for 5 min. Subsequently, TFET was added to a final concentration of 1 M 
and the pH of the peptide solution was adjusted to 6.8. The peptide was incubated for 
10 min at RT and transferred to a tube with lyophilized, truncated recombinant H3 
protein. The molar ratio peptide / protein was 7:1 or 5:1. A buffer containing 0.5 M 
TCEP was added to a final concentration of 10 mM TCEP and the reaction was 
allowed to proceed at 25 °C under Argon atmosphere. The reaction was monitored 
by analytical RP-HPLC. When the reaction had reached completion, desulfurization 
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was performed in the same tube without prior purification of the ligation product. A 
buffer containing 0.5 M TCEP was added to a final concentration of 0.25 M TCEP 
in the reaction solution. Then, glutathione and VA-044 radical starter were added to 
final concentrations of 40 mM and 20 mM, respectively. The reaction was incubated 
at 42 °C and monitored by analytical RP-HPLC and ESI-MS. When the reaction had 
reached completion, desulfurization product was purified by semi-preparative RP-
HPLC. The purified protein was characterized by analytical RP-HPLC and ESI-MS 
(Figure 27, Table 4). 
Figure 25. RP-HPLC chromatogram (A) and ESI-MS (B) of purified histone 3b H3K4me3. Gradient 
0 % - 70 % solvent B in 30 min. Calculated mass: 15251 Da, observed: 15250 Da, 587.7 [M+26H]26+, 
610.9 [M+25H]25+, 636.5 [M+24H]24+, 664.2 [M+23H]23+, 694.2 [M+22H]22+, 727.2 [M+21H]21+, 
763.5 [M+20H]20+, 803.8 [M+19H]19+, 848.1 [M+18H]18+, 897.9 [M+17H]17+, 954.2 [M+16H]16+, 
1017.6 [M+15H]15+, 1090.3 [M+14H]14+, 1173.9 [M+13H]13+. 
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Figure 26. RP-HPLC chromatogram (A) and ESI-MS (B) of purified histone 3d H3K27me3. Gradient 
0 % - 70 % solvent B in 30 min. Calculated mass: 15251 Da, observed: 15252 Da, 587.6 [M+26H]26+, 
611.1 [M+25H]25+, 636.6 [M+24H]24+, 664.2 [M+23H]23+, 694.3 [M+22H]22+, 727.3 [M+21H]21+, 
763.6 [M+20H]20+, 803.8 [M+19H]19+, 848.3 [M+18H]18+, 898.1 [M+17H]17+, 954.1 [M+16H]16+, 
1017.6 [M+15H]15+, 1090.3 [M+14H]14+. 
 
Figure 27. RP-HPLC chromatogram (A) and ESI-MS (B) of purified histone 3e H3K4me3K27me3. 
Gradient 0 % - 70 % solvent B in 30 min. Calculated mass: 15293 Da, observed: 15290 Da, 638.1 
[M+24H]24+, 665.8 [M+23H]23+, 696.0 [M+22H]22+, 729.1 [M+21H]21+, 765.4 [M+20H]20+, 805.8 
[M+19H]19+, 850.5 [M+18H]18+, 900.4 [M+17H]17+, 956.6 [M+16H]16+, 1020.3 [M+15H]15+, 1093.3 
[M+14H]14+. 
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Name Modification Synthesis method Yield 
3b H3K4me3 Standard 12 % 
3b H3K4me3 One-pot 33 % 
3d H3K27me3 Standard 26 % 
3e H3K4me3 and H3K27me3 One-pot 28 % 
Table 4. Modified, semi-synthetic histones H3 proteins. 
 
For the synthesis of histone 3c (H3K9me3), refer to Kilic et al., Nat. 
Commun., 2015.75 
In order to refold modified octamers with histones 3b, 3d and 3e, the core 
histones H2A, H2B and H4 are required. Furthermore, for refolding of unmodified 
octamer, unmodified H3 is needed. Human wild-type H4, H3_C110A, H2A and H2B 
were then recombinantly expressed and purified by cation exchange. Octamer 
refolding was performed by dissolving stoichiometric quantities of lyophilized core 
histones in a denaturing buffer followed by dialysis in a 2 M NaCl containing buffer. 
The scale was 100 - 500 µg of histone H3 with an overall protein concentration of 74 
µM. The obtained crude octamers were purified by SEC (Figure 28. A). Fractions 
containing pure octamers were pooled and concentrated to the range of 30 - 60 μM. 
SDS PAGE analysis indicates equal amounts of each core histone (Figure 28. B). 
Several types of binding assays were performed with cMAP proteins and 
nucleosomes (described in 2.2.4). For some of them, unlabelled reconstituted 
nucleosomes were used. To this end, unlabelled 601 DNA was obtained by digestion 
of a plasmid containing 32 repeats of the 601 sequence separated by restriction sites. 
For one of the binding assays, biotin-labelled nucleosomes were required. The 
biotinylated 166 bp DNA fragment with a 19 bp linker prior to the strong nucleosome 
positioning sequence 601 was produced by PCR with a biotinylated primer.73 Mono-
nucleosomes were reconstituted either at a small scale by dilution or at a larger scale 
by dialysis.406 In the first method, typically 10 or 20 pmol of 601 DNA were mixed 
with the respective histone octamers in 2 M NaCl in a volume of 10 µL. Following 
several additions of 10 mM Tris-HCl pH 7.6, the final concentration of NaCl was 0.2 
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M. In the second method, nucleosomes were reconstituted in 70 µl sample volume 
by mixing 60 pmol of DNA with the respective histone octamer at high salt 
conditions (2 M KCl) followed by gradient dialysis into low salt conditions (0.25 M 
KCl). Nucleosome concentrations were determined by UV quantification and their 
quality was assessed by native gel electrophoresis (Figure 28. C). 
Figure 28. A. Gel filtration purification of H3K4me3 octamers. The shaded region indicates the 
fractions containing pure octamers. B. SDS PAGE analysis of purified H3K4me3 octamers. C. Native 
PAGE analysis of reconstituted biotinylated nucleosomes (a: unmodified nucleosomes; b: H3K4me3 
nucleosomes; c: H3K9me3 nucleosomes; d: H3K27me3 nucleosomes; e: H3K4me3K27me3 
nucleosomes) 
 
With the goal of reconstituting trans bivalent nucleosomes, we mixed 
histones 3b and 3d in equimolar ratio during octamer refolding and used these 
octamers for nucleosome reconstitution. Histones 3b and 3d are then statistically 
distributed and these nucleosomes (called e’) consist of 50 % of trans bivalent 
nucleosomes (H3K4me3/H3K27me3), 25 % of H3K4me3 nucleosomes and 25 % of 
H3K27me3 nucleosomes. To compare e’ nucleosomes with monovalent 
nucleosomes, we reconstituted b’ and d’ nucleosomes for which we mixed 
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unmodified histone H3 and H3K4me3 (3b) or H3K27me3 (3d) histones in equimolar 
ratios. Table 5 summarizes the modifications carried by the different nucleosomes 
used in binding assays. 
 
Nucleosomes Modifications on the two H3 copies 
a Unmodified/unmodified 
b H3K4me3/H3K4me3 
c H3K9me3/H3K9me3 
d H3K27me3/H3K27me3 
e H3K4me3K27me3/H3K4me3K27me3 
b’ 2:1:1 ratio of H3K4me3/unmodified; H3K4me3/H3K4me3; 
unmodified/unmodified  
d’ 2:1:1 ratio of H3K27me3/unmodified; H3K27me3/H3K27me3; 
unmodified/unmodified  
e’ 2:1:1 ratio of H3K4me3/H3K27me3; H3K4me3/H3K4me3; 
H3K27me3/H3K27me3  
Table 5. Reconstituted nucleosomes employed in binding assays. 
 
Beside binding assays with nucleosomes, we measured affinities of cMAP3 
for monovalent and bivalent H3 histone peptides (described in 2.2.4). To this end, 
we synthesized peptides 5b (H3(1-35)K4me3 V35Y), 5d (H3(1-35)K27me3 V35Y) 
and 5e (H3(1-35)K4me3K27me3 V35Y). Here, we used the V35Y mutation to be 
able to quantify peptide concentration by UV-vis spectrometry. Since we had access 
to peptides 1b, 1d and 1e, we adopted a ligation/desulfurization strategy with the 
adaptor peptides 4 (H3(15-35) A15C,V35Y) and 4’ (H3(29-35) A29C,V35Y). 
Peptides 4 and 4’ correspond to residues 15-35 or 29-35 of human H3.1 with N-
terminal alanine (15 or 29) mutated to cysteine and valine 35 mutated to tyrosine. 
These peptides were synthesized on rink amide resin by SPPS, using the Fmoc 
protection and HBTU activation strategy. Crude peptides were purified by RP-HPLC 
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on a preparative scale. Peptides 4 and 4’ were then characterized by analytical RP-
HPLC and ESI-MS (Figure 29 - 30, Table 6). 
Figure 29. RP-HPLC chromatogram (A) and ESI-MS (B) of purified peptide 4 (H-
CPRKQLATKAARKSAPATGGY-NH2). Gradient 0 % - 70 % solvent B in 30 min. Calculated mass: 
2174.6 Da, found: 2174.4 Da, 435.8 [M+5H]5+, 544.6 [M+4H]4+, 725.8 [M+3H]3+, 1088.4 [M+2H]2+. 
 
Figure 30. RP-HPLC chromatogram (A) and ESI-MS (B) of purified peptide 4’ (H-CPATGGY-NH2). 
Gradient 0 % - 70 % solvent B in 30 min. Calculated mass: 666.8 Da, found: 667.2 Da, 667.2 
[M+1H]1+. 
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Name Sequence MW calculated 
(Da) 
MW observed 
(Da) 
Yields 
4 H-CPRKQLATKAARKS 
APATGGY-NH2 
2174.6 2174.4 45 % 
4’ H-CPATGGY-NH2 666.8 667.2 27 % 
Table 6. Peptides 4 and 4’ used for Expressed Protein Ligation to produce peptides 5b, 5d and 5e. 
 
For peptides 5b, 5d and 5e, the previously described one-pot ligation-
desulfurization strategy was used. Briefly, between 1 and 2 μmol of H3 tail peptide 
hydrazides (1b, 1d and 1e) were converted to the TFET thioesters and, after ligation 
to N-terminal cysteine peptides 4 or 4’, the cysteine at the ligation site was 
desulfurized as described above. When the reaction had reached completion, the 
peptides were purified by semi-preparative RP-HPLC. The purified peptides were 
characterized by analytical RP-HPLC and ESI-MS (Figure 31 - 33, Table 7). 
Figure 31. RP-HPLC chromatogram (A) and ESI-MS (B) of purified peptide 5b (H-
ARTK(me3)QTARKSTGGKAPRKQLATKAARKSAPATGGY-NH2). Gradient 0 % - 70 % solvent 
B in 30 min. Calculated mass: 3657.3 Da, found: 3656.6 Da, 523.2 [M+7H]7+, 610.4 [M+6H]6+, 732.2 
[M+5H]5+, 755.1 [M+TFA +5H]5+, 915.2 [M+4H]4+, 942.6 [M+TFA+4H]4+, 972.1 [M+2TFA+4H]4+, 
1219.7 [M+3H]3+ 
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Figure 32. RP-HPLC chromatogram (A) and ESI-MS (B) of purified peptide 5d (H-
ARTKQTARKSTGGKAPRKQLATKAARK(me3)SAPATGGY-NH2). Gradient 0 % - 70 % solvent 
B in 30 min. Calculated mass: 3657.3 Da, found: 3656.4 Da, 523.4 [M+7H]7+, 610.4 [M+6H]6+, 732.2 
[M+5H]5+, 755.3 [M+TFA+5H]5+, 915.1 [M+4H]4+, 943.6 [M+TFA+4H]4+. 
 
Figure 33. RP-HPLC chromatogram (A) and ESI-MS (B) of purified peptide 5e (H-
ARTK(me3)QTARKSTGGKAPRKQLATKAARK(me3)SAPATGGY-NH2). Gradient 0 % - 70 % 
solvent B in 30 min. Calculated mass: 3699.3 Da, found: 3697.6 Da, 463.2 [M+8H]8+, 529.3 
[M+7H]7+, 617.2 [M+6H]6+, 740.5 [M+5H]5+, 763.3 [M+TFA+5H]5+, 925.4 [M+4H]4+, 953.9 
[M+TFA+4H]4+, 982.3 [M+2TFA+4H]4+, 1233.6 [M+3H]3+, 1271.7 [M+TFA+3H]3+, 1309.4 
[M+2TFA+3H]3+. 
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Name Sequence MW calculated 
(Da) 
MW 
observed 
(Da) 
Yields 
5b H-ARTK(me3)QTARKSTGGKAPR 
KQLATKAARKSAPATGGY-NH2 
3657.3 3656.6 54 % 
5d H-ARTKQTARKSTGGKAPRKQL 
ATKAARK(me3)SAPATGGY-NH2 
3657.3 3656.4 46 % 
5e H-ARTK(me3)QTARKSTGGKAPR 
KQLATKAARK(me3)SAPATGGY 
-NH2 
3699.3 3697.6 57 % 
Table 7. Peptides 5b, 5d and 5e. 
 
These libraries of modified nucleosomes and peptides enabled us to 
characterize cMAPs in vitro. 
 
2.2.4 In vitro evaluation of probes binding and selectivity 
 
To evaluate binding of cMAP1-6 to H3K4me3 and H3K27me3 as well as to 
assess their preference for bivalent versus monovalent and unmodified 
nucleosomes/histone peptides, several binding assays were performed. First, 
nucleosome pulldowns were performed by incubating modified or unmodified 
nucleosomes with immobilized cMAPs and by detecting the retained nucleosomes 
with anti-H3 WB (Figure 34. A). With this method, the affinity of cMAP2, 3, 5 and 
6 were tested on nucleosomes a, b and d (Figure 34. B and C). All four probes retain 
efficiently methylated nucleosomes (b and d), whereas no binding was observed for 
unmodified nucleosomes (a), confirming that CD and PHD are folded and recognize 
their target PTM. 
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Figure 34. Pulldown of modified and unmodified nucleosomes using immobilized cMAPs. A. 
Schematic view of the experiment. B. Pulldown of nucleosomes a, d and b with cMAP3 and cMAP5. 
Nucleosome retention is visualized by anti-H3 WB. Here, 5 pmol of nucleosomes were incubated with 
20 pmol immobilized cMAP3. C. Pulldown of nucleosomes a, b and d with cMAP2, 3, 5 and 6. Upper 
panel: Relative WB band intensities were quantified and normalized. For cMAP3, band intensities 
were averaged over 2 independent replicates. Error bars: standard deviation. Lower panel: schematic 
view of nucleosomes a, b, d. 
 
To assess the preference for bivalent nucleosomes, cMAP binding was tested 
in an electromobility shift assays (EMSA) with nucleosomes a, b’, d’, e’ and 601 
DNA (Figure 35). We tested the feasibility of this assay with cMAP3. All 
nucleosomes (Figure 35. A) as well as DNA (Figure 35. D) were shifted by cMAP3 
in the range of 100 - 200 nM, indicative of a relatively high unspecific binding to 
DNA. This assay does not allow to detect the binding preference for monovalent (b’, 
d’) versus unmodified (a) nucleosomes, probably due to DNA binding (compare b’ 
and d’ lanes with a lanes in Figure 35. A). However, a slight but noticeable difference 
of affinity is visible between bivalent (e’) and monovalent/unmodified nucleosomes 
(a, b’, d’) (compare band intensity of unbound nucleosomes, at ~ 450 bp, in e’ lanes 
with a, b’, d’ lanes in Figure 35. A; arrows indicate unbound nucleosomes at 220 nM 
cMAP3). Indeed, at 220 nM cMAP3, e’ nucleosomes are almost completely shifted, 
whereas b’, d’ and a nucleosomes are only partially shifted. By plotting the unbound 
nucleosome band intensities as a function of cMAP3 concentration and fitting, 
apparent KDs showed a 1.7 and 1.6-fold preference for bivalent nucleosomes (e’) 
over H3K27me3 (d’) and H3K4me3 (b’) nucleosomes, respectively (Figure 35. B). 
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The affinity difference of 1.6-fold for e’ over b’ nucleosomes was maintained for 3 
independent triplicates (Figure 35. C). 
Figure 35. EMSA of cMAP3. A. EMSA of cMAP3 with Cy5-labeled nucleosomes. From left to right, 
0, 100, 220, 340, 460, 580 nM of cMAP3 were mixed with nucleosomes a, b’, d’ or e’ and analysed 
by native PAGE. Upper panel: Cy5 fluorescence. Arrows indicate unbound nucleosomes with 220 
nM protein. Middle panel: Venus fluorescence. Lower panel: schematic view of nucleosomes a, b’, 
d’, e’. B. Relative intensity of the unbound nucleosome band (at ~ 450 bp) as a function of cMAP3 
concentration. Fit curves: binding isotherms with KDs of 192 nM (a), 218 nM (b’), 237 nM (d’), 140 
nM (e’). C. Band intensities of unbound nucleosomes (at 220 or 150 nM protein concentration) was 
quantified, normalized and, for a, b’ and e’, averaged over 3 independent triplicates. D. EMSA of 
cMAP3 with 601 Cy5-labeled 601 DNA. From left to right, 0, 100, 150, 200, 250 nM of cMAP3 was 
mixed with DNA and analysed by native PAGE. Left panel: Cy5 fluorescence. Right panel: Venus 
fluorescence. *: this band is due to a defect of the native gel. 
 
Gel shift assays indicate that cMAP3 binds bivalent nucleosomes with higher 
affinity than monovalent nucleosomes. However, this assay does not allow to clearly 
characterize the multivalent effect because of unspecific binding to DNA. For this 
reason, we performed cMAP pulldowns by incubating cMAP proteins with 
immobilized unmodified and modified nucleosomes (Figure 36. A). The retained 
cMAPs was detected by anti-FLAG WB after extensive washing. This way, 
unspecific DNA binding does not interfere with the readout of the experiment. After 
checking the homogeneous loading of nucleosomes on beads (Figure 36. B), the 
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affinity of cMAP1-4 were tested with nucleosomes a, b, d and e. Additionally, the 
affinity of cMAP3 was tested for nucleosomes c (H3K9me3). For cMAP3, no 
binding was detected to H3K9me3 (c) nucleosomes, indicating that CD is specific 
for H3K27me3 (Figure 36. C). cMAP1 showed non-negligible binding to unmodified 
nucleosomes (a), which might be explained by the propensity of polyproline type II 
left-handed helices to form DNA-binding motifs (Figure 36. D).407,408 cMAP1-4 bind 
nucleosomes containing either H3K4me3 or H3K27me3; however, only cMAP3 and 
4 showed increased retention on the bivalent nucleosomes (e) (Figure 36. D). This 
result demonstrates that short and flexible linker sequences are required for efficient 
multivalent binding. Among the two best performing variants, we chose cMAP3 to 
continue our investigation because of its ability to be easily transformed into a BiFC 
split probe. cMAP3 exhibits an enhanced retention of 2.2- and 2.6-fold on 
H3K4me3K27me3 (e) over H3K4me3 (b) and H3K27me3 (d) nucleosomes, 
respectively. 
Figure 36. Pulldown of cMAPs using immobilized nucleosomes. A. Schematic view of the 
experiment. B. Homogeneous nucleosome loading on beads. Nucleosomes are detected by anti-H3 
(C-term) Western Blot. C. Pulldown of cMAP3 with nucleosomes a, b, c, d and e. Upper panel: 
Protein retention is visualized by anti-FLAG WB. Lower panel: schematic view of nucleosomes a, b, 
c, d and e. D. Pulldown of cMAP1-4 with nucleosomes a, b, d and e. Relative WB band intensity 
were quantified, normalized and averaged over 3 or 4 independent replicates (3 replicates for 
cMAP1,2,4 and 4 replicates for cMAP3). Error bars: standard deviation. *: Student T test p < 0.05. 
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This pulldown experiment gave qualitative but no quantitative information 
about cMAP3 selectivity for bivalent marks. Therefore, we used microscale 
thermophoresis (MST) to measure binding affinities of cMAP3 for peptides 5b, 5d 
and 5e.409,410 MST is based on the physical principle of thermophoresis, which is the 
direct movement of particles in a temperature gradient. This phenomenon depends 
on changes in the hydration shell, charge or size of molecules. In a typical MST 
experiment, a titration serie is prepared by mixing increasing concentrations of an 
unlabelled molecule with constant amounts of a fluorescently labelled binding 
partner. Upon binding, one (or several) of the three above-mentioned parameters 
changes and this change can be detected by measuring fluorescence while applying 
a temperature gradient. MST is an immobilization-free technique, which requires 
picomolar amounts of the fluorescently labelled compound. This technique was 
chosen here for the low quantities of labelled compound required, for its easy sample 
preparation and its rapidity of execution. We unsuccessfully attempted to measure 
the affinity of cMAP3 with Cy5-labeled nucleosomes as well as 601 DNA using 
MST. Therefore, MST measurements were performed with cMAP3 and histone 
peptides 5b, 5d and 5e (Figure 37). Titrating the peptides, Venus fluorescence was 
measured as a function of time upon application of a temperature gradient for 30 s 
(Figure 37. A). The difference in fluorescence between the few seconds before 
switching on the laser and the few seconds before the laser is turned off was plotted 
as a function of peptide concentration (Figure 37. B). Binding isotherms indicate a ~ 
50-fold enhancement of affinity for the bivalent peptide 5e compared to monovalent 
peptides 5b and 5d (Table 8). 
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Figure 37. Binding affinities of cMAP3 for histone peptides 5b, 5d and 5e determined by MST. A. 
Normalized fluorescence profile for peptide 5e. Legend indicates peptide concentrations. Inset: zoom 
between 20 and 30 s. B. Binding isotherms for peptides 5b, 5d and 5e. Error bars: standard deviation, 
n = 2. 
 
Peptides KD (µM) 
5b 7,9 ± 3,0 
5d 8,5 ± 2,5 
5e 0,165 ± 0,044 
Table 8. Binding affinities of cMAP3 for peptides 5b, 5d and 5e determined by MST. 
 
Together, these results show that cMAP3 preferentially bind to bivalent 
versus monovalent targets (nucleosomes and peptides). For cMAP3, cMAP pulldown 
indicates a 2 to 3-fold selectivity for bivalent (e) versus monovalent (b, d) 
nucleosomes, whereas MST shows a ~ 50-fold enhanced binding for bivalent (5e) 
versus monovalent (5b, 5d) peptides. This difference might be explained by a 
reduced accessibility of the H3 tail within nucleosomes. 
With a selective sensor in hands, we then investigated the subnuclear 
localization of cMAP3 in living cells. 
 
2.2.5 Visualization of bivalent domains in live cells 
  
In vitro binding assays showed cMAP3 selectivity for bivalent marks. With 
this functional probe, we proceeded with the visualization of bivalent chromatin in 
living ESCs. First of all, we checked the global nuclear distribution of H3K4me3 and 
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H3K27me3 in mESCs by immunofluorescence imaging using modification-specific 
antibodies (Figure 38). A granular pattern that covers the whole nucleus was 
observed for H3K4me3. H3K27me3 signal was enriched at the periphery of the 
nucleus. These results are in line with previously reported distributions for these 
marks.381 
Figure 38. Imaging of H3K4me3 and H3K27me3 by immunofluorescence in fixed mESCs. Draq5 
was used as a far-red DNA stain (scale bar: 5 µm). 
 
We then performed ChIP in mESCs (Figure 39) to confirm the coexistence of 
H3K4me3 and H3K27me3 at the promoters of 5 genes previously described as 
bivalent (Irx2, Olig1, HoxC5, HoxB13, Gata-4).241,246 As expected, these 5 genomic 
regions carried both marks. We also analysed 4 genes previously reported to have 
only H3K4me3 (Pou5f1, Polm, Gapdh, Tcf4) and one gene that carries only 
H3K27me3 (HoxA3).241,246 As expected, Pou5f1, Polm, Gapdh and Tcf4 have a high 
H3K4me3 signal and a low H3K27me3 signal, whereas HoxA3 has a high 
H3K27me3 signal and a low H3K4me3 signal. 
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Figure 39. ChIP signals for H3K4me3 (green bars) and H3K27me3 (red bars) at 11 genomic regions 
in mESCs. The left axis corresponds to H3K4me3 signal and the right axis to H3K27me3 signal. The 
negative control (IgG) is represented on the right axis (blue bars).“des. Chr1” is a desert region on 
chromosome 1 and is used here as a negative control. ChIP signals were averaged over 3 independent 
replicates. Error bars: standard deviation. 
 
When imaging transiently transfected cMAP3 in mouse ESCs using confocal 
fluorescence microscopy, fluorescent foci were observed throughout the nucleus 
(Figure 40. A, upper panel). Using an automated procedure (described in 2.2.7), we 
quantified the number of foci per nucleus for cells with similar cMAP3 expression 
levels, excluding nucleoli where FP-fusion proteins tend to accumulate (29.2 ± 1.8 
foci / nucleus, error: standard error of the mean, Figure 40. B). The localization of 
cMAP3 foci did not follow the distribution of H3K27me3 heterochromatin but 
showed a distinct pattern. 
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Figure 40. Visualizing bivalent chromatin domains in ESCs. A. Localization of cMAP3 and indicated 
mutant proteins in mouse ESCs (scale bar: 5 μm). B. Quantification of fluorescent foci in mouse ESCs 
for cMAP3 and reader domain mutants. The number of fluorescent spots detected was counted for 
each nucleus using an automated peak-finding protocol (number of cells analysed: cMAP3, n = 79; 
CD mutant, n = 81; PHD mutant, n = 41; CD-PHD mutant, n = 54) (Line: mean, Box: 25-75 % of the 
data, whiskers: 10-90 % of the data, Student T test * P < 0.05). 
 
To corroborate reader domain dependent localization, we then introduced 
point mutations in the CD and PHD. When mutating two key Trp residues to Ala in 
the CD (W47A and W50A, Figure 17. B), binding to methylated H3K27 is 
abolished.139 Introducing these mutations into cMAP3 indeed diminished subnuclear 
localization and produced homogenous staining of the whole nuclei, demonstrating 
that the PHD by itself is insufficient to result in sensor accumulation (9.6 ± 0.7 foci 
/ nucleus, Figures 40. A and B). Similarly, mutations of an Asp and Trp residue in 
the PHD to Ala (D886A and W891A, Figure 17. B) result in complete loss of 
H3K4me3 recognition.63 Similarly, these mutations reduced the formation of 
fluorescent foci significantly (15.9 ± 1.3 foci / nucleus, Figures 40. A and B), 
demonstrating that both reader domains are required for efficient chromatin 
localization. Finally, a cMAP3 construct with both CD and PHD mutated resulted in 
a largely homogenous nuclear distribution (5.4 ± 0.6 foci / nucleus, Figures 40. A 
and B).  
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Bivalent chromatin was found at about 35% of all genes in mESCs,261 
whereas it is present in much lower quantity in more differentiated cell lines.241,381 
We therefore transiently transfected HEK293 cells with cMAP3. As expected, the 
sensor adopted a homogeneous distribution in the differentiated cells (Figure 41). 
Figure 41. cMAP3 localization in HEK293 cells and mESCs (scale bar: 5 µm). 
 
Together, these results show that cMAP3 has a bivalent domain-dependant 
subnuclear localization in mouse ESCs and that cMAP3 can be employed as a 
bivalent chromatin sensor in live cells. 
 
2.2.6 Modulation of the epigenetic state with small molecules 
 
Having validated cMAP3 specificity, we employed the probe to monitor how 
small molecule epigenetic modulators change the chromatin state in ESC. We 
selected a range of available compounds (Table 9) and treated mESCs using 
published protocols. 
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Compound Enzyme(s) inhibited Conditions Observed pheno-
typic change 
UNC1999 EZH1 & EZH2 7 days, 5 µM None 
SAHA Class I & II histone 
deacetylases 
72 hours, 5 µM Apoptosis 
5 hours, 2.5 µM None 
Tranylcypromine 
(TCP) 
LSD1 72 hours, 10 µM None 
(+)-JQ1 Bromodomains of BET 
family (Mainly BRD4) 
72 hours, 500 nM Slower growth and 
differentiation 
Garcinol Histone acetyltrans-
ferases p300 & PCAF 
24 hours, 20 µM Apoptosis 
Table 9. mESC treatments with epigenetic small molecule modulators. 
 
Focusing on epigenetic modulators that did not show phenotypic changes, we 
investigated the effects of suberoylanilide hydroxamic acid (SAHA), a histone 
deacetylase (HDAC) inhibitor;411 tranylcypromine (TCP), an inhibitor of the H3K4 
specific lysine-specific demethylase 1 (LSD1);412 and UNC1999, a highly potent and 
selective inhibitor of the H3K27 specific lysine methyltransferases (KMT) enhancer 
of zeste homolog 1 and 2 (EZH1 and EZH2) (Figure 42. A).413 Treatment of mESCs 
with SAHA ( at a concentration of 2.5 µM for 5 h) or TCP (at a concentration of 10 
µM for 3 days) did not result in a statistically significant change in cMAP3 binding 
patterns and number of fluorescent foci (38.2 ± 1.5 and 40.5 ± 2.0 foci / nucleus, 
respectively, Figure 42. B and C). This reveals that inhibition of histone deacetylases 
or LSD1 has a mild influence on bivalent chromatin. In contrast, treatment with 5 
μM of UNC1999 for 7 days resulted in clear change of cMAP3 localization (Figure 
42. B and C), without phenotypic changes in the ESC. Imaging cMAP3 in mouse 
ESCs treated with UNC1999 compared to the untreated control group revealed a 
strong reduction in the number of fluorescent foci in the treated group (11.1 ± 1.1 
foci / nucleus, Figure 42. C), demonstrating that bivalent marks are largely abolished 
by UNC1999 action. 
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Figure 42. Small molecule disruption of bivalent domains. A. Chemical structures of employed 
epigenetic modulators. B. Localization of cMAP3 in mouse ESCs untreated or treated with SAHA, 
TCP or UNC1999 (scale bar: 5 μm). C. Quantification of fluorescent foci per nucleus for cMAP3 in 
mouse ESCs untreated or treated with SAHA, TCP or UNC1999 (number of cells analysed: untreated, 
n = 79; SAHA treated, n = 74; TCP treated, n = 51; UNC1999 treated, n = 44) (Line: mean, Box: 25-
75 % of the data, whiskers: 10-90 % of the data, Student T test * P < 0.05). 
 
To corroborate the loss of bivalency, we extracted histones from UNC1999 
treated and untreated cells. We then assessed H3K27me3 and H3K9me3 levels by 
WB (Figure 43. A). Indeed, H3K27me3 levels were strongly reduced due to 
inhibition of EZH2, consistent with the situation in cells carrying a knockout 
mutation in the EZH2 methyltransferase.414 Loss of H3K27me3 was further 
confirmed by immunofluorescence staining (Figure 43. B). However, H3K9me3 
level was not significantly changed by UNC1999 action. 
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Figure 43. UNC1999 treatment decreased the global level of H3K27me3 without changing the level 
of H3K9me3. A. Anti-H3K27me3 and anti-H3K9me3 WB of acid-extracted histones from mESCs 
untreated and treated with UNC1999. Upper panels: WB; Lower panels: Coomassie Blue stained gel. 
B. H3K27me3 immunofluorescence staining of mouse ESCs untreated and treated with UNC1999 
(scale bar: 5 μm). 
 
Together, these results show that cMAP3 is sensitive to changes in histone 
PTM patterns and can thus be employed to monitor the effect of epigenetic 
modulators on chromatin states at the single cell level. 
 
2.2.7 Validation of the procedure for local maxima count 
 
The local maxima analysis of images of treated or untreated mESCs 
transfected with cMAP3 or reader domain mutants was performed with ImageJ 
software (Figure 44). The following macro was applied to all images: 
 
run("Select All");  
run("Smooth", "stack");  
run("Find Maxima...", "noise=130 output=Count exclude"); 
run("Find Maxima...", "noise=130 output=[Point Selection]"); 
 
First, images were smoothed. Then the number of local maxima was counted 
with a noise tolerance of 130. Finally, the local maxima overlapping with nucleoli 
were manually subtracted. 
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Figure 44. Image treatment for local maxima count. A) Original image of cMAP3 transiently 
transfected in mESCs. B) Image in panel A smoothed. C) Image in panel B with 74 local maxima 
analysed by ImageJ with a noise tolerance 130. Maxima are represented as white dots (scale bar: 5 
μm). 
 
To investigate the dependence of the number of foci on the noise tolerance, 
we additionally performed the local maxima count with a noise tolerance of 110 on 
the images of mESCs transfected with cMAP3 and reader domain mutants as well as 
UNC1999 treated cells transfected with cMAP3 (Figure 45). 
Figure 45. Dependence of the local maxima count on the noise tolerance. A. Local maxima count for 
cMAP3 and the three reader domain mutants in mESCs with a noise tolerance of 110 and 130. B. 
Local maxima count for cMAP3 in ESCs untreated or treated with UNC1999 with a noise tolerance 
of 110 and 130. 
 
For a noise tolerance of 110, local maxima counts were only slightly higher 
compared to a noise tolerance of 130. This shows the mild influence of this criterion 
on the evaluation of probe subnuclear localization. Importantly, the local maxima 
count difference between WT cMAP3 and mutants and between treated and untreated 
cells remains statistically significant at a noise tolerance of 110. The method used 
here to quantify fluorescence granularity in nucleus is therefore valid to quantify the 
effect of reader domain mutations and of epigenetic drug treatments. 
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2.3 Discussion and conclusion 
 
The subnuclear organization and dynamics of chromatin states is not well 
understood, as tools for their detection in live cells are lacking. Here, we have 
developed a general pipeline for the design and in vitro validation of genetically 
encoded multivalent probes for patterns of histone PTMs. We applied this strategy 
for the stem cell specific bivalent chromatin state and named these probes cMAPs. 
cMAPs were engineered from a FP and a set of reader domains found in naturally 
occurring chromatin effector proteins. Several versions of cMAP were designed 
varying the following parameters: linker length and stiffness, domain organization, 
origin and length of the PHD. The binding of these variants was tested in a pulldown 
assay using a library of reconstituted nucleosomes carrying defined PTMs. Among 
the 4 tested variants, two (cMAP3-4) showed an increased affinity for bivalent 
compared to monovalent nucleosomes. This demonstrates that two reader domains 
with modest affinities for their cognate histone PTM, when connected with 
appropriate linker sequences, result in an increased affinity upon multivalent binding. 
The strategy used here consisted in creating a library of probes with different 
characteristics and assessing their selectivity for the desired target with a suitable 
binding assay. This approach is highly modular. In this case, probes were engineered 
with reader domains specific for H3K4me3 and H3K27me3. However, the strategy 
is applicable to any PTM pattern of interest by choosing other PTM-specific reader 
domains. For instance, the coexistence of H3K27me3 and H3K36me3 on 
nucleosomes in an asymmetric fashion was observed and is poorly understood.246 
The development of sensors for this pattern could help elucidate its function(s) and 
dynamics. 
After selection of cMAP3 as the most suited variant, we transiently 
transfected this probe in live mouse ESCs. Imaging by fluorescence confocal 
microscopy enabled the observation of discrete subnuclear foci, revealing the 
organization of bivalent chromatin into local clusters. The number of foci was 
significantly decreased for cMAP3 mutants in which key residues of the binding sites 
were changed to alanine. This result demonstrates that both reader domains play an 
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important role in the probe distribution. Moreover, cMAP3 enabled direct monitoring 
of the loss of bivalency upon treatment with a small molecule epigenetic modulator. 
Precisely, a reduction of fluorescent foci was observed upon inhibition of the 
catalytic subunits of PRC2 with the small molecule UNC1999, whereas no 
significant change in cMAP3 distribution of was measured upon inhibition of histone 
deacetylases or the histone demethylase LSD1. 
The organization of bivalent chromatin into discrete and local clusters 
resembles Polycomb bodies or transcription factories and suggests that bivalent 
promoters are brought together into “bivalent bodies” where genes might be 
regulated together and not individually. This hypothesis would have to be confirmed 
by further experiments. For example, CRISPR-Cas9 could be potentially used to 
include or excise a bivalent promoter from a precise genomic location and eventual 
relocation of the gene in or out of a “bivalent body” could be imaged combining 
cMAP3 (to image bivalent chromatin) with fluorescent in situ hybridization (FISH) 
(to image a precise genomic location). 
cMAP3 thus provides a novel platform to monitor bivalent chromatin 
dynamics in live cells. The developed sensor also represents a mean to target bivalent 
loci and modulate them by recruiting enzymatic activity to this specific chromatin 
state, enabling to rewrite the histone code. 
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Chapter 3. Installation and removal of a histone modification 
associated with active gene transcription 
 
Chromatin effectors called writers and erasers dynamically regulate 
chromatin states and gene expression by catalysing the enzymatic addition and 
removal of histone PTMs, respectively. Many diseases are associated with 
misregulation of writers or erasers. Among the most studied and complex histone 
marks are methyl groups on lysines. Methylated lysine comes in three flavours: 
monomethyl-, dimethyl- and trimethyllysine. Depending on the methylation state, 
the histone and the residue, methyllysine can be associated with active gene 
transcription or gene repression. Methyltransferases and demethylases can be 
specific for one or two methylation states, whereas others can catalyse the installation 
and removal of all three states, respectively.45 The mechanisms of recruitment and 
regulation of these enzymes are of high interest to the scientific community and will 
help to find answers to disorders associated with malfunctions of these proteins. This 
chapter focuses on the H3K4-specific demethylase LSD1 and the family of MLL 
H3K4-specific methyltransferases. H3K4 methylation is associated with active gene 
transcription and was proposed to counteract Polycomb repression. 
 
3.1 The demethylase LSD1 binds to unmodified nucleosomes 
 
3.1.1 Background 
 
Methyl histone PTMs were thought to be irreversible before the discovery of 
the first histone demethylase LSD1 (Lysine-specific histone demethylase 1A, also 
called KDM1A, AOF2, KIAA0601 or BHC110) in 2004.415 LSD1 is a nuclear 
homolog of amine oxidases that catalyses the removal of methyl groups from 
H3K4me1/2 (but has no activity on H3K4me3).415 In this oxidation reaction, flavin 
adenine dinucleotide (FAD) is used as cofactor and molecular oxygen is used to 
regenerate FAD (Figure 46).416 The reaction produces formaldehyde and H2O2 as 
byproducts.  
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Figure 46. Mechanism of FAD-dependent H3K4me2 demethylation by LSD1. 
 
LSD1 is a transcriptional repressor crucial for embryonic development and 
implicated in cancer.417,418 This demethylase is involved in the maintenance of 
pluripotency in stem cells and in the regulation of bivalent genes.275 Although its 
specificity for H3K4 is well established, it was suggested that LSD1 is also a H3K9-
specific demethylase.419 Therefore, LSD1 could be a transcriptional repressor or 
coactivator depending on the demethylated residue on H3. Further studies showed 
demethylase activity on other protein substrates, such as p53,420 DNMT1421 and 
MYPT1.422 LSD1 has not only multiple substrates but also multiple binding partners. 
Indeed, CoREST and HDACs are generally associated with LSD1.423–426 The protein 
BHC80 was also detected in the LSD1 complex.427 Lan et al. discovered that the 
PHD finger of BHC80 binds specifically to H3K4me0 histone peptides with a KD of 
33 µM and this interaction is abrogated by methylation of H3K4.66 The authors 
showed by RNAi and ChIP studies that LSD1 and BHC80 are dependent on one 
another to repress target genes by H3K4-demethylation. They proposed a recruitment 
role for BHC80: BHC80 binding to H3K4me0 nucleosomes would maintain LSD1 
at its target loci to prevent re-methylation by H3K4-specific methyltransferases. 
They also suggested that BHC80 recruits LSD1 to H3K4me0 nucleosomes such that 
LSD1 demethylates neighbouring nucleosomes. This type of positive feedback 
mechanism is observed for PRC2 as well (mentioned in chapter 1). On the other hand, 
other studies showed by competitive assays and SPR that LSD1 itself binds to 
unmodified H3 peptide and to full length unmodified histone H3.428,429 This is 
supported by the spacious catalytic site of the amine oxidase domain (AOD), which 
lacks specificity for the methylation states of H3K4.430 Its multiple substrates and 
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associated proteins suggest that LSD1 may have broad chromatin-associated 
functions and probably complex regulatory mechanisms. 
Several structures of LSD1 were reported after its discovery as 
demethylase.430–432 LSD1 contains an N-terminally unstructured region, dispensable 
for its activity,428 followed by a Swi3p, Rsc8 and Moira (SWIRM) domain, important 
for protein stability430,431 and enzymatic activity430 (Figure 47). Although its 
sequence is similar to DNA-binding modules, the SWIRM domain was shown to 
have no interaction with DNA in vitro.431 At the C-terminus, the tower domain 
formed by an antiparallel coiled-coil of two alpha helices is inserted into the AOD 
(Figure 47). The tower domain is crucial for demethylase activity430,431 and mediates 
association with CoREST.431 The active site of the AOD is composed of a large 
catalytic cavity.430,431 Adjacent to the active site and in close proximity to the 
SWIRM domain, a surface groove is proposed to accommodate the H3 tail.430,432 
Figure 47. Structure of LSD1. Upper panel: Domain organization of human LSD1 (isoform 2). Lower 
panel: ribbon representation of LSD1 (171-836) in complex with CoREST (308-440) (displayed in 
yellow), the H3 tail (1-16)K4M (displayed in blue) and FAD (displayed in red) (PDB: 2V1D). The 
SWIRM domain, the tower domain and the AOD are represented in light green, orange and dark green, 
respectively. 
 
3.1.2 Results and discussion 
 
The data described here is in the frame of a collaboration with the laboratory 
of Prof. Champak Chatterjee (University of Washington, USA). This collaborative 
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work is the subject of a manuscript in preparation with the following contributors: 
Abhinav Dhall, Caroline E. Weller, Patrick Shelton, Aurea Chu, Aurore M.-F. 
Delachat, Beat Fierz and Champak Chatterjee. Abhinav Dhall performed LSD1 
expression and the EMSA. Aurore M.-F. Delachat prepared the reconstituted 
nucleosomes and performed the MST assay. 
Knowing that both BHC80 PHD and LSD1 bind unmodified H3 peptides, we 
aimed to decipher the importance of each binding event for LSD1 recruitment to 
nucleosomes. For this purpose, we developed a binding assay using MST to quantify 
LSD1 binding to unmodified nucleosomes (Figure 48. A). Recombinant histones and 
Cy5-labeled DNA containing the strong nucleosome positioning sequence 601 were 
used to reconstitute nucleosomes. His6-tagged human full-length LSD1 protein was 
recombinantly expressed and purified by Ni-NTA affinity purification. Protein 
binding to unmodified mononucleosomes was first checked by EMSA (Figure 48. 
B). Then titration series were prepared with increasing concentrations of unlabelled 
LSD1 (between 8 nM and 131.7 µM) and a constant concentration of 10 nM of 
labelled nucleosomes. Cy5 fluorescence was measured as a function of time upon 
application of a temperature gradient (Figure 48. C). Binding isotherms were 
obtained from the fluorescence measurements and indicated a KD of 5.98 ± 1.66 µM 
and a Hill coefficient n of 1.49 ± 0.54 for full length LSD1 binding to unmethylated 
nucleosomes (Figure 48. D). 
Additionally, we showed that full length LSD1 binds to 601 DNA with a KD 
of 127 nM (Dhall et al., Manuscript in preparation). As LSD1 binds to both 601 DNA 
and unmodified histone H3, one can speculate about the contribution of each binding 
events to the total binding affinity. We demonstrated that LSD1 binding to 601 DNA 
is mainly electrostatic, since this interaction is greatly diminished at high salt 
concentration (Dhall et al., Manuscript in preparation). Here the MST measurement 
was done with 150 mM NaCl. At this concentration, the contribution of DNA is 
probably limited. The reported affinities of LSD1 for unmodified H3 peptide are Ki 
= 1.8 µM428 and Ki = 1.77 µM429. As for full length H3, Burg et al. reported a Ki of 
18.9 nM and a KD of 9.02 nM. These affinity constants are 3.3-fold and more than 
600-fold lower, respectively, compared to the KD of 5.98 µM for nucleosomes 
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measured by MST. However, any comparison between our measurement and 
previously reported affinities has to be cautiously interpreted for several reasons. 
First of all, our measurement was performed with 150 mM NaCl, whereas the cited 
binding assays were done without salt. LSD1 binding to H3 peptides was shown to 
be electrostatic.428,429,432 Therefore, the strength of the interaction is subjected to high 
differences upon changes in the salt concentration. Secondly, LSD1 used in our study 
was full length, whereas Burg et al. and Forneris et al. used truncated LSD1 (LSD1 
Δ1-150 for Burg et al. and LSD1 Δ1-184 for Forneris et al.). Despite being 
unstructured, the N-terminal region of LSD1 might modulate binding to 
nucleosomes. 
Figure 48. Binding affinity of LSD1 for unmodified nucleosomes. A. Scheme of the interaction 
quantified by MST. B. EMSA of unmodified mononucleosomes incubated with the indicated 
concentration of LSD1. Mononucleosomes were visualized by native PAGE. An asterisk indicates 
sub-saturated LSD1-bound species. Adapted from Dhall et al., Manuscript in preparation. C. 
Normalized fluorescence profiles. Legend indicates peptide concentrations. Adapted from Dhall et 
al., Manuscript in preparation. D. Binding isotherm for full length LSD1 and unmodified nucleosomes 
determined by MST. Error bars: standard deviation, n = 4. 
 
Compared to the affinity of BHC80 for unmodified H3 peptide, the affinity 
of LSD1 for unmodified nucleosomes measured here is ~ 5-fold stronger. This 
difference calls into question the biological importance of the interaction of BHC80 
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PHD finger with unmodified H3 peptide. As an alternative model to the one 
proposed by Lan et al., we propose that LSD1 binds to its own product, unmodified 
H3K4 nucleosomes, and this interaction maintains LSD1 at its target genes (Figure 
49). Additionally, BHC80 is proposed to have the role of fine tuning this positive 
feedback mechanism by enhancing binding to unmethylated H3K4, potentially on 
the same nucleosome (Figure 49. B, lower panel).  
Figure 49. Models for LSD1 recruitment. A. Model proposed by Lan and coworkers.66 B. New model 
in which LSD1 binds its product, H3K4me0 nucleosomes, through interaction with nucleosomal DNA 
and unmodified H3 tail. Dotted circles: fine tuning role for BHC80 and its PHD finger. 
 
3.1.3 Conclusion 
 
Previous studies showed the binding of LSD1 to H3K4me0/1/2/3 peptides. 
However, no report demonstrated the binding of LSD1 to unmodified nucleosomes. 
Here, we used MST to measure a KD of 5.98 ± 1.66 µM for the interaction of full 
length LSD1 with unmodified nucleosomes containing recombinant histones. 
Knowing that the AOD domain (together with tower domain) is responsible for 
binding to 601 DNA (Dhall et al., Manuscript in preparation) and that the catalytic 
site is large and not specific for one H3K4 methylation state, one can speculate that 
the observed binding phenomena is the result of AOD domain binding to both 
nucleosomal DNA as well as unmodified H3 tail. To confirm this, binding of 
truncated LSD1 proteins (lacking individually the N-terminal domain, the SWIRM 
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domain or the AOD/Tower domains) to nucleosomes will be tested by EMSA. To 
know the contribution of DNA binding to the total binding, MST will be used to 
measure affinity of full-length LSD1 to 601 DNA. The model proposed in Figure 49. 
B will be further tested by comparing nucleosomal affinities of BHC80 and BHC80-
LSD1 complex with the nucleosomal affinity of LSD1 by itself. 
 
3.2 Influence of bivalent marks on the activity of the methyltransferase 
SET1B 
 
3.2.1 Background 
 
Chromatin effectors are regulated by various mechanisms, among which 
histone modification crosstalks represent a complex and unclear regulatory layer. 
MLL complexes are involved in crosstalks with several histone modifications 
including their own product, H3K4 methylation. The third PHD finger of the N-
terminal part of MLL1 protein was demonstrated to bind to H3K4me3.433 
Furthermore, ASCOM, SET1A, WDR5 and RBBP5 were shown to bind to 
H3K4me3.171,212 These observations suggest a positive feedback loop for MLL 
complexes. H2BUb is required for yeast SET1-mediated H3K4 methylation.434 
PRC2 is inhibited by active chromatin marks206,207,435 and, in the same way, MLL 
complexes have reduced binding and activities on substrates containing the 
repressive mark H3K27me3.212 This observation leads to the questioning of how 
H3K4me3 and H3K27me3 can be deposited on the same nucleosomes, forming 
bivalent chromatin. 
In 2012, an MS-based immunoprecipitation method revealed that 
nucleosomes exist in the cell in both symmetric and asymmetric conformations, i.e. 
with different modifications on sister histones.246 The authors revealed that bivalent 
marks are found in an asymmetric fashion on mononucleosomes. Since then, several 
questions arose: are asymmetrically modified nucleosomes actively or passively 
produced by chromatin modifier enzymes? Does asymmetry have a biological role? 
And if yes, which one(s)? In 2016, colleagues developed a modular and traceless 
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strategy to synthesize asymmetrically modified semi-synthetic nucleosomes using 
EPL.207 In this study, symmetric and asymmetric nucleosomes were used to perform 
histone methyltransferase (HMTase) assay with PRC2. Assays with asymmetric 
H3K27me3 nucleosomes showed that PRC2 is activated by its own product, 
H3K27me3, when present on the opposite H3 tail (trans stimulation). Assays with 
symmetric and asymmetric H3K4me3 nucleosomes revealed that PRC2-mediated 
installation of H3K27me3 is inhibited by the active chromatin mark only when 
present on the same H3 molecule (cis inhibition). This suggests an active mechanism 
for the appearance of bivalent nucleosomes, i.e. PRC2 favours the installation of 
H3K27me3 on the tail opposite to H3K4me3. Assays with trans asymmetric bivalent 
nucleosomes revealed that the trans H3K27me3 activation can partially override the 
cis H3K4me3 inhibition. This finding together with the observation that bivalent 
marks are present mainly in an asymmetric fashion in the cell246,263 suggests that 
PRC2 activity at bivalent genes has to be restrained. 
 
3.2.2 Results and discussion 
 
The data presented here is in the frame of a collaboration with the laboratory 
of Prof. Jaehoon Kim (KAIST, South Korea). Jaehoon Kim provided the MLL 
complexes. Aurore M.-F. Delachat prepared reconstituted nucleosomes and 
performed the HMTase assays. Carolin C. Lechner provided the asymmetrically 
modified H3K4me3 and symmetrically modified H3K27me3 octamers. 
The use of chemically synthesized asymmetrically modified nucleosomes 
gave useful insights about the influence of pre-existing H3K4me3 and/or H3K27me3 
on the activity of PRC2. However, little is known about the activity of MLL 
complexes on asymmetrically modified nucleosomes. Here we took advantage of the 
access to asymmetrically modified nucleosomes to perform HMTase assays with 
MLL complexes. MLL complexes catalyse the installation of methyl groups on 
lysine using S-adenosylmethionine (SAM) as cofactor (Figure 50. A). The six human 
MLL complexes were obtained by purification of FLAG-tagged SET1 or MLL 
proteins from stably transfected insect cells, which allows to have a defined subunit 
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composition for the complexes. MLL1-4 complexes contained the catalytic subunit 
(containing pre-SET, SET and post-SET domains), WDR5, RBBP5, ASH2L and 
DPY30. The SET1A/B complexes contained the catalytic subunit (containing n-SET, 
SET and post-SET domains), WDR5, RBBP5, ASH2L, DPY30 and CFP1. The 
activity of the purified complexes were tested on unmodified and H2BUb 
nucleosomes in HMTase assays (Figure 50. B). MLL3 and MLL4 showed no 
detectable activity on both substrates. Similar to the yeast SET1 complex,434 human 
SET1A/B and MLL1-2 showed a H2BUb-dependent activity. In yeast, the H2BUb 
dependency was attributed to the n-Set domain, which was present in the human 
proteins used here. Among the four active complexes in our hands, SET1B showed 
the greatest activity and a mild dependency on H2BUb. These two characteristics are 
desired when studying the influence of H3K4me3 and H3K27me3 individually on 
the enzymatic activity. Therefore, we chose SET1B to perform HMTase assays with 
SAM labelled with tritium (3H-SAM). The 3H-methyl group deposited on H3 by 
SET1B were detected by fluorography after SDS PAGE and by scintillation 
counting. 
Figure 50. MLL complexes catalyse the installation of methyl groups on H3K4. A. Mechanism of 
SAM-dependent lysine methylation by MLL complexes. B. Activity of the six MLL complexes on 
unmodified or H2B ubiquitinated mononucleosomes. H3K4 methylation was detected by immunoblot 
with H3K4me1/2/3-specific antibodies. Data by Jaehoon Kim’s lab. 
 
First, we compared SET1B activity on symmetrically modified H3K27me3 
nucleosomes and unmodified nucleosomes (Figure 51). Enzymatic reactions 
performed with either 0.2 or 2 pmol of SET1B resulted in similar signals for 
H3K27me3 compared to unmodified nucleosomes after 2 hours (Figure 51. A and 
88 
 
B). Kinetic analysis revealed similar methylation levels comparing unmodified and 
H3K27me3 nucleosomes at all time points (Figure 51. C). These results showed that 
H3K27me3 has no significant influence on SET1B complex activity in these 
experimental conditions. A similar experiment was performed by Kim et al. with 
human SET1A complex and revealed a clear inhibitory effect of H3K27me3 on the 
activity of the methyltransferase.212 Despite the fact that the authors used SET1A, 
whereas we used SET1B, different methods were employed to express the enzymatic 
complexes. Kim et al. purified human SET1A complex from a FLAG-tagged subunit 
(CFP1, SET1A or WDR82) transfected in human cells. Therefore, this SET1A 
complex was composed of the full-length catalytic subunit and an undetermined 
number of endogenous subunits. We purified human SET1B complex from FLAG-
tagged SET1B protein stably transfected in insect cells. Consequently, the SET1B 
complex used here contains a truncated catalytic subunit (residue 1672 to 1966 
contains the n-SET, SET and post-SET domains) and a defined set of other subunits. 
The absence of H3K27me3 inhibition of SET1B complex observed here together 
with the clear inhibition of SET1A complex by H3K27me3 in Kim et al. revealed 
that the element responsible for this histone crosstalk resides in the difference in 
complex composition. Supporting this hypothesis, several studies showed that 
different subunit composition or different lengths of the catalytic subunit influence 
methyltransferase activity as well as sensitivity to other histone PTMs.171,181,433,434 
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Figure 51. H3K27me3 does not influence SET1B activity on H3K4. HMTase assays with SET1B 
complex, unmodified or H3K27me3 nucleosomes as substrates and 3H-SAM as cofactor. A. Histones 
were separated by SDS PAGE, stained with coomassie blue (lower panel) and probed for 3H-methyl 
incorporation by fluorography (upper panel). 0.2 pmol of SET1B was used. Stars indicate leakage of 
the sample in the neighbouring lane. B. and C. Enzymatic reactions were subjected to scintillation 
counting. For panel B, 0.2 or 2 pmol of SET1B was used and the reaction was stopped after 2 hours. 
Signals are normalized to “unmodified nucl.”. Error bars: standard deviation, n = 2. For panel C, 0.2 
or 2 pmol of SET1B was used and the reactions was stopped after 10, 30 or 120 min. Signals are 
normalized to “unmodified octamers”. n = 1. 
 
We then decided to investigate how the presence of K4me3 on one H3 tail 
influences SET1B activity on the opposite H3 molecule. HMTase assays were 
performed with 3H-SAM on asymmetric H3K4me3 (asH3K4me3) and unmodified 
nucleosomes. A 1.3-fold increased signal was measured for asH3K4me3 compared 
to unmodified nucleosomes after 2 hours reaction (Figure 52). Kinetic analysis 
indicates that this increase is also measured after 10 and 30 minutes. H3K4me3 
therefore enhances SET1B activity in trans. 
Figure 52. K4me3 on one H3 copy enhances SET1B enzymatic activity on the opposite H3 copy. 
HMTase assays with SET1B complex, unmodified or asymmetric H3K4me3 nucleosomes as 
substrates and 3H-SAM as cofactor. A. Histones were separated by SDS PAGE, stained with 
coomassie blue (lower panel) and probed for 3H-methyl incorporation by fluorography (upper panel). 
B and C. Enzymatic reactions were subjected to scintillation counting and signals normalized to 
“unmodified octamers”. Data are represented as histogram (B) or as a function of time (C). Error bars: 
standard deviation, n = 2. 
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The interpretation of this result requires some considerations. First of all, 
asH3K4me3 nucleosomes contain one site available for SET1B-mediated 
methylation, whereas unmodified nucleosomes have two. Secondly, our experiments 
did not allow to differentiate between the three states of methylation. The signal 
therefore corresponds to the sum of all methyl groups installed on nucleosomes. We 
propose two hypothesis for the mechanism of this stimulation by H3K4me3 in trans 
(Figure 53). Hypothesis 1 involves a change of mono-/di-/tri-methyl ratios due to the 
presence of H3K4me3 on one tail. On unmodified nucleosomes, SET1B would 
deposit mainly monomethylation, whereas the equilibrium is shifted to the trimethyl 
state for asH3K4me3 nucleosomes. In this model, the 3H signal with asH3K4me3 
nucleosomes as substrates would be 1.5-fold higher than with unmodified substrates. 
This mechanism might involve allosteric activation of the enzyme by one or several 
of its subunit. Supporting this idea, WDR5 was shown to bind to H3K4me2/3 
peptides and to H3K4me2 nucleosomes.171 Moreover, this subunit was demonstrated 
to be responsible for the di- to tri-methyl conversion. Further supporting hypothesis 
1, WDR5, RBBP5, ASCOM and human SET1A were shown to have an increased 
binding to H3 peptides when the latter is trimethylated at K4.212 Hypothesis 2 
involves a change in the kinetic of the enzyme. The presence of H3K4me3 would 
accelerate the installation of methyl groups on the opposite H3 molecule. These two 
hypotheses are not necessarily exclusive and other mechanisms might come into 
play. Furthermore, it is possible that the stimulation might be explained by a 
combination of hypotheses 1 & 2. 
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Figure 53. Hypothetical models for SET1B activation by H3K4me3 in trans. Pre-existing methyl 
groups at H3K4 are represented by green circles. 3H-methyl groups at H3K4 are represented by 
glowing green circles. Here one methyl group is represent by one circle.  
 
3.2.3 Conclusion 
 
The access to chemically synthesized asymmetrically modified nucleosomes 
allowed us to study the influence of pre-existing marks on the activity of SET1B. A 
previous study indicated that H3K27me3 inhibits human SET1A complex.212 
Therefore, previous to testing if H3K27me3 could inhibit SET1B in trans (with 
asH3K27me3 nucleosomes), we performed HMTase assay with SET1B on 
symmetric H3K27me3 nucleosomes. Surprisingly, we found that human SET1B 
activity on H3K27me3 nucleosomes is similar to its activity on unmodified 
nucleosomes. This result showed that the element responsible for sensitivity to 
H3K27me3 is present in the complex used by Kim et al. but is absent in the complex 
used here. In order to have further insights about this, several experiments will be 
performed. HMTase assays with WB readout will enable us to identify changes of 
activity towards the three methylation states. To rule out if the N-terminal part of the 
catalytic subunit SET1B is responsible for this crosstalk, full-length SET1B complex 
will be used in HMTase assays with H3K27me3 and unmodified nucleosomes. 
WDR5, RBBP5, ASCOM and SET1A have an enhanced binding to 
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H3K4me3 peptide versus unmodified peptide.212 However, whether the active mark 
influences the activity of MLL complexes is unclear. Here, we showed that human 
SET1B activity is enhanced on asH3K4me3 nucleosomes compared to unmodified 
nucleosomes. To investigate the mechanism of this activation, several experiments 
will be performed. To test if binding of H3K4me3 induces a conformational change 
in the complex that enhances its activity, we will test HMTase activity on unmodified 
nucleosomes with and without adding H3K4me3 peptide in trans. A higher activity 
in presence of the peptide would suggest a conformational change within the enzyme 
upon binding to H3K4me3. Equal signals with and without the peptide added in trans 
would rather suggest that H3K4me3 on one tail serves as a recruitment platform 
and/or helps to position the enzyme on the nucleosomal substrate for increased 
activity on the unmodified H3 tail. 
At completion, hypothesis 1 (Figure 53) involves a higher 3H signal for 
asH3K4me3 substrates, whereas hypothesis 2 entails a 2-fold lower 3H signal for 
asH3K4me3 substrates compared to unmodified nucleosomes. To test the validity of 
hypotheses 1 and 2, HMTase assays with WB readout as well as reactions for longer 
times will be performed. 
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Chapter 4. Materials and methods 
 
4.1 Reagents and instrumentation 
 
All solvents and reagents were purchased from commercial sources and used 
without further purification. Fmoc-Lys(Me3)-OH chloride was purchased from GL 
Biochem Ltd. (Shanghai, China). All other amino acid derivatives, 2-chlorotrityl 
chloride resin and 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3- tetramethyluronium 
hexafluorophosphate (HATU) were purchased from Novabiochem, Merck 
(Darmstadt, Germany). O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate (HBTU) was purchased from Protein Technologies 
(Manchester, United Kingdom). N,N-Dimethylformamide (DMF), N,N-
diisopropylethylamine (DIPEA) and piperidine were from Acros Organics (Geel, 
Belgium). Bovine serum albumin (BSA), D,L-Dithiothreitol (DTT), trifluoroacetic 
acid (TFA), tris(2-carboxyethyl)phosphine hydrochloride (TCEP), sodium nitrite 
(NaNO2), L-Glutathione reduced, Triton X-100, sodium fluoride (NaF), IGEPAL 
CA-630, β-mercaptoethanol, triisopropylsilane (TIS), 2,2,2- Trifluoroethanethiol 
(TFET), anti-Flag monoclonal M2 antibody mouse, anti-mouse IgG peroxidase 
conjugate, GMEM media, sodium pyruvate, PD184352, paraformaldehyde 
(powder), (±)-6-hydroxy-2,5,7,8-tetramethylchromane-2-carbo-xylic acid (Trolox) 
were from Sigma Aldrich (Taufkirchen, Germany). 2,2'-Azobis[2-(2- imidazolin-2-
yl)propane]dihydrochloride (VA-044) was purchased from Wako Pure Chemical 
Industries, Ltd. (Osaka, Japan). Chemicals and solutions for preparation of SDS 
polyacrylamide gels (acrylamide, Precision Plus Protein™ All Blue Prestained 
Protein Standard), Immuno-Blot® polyvinylidene difluoride (PVDF) Membrane for 
Protein Blotting and Clarity™ Western ECL Substrate were purchased from Bio-Rad 
(Hercules, CA, USA). Slide-A-Lyzer™ dialysis cassettes, Slide-A-Lyzer™ Mini 
Dialysis buttons (3500 Da MWCO), Slide-A-Lyzer™ MINI dialysis devices 
(MWCO 10’000 Da) and protein G magnetic beads were from Thermo Scientific 
(Rockford, IL, USA). The centrifugal concentrators vivaspin 500 (10’000 MWCO, 
PES membrane) were purchased from Sartorius Stedim (Goettingen, Germany). The 
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anti-trimethyl-Histone H3 (Lys27) (α-H3K27me3, rabbit polyclonal) antibody used 
for immunofluorescence and Western Blot of acid-extracted histones as well as 2-
mercaptoethanol and LIF for ESC culture were from Merck Millipore. UNC1999 
was purchased from Sigma Aldrich. Ampicillin, phenylmethylsulfonyl fluoride 
(PMSF), lysozyme and isopropyl-β-D-thiogalactoside (IPTG) were purchased from 
BioChemica Applichem (Darmstadt, Germany). Kanamycin was purchased from 
Roth (Karlsruhe, Germany) or Acros (Geel, Belgium). All restriction enzymes were 
purchased from New England Biolabs (Bioconcept, Allschwil, Switzerland). 5% 
CriterionTM TBE Polyacrylamide gels were purchased from Bio-rad (Cressier, 
Switzerland). ZnCl2 and H2SO4 were purchased from Fluka (Sigma-Aldrich, 
Taufkirchen, Germany). Glycerol was purchased from Fisher Chemicals (Zürich, 
Switzerland). The protease inhibitor cocktail cOmpleteTM EDTA-free and X-
tremeGENE 9 DNA transfection reagent were purchased from Roche (Switzerland). 
The Ni-NTA resin and QIAquick PCR Purification Kit were purchased from Qiagen 
(Hombrechtikon, Switzerland). Hydrazine monohydrate was purchased from Alfa 
Aesar (Heysham, UK). Dynabeads M-280 streptavidin and PureLink RNase A were 
purchased from Invitrogen (Thermo Scientific, Rockford, IL, USA). The IgG, anti-
H3K4me3 and anti-H3K27me3 antibodies used for ChIP as well as the anti-Histone 
H3 antibody were from Abcam (Cambridge, UK). The anti-rabbit HRP conjugate 
was from Perkin Elmer (Zürich, Switzerland). MEM non-essential amino acids, L-
glutamine, FBS embryonic stem cell-qualified, formaldehyde 16%, Methanol free 
and Alexa Fluor 647 antibody anti-rabbit antibody were purchased from 
LifeTechnologies (Thermo Scientific, Rockford, IL, USA). Penicillin/streptomycin 
was purchased from Bioconcept (Allschwil, Switzerland). GSK3 inhibitor XVI was 
from Calbiochem (San Diego, USA). Recombinant mouse E-cadherin Fc Chimera 
was from BioTechne AG (Zug, Switzerland). OptiMEM I 1x reduced serum medium 
was from Gibco (Thermo Scientific, Rockford, IL, USA). Draq5 was from Biostatus 
(Leicestershire, UK). Proteinase K was from Ambion (Thermo Scientific, Rockford, 
IL, USA). 
Reaction vessels for manual peptide synthesis as well as the automated 
Tribute peptide synthesizer were from Protein Technologies Inc. Bacterial cells for 
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recombinant protein expression were grown in an HT infors AG incubator. E. coli 
cells were lysed by sonication using a Vibra-cell VCX 750 Sonics & Materials 
sonicator. Sedimentations were accomplished in an Avanti J20 XPI centrifuge and 
rotors (JA-12 and JA-8.1000) from Beckman Coulter. The Mini-Protean II system 
for SDS-PAGE and the Criterion blotter Transfer Cell for Western Blot were from 
Bio-Rad. Gels and blots were imaged using a ChemiDoc MP imaging system from 
Bio-Rad. Analytical RP-HPLC analysis was performed on an Agilent 1260 series 
instrument using an analytical Agilent Zorbax C18 column (150×4.6 mm, 5 μm 
particle size) at a flow rate of 1 mL/min. All RP-HPLC analyses were done with 0.1 
% (v/v) TFA in H2O (RP-HPLC solvent A) and 90 % acetonitrile and 0.1 % (v/v) 
TFA in H2O (RP-HPLC solvent B) as mobile phases. Typically, a gradient from 0-
70 % solvent A to solvent B over 30 min was used for analytical RP-HPLC analyses 
unless otherwise stated. Preparative RP-HPLC purifications were done on an Agilent 
1260 preparative HPLC system with a preparative Agilent Zorbax C18 column 
(250×21.2 mm, 7 μm particle size) at a flow rate of 20 mL/min. Electrospray 
ionization mass spectrometric (ESI-MS) analysis was conducted on a LCQ Fleet Ion 
Trap mass spectrometer (Thermo fisher) interfaced with a Dionex Ultimate 3000 
UPLC system or Shimadzu MS2020 single quadrupole instrument connected to a 
Nexera UHPLC system. Mass spectra were acquired by electrospray ionization in 
positive ion mode in the mass range of 300-2000 m/z. UV-Vis absorption 
measurements were carried out using an Agilent 8453 UV-Vis spectrophotometer. 
The Bioruptor sonicator used for ChIP was from Diagenode. The Fragment Analyzer 
used for ChIP was from Advanced Analytical. Microscale Thermophoresis 
measurements were performed on Monolith NT.115 (Nanotemper). 
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4.2 Production of nucleosomes using site-specifically modified, semi-
synthetic histones 
  
 4.2.1 Solid phase peptide synthesis 
 
2-Chlorotrityl resin was first reacted with hydrazine as previously 
described.207 Briefly, 0.5g 2-chloro-trityl chloride resin was swollen in 3mL DMF 
for 15min and cooled to 4°C. A solution of 350µL DIPEA (2.01mmol, 3 eq.), 65µL 
hydrazine monohydrate (1.33mmol, 2 eq.) and 585µl DMF was added dropwise to 
the resin. The reaction was stirred for 1h at room temperature (RT). 
For the peptides 1b (H3(1-14)K4me3), 1d (H3(1-28)K27me3) and 1e (H3(1-
28)K4me3K27me3), the sequences corresponding to residues 1 - 14 or 1 - 28 of 
human H3.1 with lysine 4 or/and 27 trimethylated were synthesized on this resin by 
SPPS using the Fmoc protection strategy. The peptide 1b was synthesized manually 
and for the peptides 1d and 1e, serine 28 and trimethyllysine 27 were first manually 
coupled and then residues 1 to 26 were synthesized automated on the Tribute peptide 
synthesizer (PTI). HBTU was used for activation of all amino acid except trimethyl-
lysine for which HATU was used. t-Butyl side chain protection was used for Serine 
and Threonine, t-Butyloxycarbonyl (Boc) side chain protection was used for Lysine, 
pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) side chain protection was used for 
arginine and trityl side chain protection was used for Glutamine. The pseudo proline 
Fmoc-Gln(Trt)-Thr(psiMe,-Mepro)-OH was used to install Q5 and T6 in peptides 
1b, 1d and 1e. For peptides 1d and 1e, Fmoc-Ala-Thr(psiMe, Mepro)-OH and Fmoc-
Lys(Boc)-Ser(psiMe, Mepro)-OH were used to install A21-T22 and K9-S10, 
respectively. To improve synthesis yields, double couplings were performed where 
appropriate. Deprotection of the N-terminal Fmoc-group was achieved by treating 
the resin twice with 20 % (v/v) piperidine in DMF. The corresponding pre-activated 
amino acid (5 eq., activated with 4.8 eq. HBTU and 10 eq. DIPEA) was added to the 
resin and coupled for 30 min. Between coupling and deprotection steps, the resin was 
washed with DMF. After completion of peptide assembly, peptidyl-resins were 
washed with DMF, dichloromethane and methanol and dried under vacuum. 
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Following cleavage from the resin by a mixture of 95 % trifluoroacetic acid (TFA), 
2.5 % water and 2.5 % triisopropylsilane (TIS), crude peptides were washed at least 
twice with cold diethyl ether and recovered by centrifugation. Crude peptides were 
dissolved in 50 % RP-HPLC solvent B and lyophilized. The peptides were purified 
by RP-HPLC on a preparative scale using linear gradients of 0 % - 15 % solvent B 
over 40 minutes for peptide 1b, 5 % - 20 % solvent B over 45 minutes for peptide 1d 
and 0 % - 40 % solvent B over 40 minutes for peptide 1e. The peptides were 
characterized by analytical RP-HPLC and ESI-MS. 
For peptides 4 (H3(15-35) A15C,V35Y) and 4’ (H3(29-35) A29C,V35Y), the 
sequences corresponding to residues 15 - 35 or 29 - 35 of human H3.1 with N-
terminal alanine (15 or 29) mutated to cysteine and valine 35 mutated to tyrosine 
were synthesized on rink amide resin by SPPS, using the Fmoc protection and HBTU 
activation strategy. t-Butyl side chain protection was used for serine, threonine and 
tyrosine, Boc side chain protection was used for lysine, Pbf side chain protection was 
used for arginine and trityl side chain protection was used for glutamine and cysteine. 
The pseudo proline building block Fmoc-Ala-Thr(psiMe,-Mepro)-OH was used to 
install A21 and T22 in peptide 4. To improve synthesis yields, double couplings were 
performed where appropriate. For Fmoc deprotection, amino acids pre-activation, 
coupling and peptide cleavage refer to the paragraph above about peptides 1b, 1d 
and 1e.The crude peptides were purified by RP-HPLC on a preparative scale using 
linear gradients of 10%-35% solvent B over 40 minutes for peptide 4 and 0 % - 40 
% solvent B over 40 minutes for peptide 4’. The peptides were characterized by 
analytical RP-HPLC and ESI-MS. 
 
 4.2.2 Recombinant expression of truncated and wild type histones 
 
Human wild type core histones H2A, H2B, H3_C110A and H4 were 
recombinantly expressed as described previously.75 Briefly, histones were expressed 
in BL21 (DE3) pLysS cells from genes inserted into a pet15b plasmid. Cell cultures 
were grown at 37°C in LB media supplemented with 100 µg/mL ampicillin and 35 
µg/mL chloramphenicol until an OD600 of 0.6. Protein expression was induced by 
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addition of IPTG to a final concentration of 0.5 mM. Expression of the protein was 
allowed to continue until 3 h post-induction. Cells were harvested, cell pellets were 
resuspended in lysis buffer (20 mM Tris, 1 mM EDTA, 200 mM NaCl, 1 mM -
mercaptoethanol, 1x protease inhibitor cocktail, pH = 7.5). Cells were lysed by 
freeze-thawing and sonication. The inclusion body pellet was washed twice with 7.5 
mL of histone lysis buffer with 1 % triton and once without triton. Histones were 
resolubilized in histone resolubilization buffer (6 M GdmCl, 20 mM Tris, 1 mM 
EDTA, 1 mM -mercaptoethanol, pH = 7.5), dialyzed into urea buffer (7 M urea, 10 
mM Tris, 1 mM EDTA, 0.1 M NaCl, 5 mM -mercaptoethanol, pH = 7.5) followed 
by purification by cation exchange (using a HiTrap SP HP 5mL column). 
N-terminal truncated variants of human H3.1_C110A variant 2 (H3(Δ1-14, 
A15C)) and 2’ (H3(Δ1-28, A29C)) were recombinantly expressed as N-terminal 
fusion to a His6-SUMO tag in E. coli BL21 (DE3) pLysS cells. For truncated histone 
2, cells were grown in LB medium (supplemented with 50 µg/mL kanamycin and 35 
µg/mL chloramphenicol) at 37 °C until reaching an OD600 of 0.6 - 0.8. Protein 
expression was induced by addition of IPTG to a final concentration of 0.5 mM. 
Expression of the protein was allowed to continue until 4 h post-induction. For 
truncated histone 2’, cells were grown in autoinduction medium (1 % tryptone, 0.5 
% yeast extract, 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 
2 mM MgSO4, 0.5 % glycerol, 0.05 % glucose, 0.2 % α-lactose, 50 µM FeCl3•6H2O, 
20µM CaCl2, 10 µM MnCl2•4H2O, 10 µM ZnSO4•7H2O, 2 µM CoCl2•6H2O, 2 µM 
CuCl2•2H2O, 2 µM NiCl2•6H2O, 2 µM Na2MoO4•2H2O, 2 µM Na2SeO3•5H2O, 2 
µM H3BO3) at 37 °C. Protein expression was allowed to proceed for 16 h. 
Subsequently, cells were harvested by centrifugation (4000 g, 4 °C, 20 min) and the 
cell pellet was resuspended in lysis buffer (20 mM Tris-HCl, 200 mM NaCl, 1 mM 
EDTA, 1 mM β-mercaptoethanol, pH = 7.5). Cells were lysed by sonication and the 
lysate was centrifuged (15000 g, 4 °C, 30 min). The pelleted inclusion bodies were 
washed three times with lysis buffer containing 1 % Triton X-100 and twice with 
lysis buffer without detergent. Inclusion bodies were solubilized in Ni-NTA 
purification buffer A (6 M GdmHCl, 50 mM Tris-HCl, 100 mM NaCl, 5 mM 
imidazole, pH = 7.5), centrifuged (15000 g, 4 °C, 30 min) and applied to Ni-NTA 
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resin previously equilibrated with Ni-NTA purification buffer A. The protein was 
bound to the resin by gentle nutating overnight at 4 °C. The flow-through was 
collected and the resin was washed with 5 column volumes (CV) and 2 CV Ni-NTA 
purification buffer A followed by washing with 2 x 5 CV Ni-NTA purification buffer 
B (6 M Urea, 150 mM Tris-HCl, 150 mM NaCl, 50 mM imidazole, pH = 7.5). 
Finally, the protein was eluted with 4 x 1 CV Ni-NTA purification buffer C (6 M 
Urea, 150 mM Tris-HCl, 150 mM NaCl, 500 mM imidazole, pH = 7.5). Fractions 
were analysed by SDS PAGE and protein containing fractions were pooled.  
The SUMO protease ULP1 required for cleavage of His6-SUMO tag from the 
fusion protein was expressed from a pET30 plasmid in E. coli BL21 (DE3) cells. Cell 
cultures were grown in LB media supplemented with 100 µg/mL kanamycin. Protein 
expression was induced with 0.15 mM IPTG at OD600 of 0.6 and cell cultures were 
further incubated at 37 °C for 4 h. Harvesting and lysis of cells, isolation of inclusion 
bodies as well as purification by Ni-NTA affinity chromatography was done as 
described for His6-SUMO-H3(Δ1-14, A15C) and His6-SUMO-H3(Δ1-28, A29C) 
fusion proteins. Refolding and cleavage of His6-SUMO from the His6-SUMO-
H3(Δ1-14, A15C) and His6-SUMOH3(Δ1-28, A29C) fusion proteins was achieved 
by dialysis against 1 M Urea, 75 mM Tris-HCl, 150 mM NaCl, 5 mM DTT, 25 mM 
L-arginine, 5 mM L-cysteine, pH = 7.5. The fusion protein and His6-ULP1 were 
mixed in a mass ratio of 4:1 and dialyzed at 4 °C overnight. The cleavage reaction 
was checked for completeness by RP-HPLC and ESI-MS analysis. Truncated histone 
2 and 2’ were purified from crude protein mixtures by preparative RP-HPLC with 
gradients of 30 % - 75 % solvent B in 30 min and 47 % - 62 % solvent B in 30 min, 
respectively. Collected fractions were analysed by analytical RP-HPLC and ESI-MS. 
Pure fractions were pooled, lyophilized and stored at - 20 °C. Typical yields were 5 
mg of truncated histone 2 and 3mg of truncated histone 2’ per litre bacterial culture. 
 
 4.2.3 Ligation and desulfurization 
 
Initially, histones 3d (H3K27me3) and 3b (H3K4me3) were synthesized by 
standard expressed protein ligation (EPL). In a typical ligation reaction, between 1 
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and 2 μmol of H3 tail peptide hydrazide was dissolved in ligation buffer (6 M 
GdmHCl, 0.2 M Na2HPO4, pH = 3.0) to a final concentration of 2.5 mM and the pH 
readjusted to 3.0. The peptide solution was kept at - 10 °C in an ice/NaCl bath and 
NaNO2 was added dropwise from a stock of 200 mM to a final concentration of 18 
mM. After mixing, the peptide was incubated at - 10 °C for 20 min, yielding to the 
peptide-azide. Typically, 0.6 μmol of truncated recombinant H3 protein was 
dissolved in mercaptoethanol acetic acid (MPAA) ligation buffer (6 M GdmHCl, 0.2 
M Na2HPO4, 0.2 M MPAA, pH = 8.0) to a final concentration of 1 mM. The molar 
ratios peptide/protein was 4:1. The protein in MPAA ligation buffer was added to the 
peptide-azide and the pH was adjusted to 7.0. The reaction was monitored by 
analytical RP-HPLC. After 1 h, TCEP was added to a final concentration of 20 mM. 
When the reaction had reached completion, it was mixed with 1 volume of 20 % RP-
HPLC solvent B and purified by semi-preparative RP-HPLC using a gradient of 20 
% - 70 % HPLC solvent B in 40 min. The ligation product was characterized by 
analytical RP-HPLC and ESI-MS. The obtained protein was then desulfurized to 
convert the cysteine into alanine at the ligation site. The protein was dissolved in 
TCEP desulfurization buffer (6 M GdmHCl, 0.1 M Na2HPO4, 250 mM TCEP, pH = 
6.5) to a final concentration of 0.5 mM. Glutathione and VA-044 radical starter were 
added from stock solutions to final concentrations of 40 mM and 20 mM, 
respectively. The pH was adjusted to 6.5 and the reaction was allowed to proceed at 
37 °C. The reaction was monitored by analytical RP-HPLC and ESI-MS. When the 
reaction had reached completion, it was mixed with 1 Volume of 30 % RP-HPLC 
solvent B and purified by semi-preparative RP-HPLC using a gradient of 30 % - 70 
%B in 40 min. The purified protein was characterized by analytical RP-HPLC and 
ESI-MS. 
For histones 3e (H3K4me3K27me3) and 3b, a previously described one-pot 
ligation-desulfurization strategy was used.207,367 Briefly, between 1 and 2 μmol of H3 
tail peptide hydrazide was dissolved in ligation buffer to a final concentration of 10 
mM and the pH readjusted to 3.0. The peptide solution was kept at - 20 °C in an ice 
/ NaCl bath and NaNO2 was added dropwise from a stock of 500 mM to a final 
concentration of 15 mM. After mixing, the peptide was incubated at - 20 °C for 5 
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min. Subsequently, TFET was added to a final concentration of 1 M and the pH of 
the peptide solution was adjusted to 6.8. The peptide was incubated for 10 min at RT 
and transferred to a tube with lyophilized, truncated recombinant H3 protein. The 
molar ratio peptide/protein was 7:1 or 5:1. TCEP buffer (0.5 M TCEP, 6 M GdmHCl, 
0.2 M Na2HPO4, pH = 6.5) was added to a final concentration of 10 mM TCEP and 
the reaction was allowed to proceed at 25 °C under Argon atmosphere. The reaction 
was monitored by analytical RP-HPLC. When the reaction had reached completion, 
desulfurization was performed in the same tube without prior purification of the 
ligation product. TCEP desulfurization buffer (0.5 M TCEP, 6 M GdmHCl, 0.2 M 
phosphate, pH = 7) was added to a final concentration of 0.25 M TCEP in the reaction 
solution. Then, glutathione and VA-044 radical starter were added from stock 
solutions to final concentrations of 40 mM and 20 mM, respectively. The reaction 
incubated at 42 °C and monitored by analytical RP-HPLC and ESI-MS. When the 
reaction had reached completion, it was mixed with 2 Volumes of RP-HPLC solvent 
A and purified by semi-preparative RP-HPLC using a gradient of 30 % - 70 % RP-
HPLC solvent B in 45 min. The purified protein was characterized by analytical RP-
HPLC and ESI-MS. 
For peptides 5b (H3(1-35)K4me3 V35Y), 5d (H3(1-35)K27me3 V35Y) and 
5e (H3(1-35)K4me3K27me3 V35Y), the previously described one-pot ligation-
desulfurization strategy was used.207,436 Briefly, between 1 and 2 μmol of H3 tail 
peptide hydrazides (1b, 1d and 1e) were converted to the TFET thioesters and, after 
ligation to N-terminal cysteine peptides 4 or 4’, the cysteine at the ligation site was 
desulfurized as described above. When the reaction had reached completion, the 
peptides were mixed with 2 Volumes of RP-HPLC solvent A and purified by semi-
preparative RP-HPLC using a gradient of 0% - 40 % RP-HPLC solvent B in 40 min. 
The purified peptides were characterized by analytical RP-HPLC and ESI-MS. 
 
 4.2.4 Octamer refolding and nucleosome reconstitution 
 
Lyophilized core histones were dissolved in unfolding buffer (6 M GdmHCl, 
20 mM Tris-HCl pH = 7.5, 5 mM D,L-dithiothreitol) and mixed in stoichiometric 
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quantities (1 equivalent of H3 and H4 and 1.1 equivalent of H2A and H2B). The 
scale was 100 - 500 µg of histone H3 with an overall protein concentration of 74 µM. 
Histones were dialysed against 3 buffer changes of 3 h, 15 h and 3 h in refolding 
buffer (2 M NaCl, 10 mM Tris-HCl pH = 7.5, 1 mM EDTA, 1 mM D,L-dithiothreitol) 
in Slide-A-Lyzer™ dialysis cassettes. The obtained crude octamers were applied to 
a Superdex 200 10/300 column (GE Healthcare) and resolved in refolding buffer. 
Fractions containing pure octamers were pooled and concentrated in Vivaspin 500 
centrifugal concentrator (10’000 MWCO) to the range of 30 - 60 μM. Octamers were 
stored at - 20 °C in 50 % v/v glycerol. Octamers were analysed by SDS PAGE. 
For cMAP pulldown assays, a biotinylated 166 bp DNA fragment with a 19 
bp linker prior to the strong nucleosome positioning sequence 601437 was produced 
by PCR as described previously.73 For nucleosome pulldown, unlabelled 601 DNA 
was obtained from a plasmid containing 32 repeats of the 601 sequence separated by 
restriction sites. Milligram amounts of this plasmid was prepared by E. Coli culture, 
processed with alkaline lysis and purified by size exclusion chromatography with a 
sepharose 6 Fast Flow column (GE Healthcare). Following digestion with EcoRV 
(New England Biolab), the 153bp 601 DNA was purified by PEG precipitation and 
concentrated to 1.5 - 2.5 µg/µL by ethanol precipitation. For EMSA with cMAP3 
and for MST with LSD1 and unmodified nucleosomes, Cy-5 labelled 601 DNA was 
obtained by PRC. 
Mononucleosomes were reconstituted either at a small scale by dilution or at 
a larger scale by dialysis as described previously.406 Briefly, in the first method, 
typically 10 or 20 pmol of 601 DNA were mixed with the respective histone octamers 
in 2 M NaCl in a volume of 10 µL. Following several additions of 10 mM Tris-HCl 
pH = 7.6, the final concentration of NaCl is 0.2 M. In the second method, 
nucleosomes were reconstituted in 70 µl sample volume by mixing 60 pmol of DNA 
with the respective histone octamer at high salt conditions (2 M KCl, 10 mM Tris-
HCl pH = 7.5, 1 mM EDTA) followed by gradient dialysis into low salt conditions 
(0.25 M KCl, 10 mM Tris-HCl pH = 7.5, 1 mM EDTA). Dialysis was carried out in 
Slide-A-Lyzer™ MINI dialysis devices using a two-channel peristaltic pump (1 
mL/min) over 16 h at 4°C. Nucleosome concentrations were determined by UV 
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quantification and the quality of nucleosome reconstitution was assessed by native 
gel electrophoresis. 
 
4.3 Cloning, expression and purification of multivalent sensors for 
bivalent chromatin 
 
QuikChange II XL site-directed mutagenesis kit (Agilent), Gibson cloning438 
or classical (restriction enzymes) cloning was used to clone the 6 cMAP variants in 
pET28b(+) or pET15b bacterial vectors (Table 10). DH5α E. coli cells were used for 
all cloning steps. The Chromo-domain (CD) of the Drosophila Polycomb group 
protein Pc corresponds to entry P26017 on uniprot.org, residues 23 - 84. The Plant 
Homeo Domain (PHD) of the mouse inhibitor of growth protein 2 (ING2) 
corresponds to entry Q9ESK4 on uniprot.org, residues 207 - 281. The PHD of the 
human transcription initiation factor TFIID subunit 3 (TAF3) protein corresponds to 
entry Q5VWG9 on uniprot.org, residues 855 - 924. All primers and synthetic genes 
were obtained from Integrated DNA Technologies (IDT, Leuven, Belgium). 
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Variant Cloning 
method 
Primers/gene fragment Template 
cMAP1 Digestion by 
restriction 
enzymes and 
ligation 
gBlock gene fragment encoding mouse 
ING2 PHD flanked by desired restriction 
sites (IDT) 
cMAP6 
cMAP2 -- gBlock gene fragment (IDT)  
cMAP3 Quikchange 
mutagenesis 
5'-gcgggggtggtagcgtctcgaaaggaga-3' 
5'-tctcctttcgagacgctaccacccccgc-3'  
5'-catggacgaactgtataagggcggttacccggg-3' 
5'-cccgggtaaccgcccttatacagttcgtccatg-3’ 
cMAP2 
cMAP4 Quikchange 
mutagenesis & 
digestion by 
restriction 
enzymes and 
ligation 
5’-accggcagcggacctcccccgc-3’ 
5’-gcgggggaggtccgctgccggt-3’ 
5’-taagcaaagcttggcagcggaga-3’ 
5’-tgcttaggatccgctaccacccc-3’ 
cMAP6 & 
cMAP3 
cMAP5 Quikchange 
mutagenesis 
5'-tctgtccgaaatgtgcgaataaaggtggtag 
ccgtgct-3' 
5’-agcacggctaccacctttattcgcacatttcg 
gacaga-3’ 
cMAP2 
cMAP6 Quikchange 
mutagenesis 
5'-gcggcacaccaagcaaacctcccccgccac 
ccgtctcgaaaggagagg-3' 
5'-cctctcctttcgagacgggtggcgggggag 
gtttgcttggtgtgccgc-3' 
5'-gcatggacgaactgtataagcccccgcctc 
caccgtacgtaatcagagacgagtg-3' 
5'-cactcgtctctgattacgtacggtggaggcg 
ggggcttatacagttcgtccatgc-3' 
cMAP2 
Table 10. Primers used to clone cMAP constructs in bacterial vectors. 
 
cMAPs were expressed in LB medium in E. Coli BL21 (DE3) by the addition 
of 0.5 mM IPTG and 10 μM ZnCl2. In general, cells were induced at 37 °C for 4 h. 
For cMAP4, cells were induced overnight at 16 °C. Cell pellets were resuspended in 
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a lysis buffer consisting of a solution of 50 mM NaH2PO4 pH = 7.5, 300 mM NaCl, 
10 mM imidazole, 1 % v/v IGEPAL CA-630, 10 % w/v glycerol, 10 μM ZnCl2, 0.5 
mM PMSF, 0.5 mM β-mercaptoethanol, 1x protease inhibitor cocktail. Cells were 
then lysed by addition of lysozyme to a final concentration of 1 mg/mL followed by 
sonication. The lysates were clarified by centrifugation and the supernatants were 
applied to Ni-NTA affinity purification. The resin-bound proteins were washed three 
times with a wash buffer consisting of 50 mM NaH2PO4 pH = 7.5, 1 M NaCl, 20 mM 
imidazole, 10 µM ZnCl2, 0.5 mM β-mercaptoethanol. The proteins were eluted with 
a buffer consisting of 50 mM NaH2PO4 pH = 7.5, 150 mM NaCl, 500 mM imidazole, 
10 µM ZnCl2, 1 mM β-mercaptoethanol.  
For nucleosome pulldowns, cMAP2, 3, 5, 6 were dialyzed in 50 mM Tris-
HCl pH = 7.4, 150 mM NaCl, 1 mM DTT, 10 µM ZnCl2. For EMSA, cMAP2 was 
dialyzed in 50 mM Tris-HCl pH = 7.4, 150 mM NaCl, 1 mM DTT, 10 µM ZnCl2, 5 
% w/v glycerol. For cMAP pulldown assays, proteins were dialysed overnight into a 
buffer consisting of 50 mM Tris-HCl pH = 7.4, 150 mM NaCl, 1 mM β-
mercaptoethanol, 10 μM ZnCl2, 5 % w/v glycerol.  
cMAPs were stored in 30 % glycerol at - 80°C or used freshly. cMAP2 was 
confirmed to be monomeric by gel filtration with an isocratic elution with a buffer 
consisting of 50 mM NaH2PO4, 50 mM NaCl, 1 mM DTT, pH = 7.8 (Superdex 200 
10/300GL column GE Healthcare) after anion exchange chromatography (HiTrap Q 
FF column GE Healthcare). 
 
4.4 In vitro binding assays 
 
Nucleosome pulldown with immobilized cMAPs 
20 µL of anti-FLAG M2 affinity gel (Sigma) (corresponding to 10 µL resin) 
are washed 2 x with 50 mM Tris-HCl pH = 7.4, 150 mM NaCl., 2 x with 0.1 M 
glycine pH = 3.5 and 4 x with PD buffer 1 (10 mM Tris-HCl pH = 7.4, 50 mM NaCl, 
1 mM MgCl2, 1 % v/v Triton X-100, 0.5 mM PMSF). Then, 1 or 20 µg of one of the 
cMAP variant was immobilized on the beads in 200 µL PD buffer 1 for 2 h at 4 °C. 
The resin was then washed 5 x with 200 µL PD buffer 1 to remove unbound cMAPs 
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and subjected to incubation with 3 or 5 pmol of mononucleosomes in 200 µL PD 
buffer 1 for 1 h or overnight at 4 °C. Subsequently, the resin was washed 3 or 4 x 
with 200 µL wash buffer (10 mM Tris-HCl pH = 7.4, 300 mM NaCl, 1 % Triton X-
100, 0.5 mM PMSF) and boiled in 2 x Laemmli sample buffer. Beads were removed 
by filtration with Ultrafree-MC centrifugal units (Millipore) at 12’000 xg for 4 min. 
Samples were run on a 12 % SDS-PAGE followed by transfer on a PVDF membrane 
in transfer buffer (10 % methanol, 25 mM Tris, 200 mM Glycine) at 200 mA for 2 h 
at 4 °C. The blot was incubated in blocking solution (10 % non-fat milk in tris buffer 
saline (TBS) with Tween-20) for 2 h at RT and then incubated in blocking solution 
supplemented with anti-H3 rabbit polyclonal antibody (anti-H3 C-terminus, 1:1000) 
for 1 h at RT. After 3 washes with TBS-Tween, the blot was incubated in blocking 
solution supplemented with anti-rabbit HRP conjugate (1:2000) for 1 h at RT. After 
3 washes with TBS-Tween, the blot was imaged after applying Clarity Western ECL 
substrates with Chemidoc MP imaging system Bio-Rad Gel imager. 
 
EMSA with cMAP3 and nucleosomes 
0.3 pmol of Cy5-labeled nucleosomes were mixed with various 
concentrations of cMAP3 in gel shift buffer (20 mM HEPES, pH = 7.5, 100 mM 
KCl, 0.05 % NP40, 0.1 mg/mL BSA) in a total volume of 10 µL and incubated for 
30 min at 30 °C. For the gel shift with Cy5-labeled 601 DNA, conditions are identical 
except the concentration of BSA which was 0.5 mg/mL. 2 µL of sucrose 25 % was 
added in all samples and they were analysed by native gel electrophoresis. 
 
cMAP pulldown with immobilized nucleosomes 
200 µg Dynabeads M-280 streptavidin are washed with 1 mL PD buffer 2 (10 
mM Tris-HCl pH = 7.5, 150 mM NaCl, 0.1 % v/v Triton X-100, 5 % w/v glycerol, 
0.1 mg/mL BSA, 1 mM D,L-dithiothreitol). Then, 4 pmol biotinylated 
mononucleosomes were immobilized on the beads in 200 µL PD buffer 2 for 1 h at 
4 °C. The resin was then washed twice with 500 µL PD buffer 2 to remove unbound 
nucleosomes and subjected to incubation with 30 pmol of one of the cMAP variants 
in 200 µL PD buffer 2 for 4 h at 4 °C. Subsequently, the resin was washed 6 x with 
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500 µL PD buffer 2 for 10 min at 4 °C and boiled in 2 x Laemmli sample buffer. 
Samples were run on a 12 % SDS-PAGE followed by transfer on a PVDF membrane 
in transfer buffer (10 % methanol, 25 mM Tris, 200 mM Glycine) at 200 mA for 2 h 
at 4 °C. The blot was incubated in blocking solution (10 % non-fat milk in TBS-
Tween) for 2 h at RT and then incubated in blocking solution supplemented with 
anti-FLAG monoclonal M2 antibody mouse (1:1’000) for 1 h at RT. After 3 washes 
with TBS-Tween, the blot was incubated in blocking solution supplemented with 
anti-mouse peroxidase conjugate (1:12’000). After 3 washes with TBS-Tween, the 
blot was imaged after applying Clarity Western ECL substrates with Chemidoc MP 
imaging system Bio-Rad Gel imager. Each pulldown was performed in independent 
triplicates. 
In order to take into account the variability in the amount of nucleosomes 
loaded on the beads, one of the two following experiments was performed. The anti-
FLAG blot was stripped and an anti-H3 Western Blot was performed on the same 
membrane with anti-H3 rabbit polyclonal antibody (anti-H3 C-terminus, 1:1000) and 
anti-rabbit HRP conjugate (1:2000). The anti-FLAG bands were then normalized to 
the anti-H3 bands. Alternatively, the anti-H3 Western Blot was performed prior to 
the anti-FLAG blot and a corrected volume of the sample was loaded on the anti-
FLAG SDS gel. The nucleosome loading on the beads was then found to be 
homogeneous (Figure 34. B). 
 
MST with cMAP3 and modified histone peptides 
cMAP3 binding to H3 peptides was determined by performing titrations using 
microscale thermophoresis for a readout of the interaction. Lyophilized peptides 5b, 
5d and 5e were each dissolved in MST buffer (50 mM Tris-HCl pH = 7.4, 150 mM 
NaCl, 10 µM ZnCl2) and quantified by UV-VIS spectrophotometry using tyrosine 
absorption. A titration series was then performed by mixing recombinant cMAP3 
with increasing concentrations of peptides 5b, 5d or 5e in a total volume of 20 µL 
MST buffer containing Tween-20 to a final concentration of 0.05 %. The samples 
were centrifuged for 10 minutes to eliminate any aggregates. Samples were loaded 
into premium coated capillaries (Nanotemper) and binding was determined using a 
110 
 
detection LED power of 40 % and laser heating power (MST power) of 40 %. 
Experiments were performed in independent duplicates. The experimental data was 
averaged, normalized and analysed by nonlinear fitting using a single-site binding 
isotherm in Origin (OriginLab). 
 
MST with LSD1 and unmodified nucleosomes 
Titrations using microscale thermophoresis were done on a MonoLith 
NT.115 instrument equipped with green/red filters from NanoTemper technologies. 
LSD1 protein from a main stock was serially diluted in titration buffer (150 mM 
NaCl, 20 mM Tris-HCl, 5 % glycerol, pH = 7.8) to cover the concentration range 8 
nM - 131 μM. Tween-20 was added to a final concentration of 0.05 %. Cy5-labeled 
mononucleosomes were added to a final concentration of 10 nM. After centrifugation 
for 10 min at 15,000 rpm, samples were loaded into premium coated capillaries and 
cap scanning done at 80 % LED power. Thermophoresis was done at 40 % IR laser 
power. Data was normalized and fitted to the Hill equation using Origin. 
 
4.5 Mouse ESCs 
 
 4.5.1 Culture conditions  
 
Mouse E14 ESCs were cultured in feeder-free conditions. Cells were grown 
on 0.1 % gelatin-coated Petri dishes in GMEM supplemented with MEM non-
essential amino acids (consisting of glycine, L-alanine, L-asparagine, L-aspartic acid, 
L-glutamic acid, L-proline and L-serine all with a final concentration of 100 µM), 
sodium pyruvate at a final concentration of 2 mM, penicillin/streptomycin at final 
concentrations of 100 U/mL and 100 µg/mL, respectively, L-glutamine at a final 
concentration of 2 mM + 2-mercaptoethanol at a final concentration of 10 µM + 10 
% FBS embryonic stem cell-qualified + 10 ng/mL LIF. The medium was 
supplemented with 3 μM GSK3 inhibitor XVI + 800 nM PD184352. Cells were 
cultured at 37 °C with 5 % CO2. 
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For treatments with small molecule modulators, compounds were dissolved 
in DMSO at an appropriate concentration. The medium was then supplemented 
according to the conditions in Table 9. 
 
 4.5.2 Transient transfection and confocal microscopy 
 
ESCs were plated on E-cadherin coated wells as previously described.439 
Between 4 and 5 h later, cells were transfected with plasmids pcDNA3.1 containing 
cMAP3 wild type or mutants under a cytomegalovirus (CMV) promoter using X-
tremeGENE 9 DNA transfection reagent and OptiMEM I 1x reduced serum medium. 
Between 20 h and 24 h later, cells were analysed on a confocal microscope LSM 510 
Meta (Zeiss) with Draq5 as DNA stain. 
 
 4.5.3 Immunofluorescence 
 
Cells were plated on E-cadherin coated wells. Between 20 h and 24 h later, 
cells were fixed with 4 % paraformaldehyde for 15 min, washed 3 x with phosphate 
buffer saline (PBS) and permeabilised with 1 % Triton X-100 in PBS for 20 min. 
After washing 5 x with PBS, cells were incubated in blocking buffer (1 % BSA in 
PBS) for 30 min. Cells were then incubated in blocking buffer supplemented with 
rabbit polyclonal antibody against H3K27me3 (dilution 1:1000) for 1 h. Cells were 
washed 3 x with PBS for 5 min and incubated in blocking buffer supplemented with 
Alexa Fluor 647 antibody anti-rabbit antibody (1:1000) for 1 h. After washing 1 x 
with PBS for 5 min, cells were incubated in 4’,6-diamidino-2-phenylindole (DAPI) 
in PBS for 5 min. After a final wash in PBS for 5 min, cells were imaged with a 
confocal microscope LSM700 (Zeiss) in PBS supplemented with 1 mM of the 
antioxidant compound Trolox which serves as an antifading agent. 
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 4.5.4 Western Blot of acid-extracted histones 
 
Cells were washed with PBS, pelleted and incubated in hypotonic lysis buffer 
(10 mM Tris-HCl pH = 8.0, 1 mM KCl, 1.5 mM MgCl2, 1 mM DTT, Protease 
Inhibitor Cocktail cOmpleteTM EDTA-free, 1 mM PMSF, 1 mM NaF) at 4 °C for 30 
min. Nuclei were pelleted and incubated in 0.2 M H2SO4 for 2 h at 4 °C. After 
centrifugation, acid-extracted histones were dialysed against water with 2.5 % v/v 
acetic acid in Slide-A-Lyzer Mini Dialysis buttons (3’500 Da MWCO) overnight at 
4 °C. The histone containing solution was removed from the dialysis device and 
lyophilized, redissolved in 50 µL water and run on a 12 % SDS PAGE. Proteins were 
transferred on a PVDF membrane in transfer buffer (10 % methanol, 25 mM Tris, 
200 mM glycine) at 200 mA for 2 h at 4 °C. The blot was incubated in blocking 
solution (10 % non-fat milk in TBS-Tween) for 2 h at RT and then incubated in 
blocking solution supplemented with rabbit polyclonal antibody against H3K27me3 
(1:1000) overnight at 4 °C. After washing 3 x with TBS-Tween, the blot was 
incubated with blocking solution supplemented with anti-rabbit HRP conjugate 
(1:2000) for 1 h at RT. After 3 washes with TBS-Tween, the blot was reacted with 
Clarity Western ECL Blotting substrates and imaged by Chemidoc MP imaging 
system Bio-Rad gel imager. 
 
 4.5.5 Chromatin immunoprecipitation 
 
Growth and harvest 
6 confluent plates of mouse E14 ESCs were cross-linked with 1 % 
formaldehyde (16 % stock solution, Methanol free) and incubated 10 min at RT. The 
fixation was quenched with 125 mM glycine. Cells were washed 2 x with 10 mL cold 
PBS and scraped off. After centrifugation, about 70 million cells were stored at - 80 
°C. 
Chromatin extraction 
Chromatin preparation and immunoprecipitation was performed as described 
previously440 with some modifications. Briefly, the cell pellet was resuspended in 10 
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mL cold buffer A (20 mM HEPES-KOH pH = 7.5, 10 mM EDTA, 0.5 mM EGTA, 
0.25 % Triton-X-100, Protease inhibitor cocktail) and rotated at 4 °C for 10 min. 
After centrifugation, the pellet was washed with 10 mL cold buffer B (50 mM 
HEPES-KOH pH = 7.5, 150 mM NaCl, 1 mM EDTA, Protease inhibitor cocktail) at 
4 °C for 10 min. After centrifugation, the pellet was resuspended in 1 mL cold buffer 
C (20 mM HEPES-KOH pH = 7.5, 1 mM EDTA, 0.5 mM EGTA, 0.05 % SDS, 
Protease inhibitor cocktail). Cells were sonicated using a Bioruptor sonicator for 20 
x on high power (30 sec on / 30 sec off) at 4 °C. Sonication efficiency was checked 
by Fragment Analyzer. Sonicated chromatin was transferred to a 1.5 mL eppendorf 
and centrifuged at 14000 g/ 10 min/ 4 °C. The supernatant was collected and used for 
chromatin immunoprecipitation (100 µL per ChIP). 
ChIP 
40 µL of Protein G magnetic beads were used per IP. Beads were first washed 
three times with incubation buffer (10 mM Tris-HCl pH = 8.0, 150 mM NaCl, 1 mM 
EDTA, 0.5 mM EGTA, 0.15 % SDS, 1 % Triton X-100, Protease inhibitor cocktail). 
Beads were then blocked overnight at 4 °C in 1.2 mL incubation buffer supplemented 
with 0.1 % BSA. In parallel, 1 µL of the sonicated chromatin was removed for the 
input sample while aliquots of 100 µL were incubated overnight at 4 °C with 4 µg of 
IgG, anti-H3K4me3 or anti-H3K27me3 in incubation buffer supplemented with 0.1 
% BSA. After overnight incubation, blocked beads were added to each chromatin 
preparation and incubated for 2 h at 4 °C in a rotating wheel. Beads were then washed 
twice with 1 mL Wash Buffer 1 (10 mM Tris pH = 8.1, 150 mM NaCl, 1 mM EDTA, 
0.5 mM EGTA, 0.1 % SDS, 0.1 % sodium deoxycholate, 1 % Triton X-100), once 
with 1 mL Wash Buffer 2 (10 mM Tris pH = 8.1, 500 mM NaCl, 1 mM EDTA, 0.5 
mM EGTA, 0.1 % SDS, 0.1 % sodium deoxycholate, 1 % Triton X-100), once with 
1 mL Wash Buffer 3 (10 mM Tris pH = 8.1, 250 mM LiCl, 1 mM EDTA, 0.5 mM 
EGTA, 0.5 % sodium deoxycholate, 1 % NP-40) and twice with 1 mL Wash Buffer 
4 (10 mM Tris pH = 8.1, 1 mM EDTA, 0.5 mM EGTA). Co-immunoprecipitated 
DNA fragments were eluted from the beads in 400 µL elution Buffer (10 mM Tris 
pH = 7.5, 1 mM EDTA, 1 % SDS, 100 mM NaHCO3, 200 mM NaCl). 10 µL of 20 
mg/ml PureLink RNase A was added to DNA fragments and incubated for 30 min 
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37 °C. RNA-digested chromatin was incubated for 4 h at 65 °C with proteinase K to 
digest proteins and reverse crosslink, and the DNA was purified using the QIAquick 
PCR Purification Kit.  
qPCR 
Quantitative PCR was performed using a StepOnePlus™ System (Applied 
Biosystems) on 1 μL of IP, input which were mixed to 10 µL 2 X SYBR Select 
Master Mix (Applied Biosystems), 0.8 µL 10 µM forward / reverse primers, and 7.4 
µL H2O. The PCR program was performed as follows: 2 min at 50 °C; 10 min at 95 
°C; and then 40 cycles of 95 °C for 3 sec and 60 °C for 30 sec. Primers listed in Table 
11 were used for qPCR analysis. 
 
Name Forward primer Reverse primer 
Pou5f1 5’- ggc tct cca gag gat ggc tga g -3’ 5’- tcg gat gcc cca tcg ca -3’ 
Polm 5’- tga cgg gca caa tta cac ca -3’ 5’- aaa ggc ttc cgc gtc cta ga-3’ 
Gapdh 5’- ggg ttc cta taa ata cgg act gc -3’ 5’- ctg gca ctg cac aag aag atg -3’ 
Tcf4 5’- cgg atg tga atg gat tac aat g -3’ 5’- att gtt ctt cgg tct tgt tgg t -3’ 
HoxA3 5’- aat tac ctc cct gca tct caa a -3’ 5’- tta tca gag cag acc cac aat g -3’ 
Irx2 5’- taa cac ggc ctg aaa tct tct c -3’ 5’- gca tcc cac ttc tac agt cct c -3’ 
Olig1 5’- ggg tta cag gca gcc acc ta -3’ 5’- atg cgg tgg aag agg atg ag -3’ 
HoxC5 5’- gta ctg cta cgg cgg att gg -3’ 5’- tac ccc gtg gag aga gtt gg -3’ 
HoxB13 5’- ttc gag ctg gga gcg att ta -3’ 5’- agc cga ggg tga ggg ttc ta -3’ 
Gata-4 5’- aag agc gct tgc gtc tct a -3’ 5’- ttg cta gcc tca gat cta cgg -3’ 
des. chr1 5’- gga agc tgg ttt cac atg gt -3’ 5’- ccc ttg att tct cga agg ag -3’ 
Table 11. List of oligonucleotides used for qPCR. 
 
4.6 Histone methyltransferase assays 
 
Asymmetrically modified H3K4me3 nucleosomes (one H3 unmodified and 
one H3 with K4me3) were obtained as previously described.207 Briefly, a small 
peptide named lnc-tag containing an N-terminal cysteine with acetamidomethyl 
(Acm) protection and a TEV cleavage site was used for the traceless synthesis of 
asymmetrically modified octamers. N-terminal tail of H3 (with or without K4me3) 
with lnc-tag at the N-terminus were obtained by SPPS and subsequently ligated with 
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truncated H3. Following desulfurization, the N-terminal cysteine of both modified 
and unmodified H3 molecules were deprotected. The disulfide bond between 
unmodified H3 and H3K4me3 was done by activating one of the cysteine with 5,5′-
Dithiobis(2-nitrobenzoic acid) (DTNB). Octamers were refolded using the H3 
heterodimer, H4, H2A and H2B. Following nucleosome reconstitution, the lnc-tags 
were cleaved by TEV protease. 
10 pmol nucleosomes were mixed with 0.2 or 2 pmol of SET1B complex and 
1 µCi of 3H-SAM in HMT buffer (50 mM Tris-HCl, pH = 8.5, 30 mM KCl, 5 mM 
MgCl2, 4 mM DTT) in a total volume of 25 µL and incubated at 30 °C for 10 min, 
30 min or 2 h. In parallel, 15 pmol octamers were mixed with 0.8 pmol of SET1B 
complex and 1 µCi of 3H-SAM in the same buffer in a total volume of 25 µL and 
incubated at RT or 30 °C for 2 h. 20 µL of each samples was boiled in 5 x Laemmli 
sample buffer and run on a 12 % MINI-Protean TGX Precast gel (Bio-Rad). 
Following staining with coomassie blue and destaining, the gel was incubated in 
Amersham Amplify NAMP100V (GE healthcare) for 30 min and dried with 
DrygelSr. Slab gel dryer (Hoefer Scientific Instruments) for 2 h at 80 °C. Carestream 
Kodak BioMax MS film was exposed to the dry gel overnight at - 80 °C and the film 
was developed with the developer CURIX 60 (AGFA). The 5 µL left of the samples 
were spotted on P81 Ion Exchange Cellulose Chromatography Paper (Reaction 
Biology) and dried for 40 min at least. Following 3 washes with 50 mM NaHCO3 pH 
= 9, filter papers were dried on DrygelSr. Slab gel dryer at 40 °C for 15 min. Filter 
papers were then mixed with 5 mL of Ultima Gold F scintillation cocktail (Perkin 
Elmer) and vortexed for 30 s. After 1 h incubation at RT, scintillation counting was 
performed with Tri-Carb 3100TR Perkin Elmer Liquid scintillation analyser. 
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